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ABSTRACT 
 
Background 
In settings with a high burden of tuberculosis, children with unrecognised culture-
confirmed pulmonary tuberculosis (PTB) may be discharged from hospital before 
mycobacterial culture results are available; in these cases clinical improvement may have 
been due to successful treatment of an intercurrent viral or bacterial co-infection. 
 
Aim 
To estimate the burden of tuberculosis in children who were enrolled in a double-blind, 
placebo-controlled pneumococcal conjugate vaccine (PCV) trial, and to probe for the 
presence of pneumococcal co-infection in trial participants who had a hospital-based 
diagnosis of PTB. 
 
Methods 
A retrospective case-finding strategy was adopted in order to define the tuberculosis case 
load amongst 39 836 children that had been enrolled in a PCV efficacy trial in Soweto, 
Gauteng Province. The trial follow-up period was 5.3 years. Children with a hospital-based 
diagnosis of tuberculosis were categorised by strength of evidence for the disease, HIV 
status and PCV vaccination status. Incidence rates and risk ratio assessments were 
conducted using standard statistical methods. 
 
 
 
  vi 
Results 
Four-hundred and ninety-two episodes of tuberculosis arose amongst 425 of the 39 836 
PCV Study participants. Tuberculosis incidence was 1067 per 100 000 children (95% 
Confidence Interval [CI], 968 – 1173), with the greatest burden observed amongst HIV-
infected children (10 633 per 100 000 children [95% CI, 9411 – 11 969]; Risk Ratio [RR] 
27.5 [95% CI, 22.6 – 33.5], P<0.001). The burden of PTB in the cohort was 982 cases per 
100 000 children (95% CI, 887 – 1084): 9895 per 100 000 (95% CI, 8718 – 11 187) in the 
HIV-infected children and 352 per 100 000 (95% CI 294 – 417) in the HIV-uninfected 
children (RR 28.1; 95% CI, 22.9 – 34.6), P<0.001. 
 
PCV recipients exhibited a 44 percent (95% CI, 11 – 65), P=0.010, reduction in incident 
culture-confirmed PTB compared to placebo recipients; this apparent reduction was 
demonstrated chiefly in PCV-vaccinated HIV-infected children (RR 0.53; 95% CI, 0.31 – 
0.90) compared to HIV-infected placebo recipients, P=0.017. 
 
Conclusions 
A high burden of tuberculosis is carried by children under 5.3 years in the study setting, 
with HIV-infected children bearing the brunt of the morbidity. Pneumococcal co-infections 
are common in the context of hospitalised PTB in the study setting.  
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1.0 INTRODUCTION 
 
1.1 The Global and Local Burden of Tuberculosis 
Tuberculosis is considered to be the most prevalent infectious disease globally, with a third 
of the world‟s population estimated as being infected with the causative organism, 
Mycobacterium tuberculosis (MTB)
1
. In 1989, it was estimated that 1.3 million new 
paediatric tuberculosis cases and 450 000 tuberculosis-related childhood deaths occur 
annually, with the overwhelming burden of infection occurring in the developing world
1
.  
 
Studies conducted in the Western Cape Province over the past decade have determined that 
the region has one of the highest global incidences of tuberculosis with incidences in excess 
of 1000 per 100 000 population in certain communities within the province
2
 
3
. Based on 
data from 2006, South Africa is ranked fourth in the world in terms of its tuberculosis 
disease burden with an incidence of active tuberculosis disease of 940 cases per 100 000 
persons per year, and a prevalence of 998 per 100 000
4
. This tuberculosis disease incidence 
has increased significantly since 1999 when it was 392 per 100 000 population per year
5
.  
 
1.2 Tuberculosis in Children 
Children under 14 years of age contribute approximately 25 to 40 percent of the burden of 
notified tuberculosis cases in developing countries, and MTB causes severe disease in the 
paediatric age group
6
. This is due to numerous factors, primarily immaturity of the 
developing immune system, but factors such as socio-economic deprivation and 
malnutrition which impact negatively on childhood well-being are also important
6
. 
  2 
Extrapulmonary tuberculosis (EPTB), including tuberculous meningitis (TBM) and miliary 
tuberculosis (the most severe manifestations of the disease), is frequently encountered in 
children in settings with a high burden of tuberculosis. 
 
Risk of progression to active disease after primary infection is increased the younger an 
individual is at first exposure to MTB: there is a 30 to 40 percent risk for progression to 
active pulmonary tuberculosis (PTB) and a 10 to 20 percent risk of progression to miliary 
tuberculosis or TBM after infection with the organism in children under one year of age
7
. 
This needs to be compared with the estimated 5 to 10 percent lifetime risk for progression 
to active disease in immunocompetent adults infected with MTB. 
 
Childhood tuberculosis is contracted by means of aerosolisation, primarily from inhalation 
of droplet nuclei produced by sputum smear positive („open‟) adult close contacts with 
cavitary pulmonary reactivation of a previously quiescent pulmonary focus of latent 
tuberculosis. Hence, childhood tuberculosis represents the adequacy of local tuberculosis 
control programmes in detecting and treating existing adult patients with active disease: if 
these adult cases were identified early and treated effectively there would be fewer 
childhood tuberculosis cases. Importantly, the current burden of childhood tuberculosis 
represents concern for future control of this infection as a large population of children with 
untreated latent tuberculosis infection (LTBI) could ostensibly survive to become a large 
cohort of tuberculosis-infected adults with propensity to reactivate their tuberculosis in the 
future
8
 
9
. The current burden of childhood tuberculosis poses tremendous challenges for 
future tuberculosis control in South Africa.  
 
  3 
1.3 Tuberculosis in the Era of HIV 
The human immunodeficiency virus (HIV) pandemic has created a substantial pool of 
immunocompromised individuals at increased risk for progressing from a state of LTBI to 
tuberculosis disease through disruption of the cell mediated immune mechanisms 
responsible for maintaining latency of the infection, and HIV co-infected individuals are at 
risk for developing severe forms of tuberculosis
10
 
11
. An intact cell mediated immunity 
(CMI) has been elucidated as being the most crucial factor in containing tuberculosis 
infection and preventing progression from latency to disease
12
 
13
 
14
. The risk of progression 
to disease is 10 percent per year in HIV-infected adults co-infected with MTB compared to 
the 5 to 10 percent lifetime risk of progression to disease in HIV-uninfected adults with 
LTBI. Untreated tuberculosis is rapidly progressive and fatal in HIV-infected individuals: 
children with HIV and tuberculosis co-infection have a two- to ten-fold greater risk of early 
mortality compared to children with tuberculosis alone
15
 
16
 
17
. 
 
1.4 Tuberculosis Diagnostic Algorithms  
It is challenging to make a definitive diagnosis of tuberculosis disease in paediatric patients 
as representative microbiologic confirmation is difficult to establish, especially in young 
children. Furthermore, resource limited settings with the greatest burden of childhood 
tuberculosis are often ill-equipped to investigate possible cases of the disease because of 
lack of radiological and laboratory facilities
18
. Compared to adult cases, childhood PTB 
tends to be paucibacillary, as cavitary disease with expectoration of large quantities of acid-
  4 
alcohol fast bacilli (AFB) is infrequent in young children: microbiological methods of 
diagnosing the infection are frequently negative as a result of this phenomenon.  
 
Non-microbiological methods are frequently utilised in order to substantiate a suspected 
diagnosis of tuberculosis in paediatric patients, with features on patient history, clinical 
examination and investigations all helping to bring the clinician closer to a likely diagnosis 
of tuberculosis in situations where microbiological data are lacking. 
 
Diagnostic algorithms, such as the one advocated for use by the South African National 
Tuberculosis Programme (SANTP) Guidelines (2004)
 19
 (Appendix 1, page 127), are a 
means of coalescing various features on patient history, examination and clinical response 
to treatment, in order to arrive at a likely diagnosis of active tuberculosis. These tools are 
useful in resource-poor settings with low HIV prevalence and limited access to laboratory 
facilities or chest radiographs
20
, but have been found to be lacking in sensitivity and 
specificity, with both under- and over-diagnosis of tuberculosis being a concern when 
algorithms are used as the sole means of arriving at a diagnosis of tuberculosis in areas with 
high HIV prevalence
18 21
 
22
. 
 
A further shortcoming of diagnostic algorithms in the diagnosis of tuberculosis in children 
is that the parameters used therein (e.g. weight loss not responding to nutritional 
rehabilitation, organomegaly with ascites, gibbus) often adopt features encountered in cases 
of chronic tuberculosis or established EPTB disease, placing the patient presenting with 
acute PTB at risk of not being diagnosed as such at initial presentation.  
  5 
1.5 Acute Presentations of PTB 
Childhood PTB may present acutely, and the disease can be indistinguishable from acute 
viral or bacterial pneumonia in its initial presentation as has been demonstrated in three 
South African studies
23
 
24
 
25
, where investigators reported that 8 to15 percent of  HIV-
infected and -uninfected children admitted with acute community-acquired pneumonia had 
culture-proven tuberculosis, which was predominantly identified by performing gastric 
aspirates. As the sensitivity of gastric aspirates is only 20 to 40 percent
9 26
, these figures 
may under-represent the true proportion of acute pneumonia which may be due to MTB.  
 
Furthermore, a study conducted by Graham and co-workers in Malawi achieved a diagnosis 
of PTB in 6 percent of a cohort of infants presenting with Pneumocystis jiroveci 
pneumonia
27
. Although none of these tuberculosis cases were confirmed microbiologically, 
the diagnosis was inferred because of a history of a positive contact for tuberculosis and 
suggestive chest radiographic findings.  
 
In a retrospective review of cases admitted to a Durban hospital in 1998 and 1999, Jeena 
and co-workers demonstrated that 43 percent of a cohort of children with culture-confirmed 
tuberculosis had in fact presented acutely with symptom duration of less than 10 days. 
HIV-infected children were equally as likely as HIV-uninfected children to have presented 
with acute symptoms according to that study
15
. Additional work conducted in Durban in 
2002, in which 358 children under 5 years of age were enrolled in a prospective trial 
investigating the cause of their respiratory illness as well as their response to empiric 
management according to the World Health Organization (WHO) guideline for severe 
  6 
community-acquired pneumonia, identified culture-confirmed tuberculosis in 38 (15.7%) of 
242 HIV-infected and 15 (12.9%) of 116 HIV-uninfected participants: 45 (84.9%) of these 
children presented with symptoms of less than 2 weeks‟ duration25, providing further 
evidence to support the importance of acute presentations of childhood tuberculosis. 
 
Complicating the picture, however, is that a study conducted in Soweto at Chris Hani 
Baragwanath Hospital (CHBH)
28
 established that only 49 percent of children with 
bacteriologically-confirmed tuberculosis had been notified for this disease process and were 
started on antituberculous treatment. This may suggest that those children with culture-
confirmed PTB who were not notified improved because of possible spontaneous resolution 
of their disease
7
, albeit unlikely, or that the precipitating cause for hospitalisation in these 
children was a superimposed bacterial or viral infection which was successfully treated and 
resulted in clinical improvement, despite not treating the underlying tuberculosis disease. 
The long-term outcome of the children with culture-confirmed PTB who were not treated 
for their disease was not evaluated in that retrospective folder review. 
 
Streptococcus pneumoniae infections in children have been purported to be important 
immunological disruption trigger events, predisposing to progression from a state of LTBI 
to active tuberculosis
29
. Additional data that support the importance of acute presentations 
of PTB and its occurrence in the context of dual infections, particularly S. pneumoniae, are 
well described in the paediatric and adult medical literature: studies from sub-Saharan 
Africa, North America and Asia have highlighted the fact that PTB can present as acute 
community-acquired pneumonia in adult and paediatric patients, occasionally with bacterial 
co-infection 
30
 
31
 
32
 
33
 
34
 
35
 
36
 
37
 
38
. 
  7 
 
Adegbola and co-workers documented the occurrence of culture-confirmed tuberculosis in 
5 (3.1%) of 159 malnourished children presenting with radiologic evidence of pneumonia 
in The Gambia, one of these patients having confirmed dual infection with Haemophilus 
influenzae. None of the199 well-nourished children with pneumonia which had been 
enrolled in the study were found to have tuberculosis
30
.  
 
Echave and co-workers enrolled 140 children between the ages of 2 and 59 months in a 
prospective study in Senegal from March to May 2000 in order to describe the aetiology of 
paediatric acute community-acquired pneumonia in that setting. Pneumococcus and          
H. influenzae were the most frequently isolated organisms, being identified in 73 percent of 
the participants. Co-morbidities listed as conferring a poorer outcome in the cohort were 
tuberculosis, malaria, malnutrition and HIV infection
31
. 
 
Chintu et al. described autopsy findings confirming the presence of acute pyogenic 
pneumonia with tuberculosis co-infection in 12 children who died of respiratory illness at 
the University Teaching Hospital, Lusaka, Zambia between 1997 and 2000, highlighting 
the fact that this combination of co-infection was the most-frequently encountered one in 
the study cohort of 264 autopsy cases
32
. Tuberculosis was the fourth most common 
diagnosis made at autopsy after acute pyogenic pneumonia, P. jiroveci pneumonia and 
cytomegalovirus pneumonitis in this cohort of children, and was noted to occur commonly 
in all age groups, regardless of HIV-infection status
32
. 
 
  8 
A prospective study describing the aetiology of acute community-acquired pneumonia in 
522 adults admitted to a municipal-county hospital in Seattle from June 1994 to May 1996, 
identified MTB in 21 (5.1%) of 410 HIV-uninfected patients and 13 (11.6%) of 112 HIV-
infected patients
33
.  
 
Reporting on their experience in managing 281 adult patients who presented with acute 
pneumonia to two public hospitals in Kenya from 1994 to 1996, Scott and colleagues were 
able to identify a defined aetiology in 182 (64.8%) of their patients. Pneumococcus was the 
most frequently isolated infectious agent (identified in 46 percent of cases) but MTB was 
identified in 26 (9.3%) of the cases. Twelve patients had dual mycobacterial and 
pneumococcal infection in this series however the details of the mycobacterial isolates 
which were identified in co-infections are not fully described in that paper
34
. 
 
Nyamande and colleagues, reporting on the aetiology of acute community-acquired 
pneumonia (with mean symptom duration of 10 days) in a cohort of 430 adult patients 
admitted to a Durban hospital from June 2000 to October 2001, isolated MTB in 101 study 
participants (39.6 percent of the 255 positive isolates in their cohort): culture-confirmed 
tuberculosis was the most frequently identified cause of acute community-acquired 
pneumonia, regardless of HIV infection status, in this study. Pneumococcus (which 
accounted for 34.5 percent of the identified pathogens) was the second most frequently 
isolated organism. Thirty-four of the study participants had polymicrobial disease, 11 
(32.4%) of whom had co-infection with MTB and S. pneumoniae which was the most 
frequently encountered combination of pathogens in the patients with identified co-
infections
35
. 
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Schleicher and Feldman reported their experience in managing 9 HIV-infected adult 
patients with dual pneumococcal and MTB infection at the Johannesburg Hospital between 
January 1999 and March 2003: these patients presented with a „brief history of respiratory 
symptoms and fever‟, all had blood cultures positive for S. pneumoniae and  all of them had 
bacteriologically-confirmed tuberculosis. The authors recommended that a diagnosis of 
tuberculosis should be actively sought in HIV-infected adult patients in sub-Saharan Africa 
who present with acute community-acquired pneumonia
36
.  
 
A study from Korea which draws from a cohort of 1010 adult patients with 
bacteriologically-confirmed PTB, describes the radiological findings in 17 (1.7%) patients 
who presented with acute respiratory failure: all of these patients were HIV-uninfected and 
13 had underlying chronic disease processes (alcoholism, malnutrition, chronic liver 
disease or diabetes mellitus) which were likely contributors to the severity of symptoms at 
presentation and rapid progression of tuberculosis. Symptom duration in these patients 
ranged from 1 to 7 days (median 3 days) 
37
. Likewise, Wei and co-workers, reporting from 
Taiwan, describe the chest computed tomography findings in 46 HIV-uninfected adult 
patients who presented with acute pulmonary tuberculosis (symptom duration less than 3 
days in each case) and reiterate that underlying illnesses such as diabetes mellitus, 
malignancies, chronic renal failure and aplastic anaemia are important contributors to rapid 
disease progression in tuberculosis
38
. 
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1.6 The Use of Vaccines as Probes   
A novel manner in which the importance of bacterial co-infections in children with PTB 
can be evaluated is by using an efficacious vaccine, in the context of a double-blind placebo 
controlled trial, as a probe in order to elucidate the difference in incidence of PTB between 
vaccinees and placebo recipients. This strategy has been successfully adopted previously in 
determining the contribution of H. influenzae type b as a cause of radiologically-confirmed 
pneumonia in The Gambia
39
, as well as more recently in defining the minimal role of         
S. pneumoniae in hospitalisation for respiratory virus associated pneumonia
40
.  
 
The Gambian study, conducted by Mulholland and co-workers, indicated that at least 20 
percent of radiologically-confirmed pneumonia in a cohort of children enrolled in an         
H. influenzae type b vaccine trial was attributable to H. influenzae type b, despite the 
pathogen being infrequently isolated in blood cultures
39
.  
 
Madhi and Klugman, by using a 9-valent pneumococcal conjugate vaccine (PCV) as a 
probe, reported that at least 30 to 40 percent of severe viral-associated pneumonias occur in 
the context of concurrent pneumococcal infections despite pneumococcus being isolated 
from blood cultures in fewer than 5 percent of children with community-acquired 
pneumonia in which respiratory viruses were isolated. As the vaccine included only 9 of the 
91 currently-identified pneumococcal serotypes and only prevented 36 percent of all 
invasive pneumococcal disease, the true burden of pneumococcal co-infection in children 
with severe viral associated pneumonia may be even higher
40
. 
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In this study, a similar strategy of using the PCV as a probe was used to delineate the role 
of pneumococcal co-infections in children hospitalised for microbiologically-confirmed 
and/or clinically diagnosed tuberculosis.  
 
Furthermore, we used the clinical information that was systematically collected during the 
study to evaluate the usefulness of a widely-used tuberculosis scoring system in diagnosing 
tuberculosis among hospitalised children with culture-confirmed disease. Hospital-based 
surveillance of the study cohort, conducted over 5.3 years, also allowed for calculation of 
the incidence of MTB disease in the study participants. 
 
1.7 Aims and Objectives 
1.7.1 Primary objective 
To define the burden of tuberculosis (bacteriologically-confirmed, probable PTB, probable 
EPTB and suspected tuberculosis) in a cohort of HIV-infected and -uninfected children 
followed up over 5.3 years. 
 
1.7.2 Secondary objectives 
1. To define the contribution of pneumococcal co-infections on the burden of 
hospitalisation amongst children with bacteriologically-confirmed PTB and 
clinically diagnosed PTB using a double-blind, placebo-controlled trial of PCV as a 
probe. 
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2. To evaluate the sensitivity of the diagnostic algorithm utilised by the 2004 SANTP 
guidelines
19
 (Appendix 1, page 127) in diagnosing tuberculosis among HIV-
infected and -uninfected children hospitalised with culture-confirmed tuberculosis. 
 
3. To describe the clinical manifestations and outcomes of tuberculosis encountered in 
the study participants. 
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2.0 MATERIALS AND METHODS 
 
2.1 Study Site and Sample 
The Respiratory and Meningeal Pathogens Research Unit (RMPRU), a research unit 
affiliated with the University of the Witwatersrand, enrolled 39 836 infants from 2
nd
 March 
1998 to 30
th
 October 2000, with the primary objective of investigating the efficacy of a     
9-valent PCV in preventing invasive pneumococcal disease and pneumonia in a cohort of 
children resident in Soweto, Gauteng Province. Study participants were between 28 and 84 
days of age at enrolment, and were randomised to receive three doses of either a 9-valent 
PCV or placebo, together with other childhood vaccines including H. influenzae type b 
conjugate vaccine. All children were vaccinated with bacille Calmette-Guérin (BCG) at 
birth. The detailed demographic information and PCV composition details used in the study 
have been published 
40 41
 
42
.  
 
Information regarding illness in the participants was collected in a systematic manner (see 
Appendix 2, page 128) by RMPRU-affiliated staff. Blood cultures, nasopharyngeal 
aspirates for respiratory viruses and chest radiographs were performed on children 
hospitalised with lower respiratory tract infections. The clinical management of the children 
and the decision as to whether to investigate for tuberculosis was at the discretion of the 
attending physicians. Tuberculosis was diagnosed based on clinical and radiological 
suspicion or confirmed bacteriologically.  
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Most paediatric tuberculosis diagnoses made at CHBH are made in children admitted to the 
general paediatric wards where an approach utilising the collection of up to three gastric 
aspirates on three consecutive days (in an attempt  to attain a microbiological diagnosis of 
tuberculosis), is frequently adopted. As there was a possibility that not all PCV Study 
participants that had been diagnosed with tuberculosis had been identified as such in the 
PCV Study database, all of the participants admitted to the general paediatric wards at 
CHBH during the study surveillance period were included for the purposes of this report, 
and various sources (described in Section 2.3) were utilised in order to trace PCV Study 
participants whose tuberculosis diagnoses had not been identified in the PCV database. 
 
All PCV Study participants with a known discharge diagnosis of tuberculosis as extracted 
from the electronic PCV Study database by review of discharge diagnoses as recorded 
using International Classification of Disease, 9
th
 Revision (ICD-9) codes at the RMPRU 
(n=224, with 302 tuberculosis events recorded between them), formed a reference point 
from which other cases were sought.  
 
Study participants admitted to CHBH underwent HIV testing at the discretion of the 
attending physician and/or with parental consent according to the PCV Study protocol. 
Negative HIV status was confirmed by a negative enzyme-linked immunosorbent assay 
(ELISA) for HIV antibodies (Axsym system, HIV 1/2, Abbott) or by a negative HIV-1 
DNA polymerase chain reaction (PCR) assay (Amplicor
 
version 1.5, Roche) in children 
who were younger than 18 months of age and whose ELISA was reactive for HIV 
antibodies. 
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The prevalence of HIV infection in the study cohort was inferred to be 6.5 percent based 
upon the 24.9 percent prevailing prevalence of HIV among mothers attending antenatal 
clinics during the course of the study
43
 coupled with a vertical transmission rate of 26.0 
percent
44
. This figure was used to estimate the denominators for the number of HIV-
infected and HIV-uninfected children in the vaccinated and placebo groups (Table 1).   
 
 Sample size 
PCV group Placebo group Total 
Study sample 
population 
41
 
Intention-to-treat * 19 922 19 914 39 836 
HIV-uninfected 
40
 Intention-to-treat * 18 633 18 626 37 259 
Per-protocol 
+
 17356 17350 
 HIV-infected 
40
 Intention-to-treat * 1289 1288 2577 
Per-protocol 
+
 1201 1200 
Table 1: Pneumococcal conjugate vaccine trial randomisation, with projected HIV status in vaccinated 
and placebo groups 
 
*Intention-to-treat signifies all PCV efficacy trial participants, including those children who did not complete 
a full course (3 doses) of PCV or placebo. 
+
 Per-protocol signifies all children who completed 3 doses of PCV or placebo as per study schedule and in 
whom vaccine efficacy-related events occurred more than 14 days following the third dose of study vaccine. 
 
Surveillance for all-cause hospitalization among children that participated in the study 
continued until 31
st
 October 2006. 
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2.2 Ethics and Consent 
The PCV Study was approved by the Ethics Committee for research on Human Subjects of 
the University of the Witwatersrand. Signed informed consent was obtained from legal 
guardians of the children before their enrolment into the Study.  
 
Human Research Ethics Committee (Medical) of the University of the Witwatersrand 
granted permission for commencement of this Masters of Medicine (MMed) research report 
on 3
rd
 April 2006: Protocol M060344 (Appendix 3, page 130). 
 
2.3 Data Sources Used 
For the purposes of this MMed report, an Excel (Microsoft, Redmond, WA) database was 
developed by coalescing information from five data sources, the aim being to seek out as 
far as possible all tuberculosis diagnosis events amongst the PCV-efficacy trial participants 
that were evaluated at CHBH during the study surveillance period. Sources of data from 
which the database was compiled are listed below. 
 
1. The RMPRU PCV Study databases 
The electronic PCV Study database was used to source all admission events to the general 
paediatric wards at CHBH amongst Study participants during the period of surveillance, as 
well as all those with a discharge diagnosis of tuberculosis. Information relevant to the 
process by which tuberculosis diagnoses were made or excluded in the children as well as 
details regarding aspects of a family‟s or participant‟s past tuberculosis history was 
obtained through the PCV Study source documents. 
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2. The TB Care Centre database  
The TB Care Centre (TBCC) at CHBH was established in 2003 in response to the finding 
that only half of all patients who had been diagnosed with tuberculosis at the hospital 
attended the Soweto Clinics for continuation of their antituberculous therapy within two 
weeks of discharge, and that 21 percent did not access care at any Soweto clinic
45
.  
 
An electronic database has been maintained at the TBCC since November 2003, from 
which details of all children under 14 years of age (n=2546) registered at the TBCC from 
November 2003 to July 2006 were extracted. The MMed database and the paediatric data 
derived from the TBCC were compared in order to incorporate information regarding 
tuberculosis diagnoses amongst PCV Study participants which may not have been available 
from review of the RMPRU databases alone. 
 
3. Databases of the paediatric HIV clinics at CHBH  
Databases of the two paediatric HIV treatment clinics, namely Harriet Shezi Clinic and the 
Perinatal HIV Research Unit (PHRU), which supervise the outpatient follow-up of HIV-
infected children at CHBH, were utilised in order to ascertain if any of the HIV-infected 
PCV Study participants attending those clinics had been diagnosed with tuberculosis during 
the course of their HIV clinic follow-up. 
 
4. Notification booklets  
Notification booklets from the general paediatric wards and the paediatric outpatient 
department at CHBH were used in order to source additional PCV Study participants who 
were diagnosed with tuberculosis at the hospital. This was a particularly difficult source to 
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use as there is no central filing system for these booklets at CHBH. Booklets dating from 
before May 2002 were unobtainable, and many dated subsequent to 2002 were missing. If 
booklets were available, only patients who were at the anticipated age of the PCV Study 
participants at tuberculosis notification were evaluated (n=352): details were entered into 
an Excel database and these were merged against the MMed database.  
 
5. The National Health Laboratory Service databases  
The National Health Laboratory Service (NHLS) changed its data recording and retrieval 
system from the Apex system to the Disa system in 2000 and this posed difficulties when it 
came to retrieving data for children who had been investigated for tuberculosis prior to 
2000. PCV Study participant hospital identification numbers, derived from the participants‟ 
source documents, were used to retrieve data from the NHLS database. Positive 
tuberculosis microscopy and culture results were obtained and entered into the MMed 
database.  
 
Occasionally, study participants were investigated for tuberculosis at time points other than 
during hospitalisation. These represented occasions when clinical suspicion had prompted 
medical personnel to consider a diagnosis of tuberculosis in these children at hospital-based 
outpatient evaluations. The tuberculosis diagnostic algorithm could not be evaluated in 
such instances as there was no information regarding the child‟s clinical status or 
symptomatology at the time of specimen submission. 
 
The flow of data collection is summarised in Appendix 4 (page 131).  
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2.4 Categorisation of Children with Tuberculosis   
Children identified as having been diagnosed with tuberculosis during the course of the 
PCV Study surveillance period were classified using a modification of the WHO 
definitions for tuberculosis in children
46
 
47
 (Appendix 5, page 132) according to the 
strength of evidence available in arriving at a diagnosis of active tuberculosis in each case. 
 
1. Bacteriologically-confirmed tuberculosis: cases in which MTB was detected on 
smear or culture from secretions or tissues. This category of patients was further 
stratified into the following groups based on culture- or smear positivity and site of 
disease: 
 
a) Definite PTB: culture confirmation of disease caused by MTB where 
samples submitted for culture were derived from the respiratory tract. 
Specimens cultured included gastric aspirates or sputum. 
 
b) Definite EPTB: culture confirmation of disease caused by MTB where 
samples were derived from extra-pulmonary sites. Specimens cultured 
included blood, bone marrow, cerebrospinal fluid, pleural fluid or tissue. 
According to current convention, cases of definite EPTB in which 
respiratory specimens were also culture-positive for MTB, were categorised 
as definite PTB cases. 
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c) Confirmed PTB: microscopy of respiratory secretions (gastric aspirates and 
sputum specimens) positive for AFB but without culture confirmation.   
 
2. Probable tuberculosis: these cases were stratified into two groups according to the site 
of their disease: 
 
a) Probable PTB: children with a respiratory illness suggestive of PTB but 
without bacteriological confirmation of the disease process. Children with 
dual (probable) PTB and EPTB were classified as probable PTB cases 
according to current categorisation policy, because these cases (with 
respiratory involvement) may pose a public health risk for dissemination of 
MTB by the production of infectious droplet nuclei. 
 
b) Probable EPTB: those with histological evidence of tuberculous 
involvement of extrapulmonary sites, but without culture confirmation of 
tuberculosis.  
 
Both categories of probable tuberculosis patients fitted the WHO definition of suspected 
tuberculosis (see below), with additional evidence which strengthened the probability of the 
diagnosis. These included any of the following: 
 
i. A positive tuberculin skin test (TST), defined as being ≥ 5 mm in HIV-
infected or malnourished children and ≥ 10 mm in HIV-uninfected children; 
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ii. A suggestive chest radiograph (for the purposes of this study, this was 
defined as the presence of hilar adenopathy as this is the only radiographic 
finding featured for scoring by the tuberculosis score chart); 
iii. Suggestive histology; 
iv. A favourable response to anti-tuberculous therapy (defined for the purposes 
of this study as being any improvement in weight gain between the time of 
tuberculosis diagnosis and a subsequent hospitalisation where weight had 
been recorded in a child who had been started on anti-tuberculous therapy). 
 
3. Suspected tuberculosis: according to the WHO definition, this category applies to: 
 
a) Any ill child with a history of contact with a confirmed case of PTB, or  
 
b) Any child:  
 
i. Not regaining health after an episode of measles or pertussis; 
ii. With weight loss, cough or wheeze not responding to antibiotic therapy for 
a respiratory illness; 
iii. With painless swelling in a group of superficial lymph nodes. 
 
4. Same-episode tuberculosis: children with a previous diagnosis of tuberculosis who 
required hospitalisation within six months of that diagnosis (six months being the 
usual time period over which anti-tuberculous therapy is administered for drug-
susceptible disease), and who had been classified on the subsequent discharge as 
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having tuberculosis were included in this category. This classification was adopted in 
order not to over-estimate the number of tuberculosis episodes identified in the 
cohort. 
 
5. Recurrent tuberculosis: children who had a previous diagnosis of tuberculosis (more 
than six months previously) who were subsequently diagnosed with tuberculosis, 
regardless of HIV infection status. The exception to this rule were 2 cases of probable 
PTB, i.e. not bacteriologically confirmed, who were completing a course of anti-
tuberculous therapy but who had culture-confirmed disease at a point beyond 5 
months into the course of therapy for the previous episode of tuberculosis; whilst 
these may reflect failing therapy in children with drug-resistant disease, they were 
placed in this category in order to limit the number of disease categories. 
 
6. Untreated tuberculosis: children with bacteriological evidence of tuberculosis who 
were not diagnosed with the disease at hospital discharge as evidenced by review of 
the PCV source documents and who were not started on anti-tuberculous treatment 
based on review of the other data sources mentioned in Section 2.3. 
 
2.5 Assessment of the SANTP Tuberculosis Scoring System 
The SANTP Guidelines (2004) recommend the use of a scoring chart to guide clinical staff 
in achieving a diagnosis of tuberculosis in children
19
. The system is tabulated in Appendix 
1, page 127.  
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Parameters on patient history and examination as recorded in PCV study source documents 
were used to score participants using the tuberculosis scoring chart. The chart emphasises 
six general features and six local features which are scored in order to arrive at a threshold 
total score of at least 7 (the cut-off which suggests active tuberculosis according to the 
scoring system).  
 
General features, obtained from patient history, anthropometric evaluation and vital signs 
include: 
 
1. Duration of illness (for the purposes of this study, where clinical information was 
derived from study source documents only, duration of illness was taken to represent 
the duration of cough in days as reported to study investigators); 
2. Percentage of expected weight for age. Children who were born prematurely were 
scored according to their corrected weight for age, in order to minimise the effect of 
prematurity on age-related weight trends; 
3. Family history of tuberculosis; 
4. TST reaction; 
5. Response of poor weight gain to nutritional supplementation: response in weight in 
terms of mass (in kilograms) and percentile (as percentage of expected weight for age) 
were calculated in children who had multiple admission episodes with weights 
recorded in PCV Study source documents at each admission; 
6. Unexplained fever.  
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Local features (which screen for the presence of different forms of EPTB) include 
assessment for the presence of: 
 
1. Lymphadenitis;  
2. Arthritis; 
3. Features suggestive of abdominal tuberculosis;  
4. Features suggestive of TBM; 
5. Chest radiographic changes indicative of intrathoracic hilar adenitis;  
6. Spinal tuberculosis as evidenced by gibbus deformity on lateral chest radiograph. 
 
For the purposes of this study, where assessment of the sensitivity of the score chart was 
one of the research objectives, a potential confounding factor which would impact on the 
score sensitivity analysis would be that of scoring children where all parameters had not 
been fully assessed: if score sensitivity were routinely evaluated using few of the 
parameters, there would be a tendency for the score chart to under-perform. In order to 
achieve as accurate a score sensitivity evaluation as possible, only children with known 
HIV status whose score could be evaluated using at least 9 of the 12 parameters and whose 
score included the result of a TST, were assessed. 
 
Children were scored at the index tuberculosis admission episode if clinical data were 
available: children classified as having „same-episode tuberculosis‟ were not scored.  
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2.6 Statistical Analysis 
Anthropometric data were analysed using Epi Info version 6.04d (Centres for Disease 
Control and Prevention [CDC], Atlanta, Georgia, USA) to calculate weight-for-age           
z-scores (using 1978 CDC/WHO Growth Reference Curves) for study participants whose 
weight data was recorded in PCV Study source documents. 
 
Application of the „vaccine efficacy‟ calculation48 was made in order to derive the 
Incidence Rate Ratio (IRR)
49
 for tuberculosis between BCG-vaccinated HIV-infected and   
-uninfected children (Appendix 6, page 133); this was used to gauge the degree of risk 
which an HIV-affected immune system confers to a BCG-vaccinated child for developing 
active tuberculosis, relative to HIV-uninfected children. 
 
STATA version 9.2 (StataCorp LP, College Station, Texas, USA) was used for the 
following analyses:  
 
1. Measuring the relative burden of tuberculosis (all categories) in  HIV-infected 
compared to HIV-uninfected children using risk ratio methods; 
 
2. Probing the importance of pneumococcal co-infections in children hospitalised with 
tuberculosis by stratifying data based on PCV status and comparing the incidence 
rate of tuberculosis in vaccinees with that observed in placebo recipients; means and 
95 percent confidence intervals for disease incidences were calculated using the 
Poisson distribution. The importance of pneumococcal co-infections was attributed 
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based on the difference observed in the incidence of hospitalisation for tuberculosis 
between the PCV vaccinated and unvaccinated children. Data was also stratified by 
HIV infection status and the degree of certainty of the tuberculosis diagnosis; 
 
3. Sensitivity calculations relating to the SANTP diagnostic algorithm, calculated 
using standard methods
50
; 
 
4. Use of the unpaired Student‟s t test for continuous variables with normal 
distributions. Numerical variables with skewed distributions were analysed using 
the two-sample Wilcoxon rank-sum test;  
 
5. Analysis of categorical variables using the Pearson χ2 test. Fisher‟s exact test was 
used if the anticipated observation in any cell was less than or equal to 5.  
 
An α ≤ 0.05 was considered as being significant (all quoted P-values are two-tailed). 
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3.0 RESULTS 
 
3.1 The Spectrum of Tuberculosis Disease Encountered in the Study Cohort 
3.1.1 General demographics of tuberculosis cases 
Four hundred and twenty-five PCV Study participants were identified as ever having 
tuberculosis following admission to CHBH. Data sources from which patients with 
tuberculosis were identified are tabulated below (Table 2). 
 
Table 2: Data sources used, and yield of tuberculosis-related episodes from each source 
* Cases listed as having been identified through each data source are exclusive to each source,  
and have been tabulated once only. 
 
Two hundred and thirty-one (54.4%) first-episode tuberculosis cases arose in boys and 194 
(45.6%) occurred in girls.  
 
Data source utilised to identify 
tuberculosis cases arising in the 
PCV Study cohort 
PCV Study patient tuberculosis episodes 
identified at each data source * 
First tuberculosis 
diagnosis episodes: 
„incident episodes‟ 
All tuberculosis 
episodes 
1. PCV Study databases 332 375 
2. TBCC database 14 20 
3. (a). Harriet Shezi database  
 
3. (b). PHRU database  
11 
 
4 
13 
 
4 
4. Notification booklets 5 11 
5. NHLS database 
 
59 69 
Total number of tuberculosis episodes 
identified  
425 492 
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Two hundred and seventy-four (64.5%) of the children who had ever been diagnosed with 
tuberculosis were HIV-infected, 144 (33.9%) were HIV-uninfected and 7 (1.6%) had no 
definitive HIV result (Table 3).  
 
Median age at first tuberculosis episode was older in HIV-infected children (19.8 months: 
Interquartile Range [IQR] 7.7 – 44.3) compared to HIV-uninfected children (12.3 months: 
IQR 6.0 – 26.3), P<0.001, indicating that HIV-infected children had an ongoing risk 
beyond early childhood of developing active tuberculosis over HIV-uninfected children. 
 
3.1.2 Categorisation of tuberculosis cases by HIV status  
One hundred and eighteen (27.7%) of all first episode tuberculosis cases were confirmed 
bacteriologically, with no significant difference in rates of culture- (P=0.801) or smear-
positivity (P=0.351) between HIV-infected and -uninfected children. The proportions of the 
different categorisations of tuberculosis between HIV-infected and -uninfected children for 
definite tuberculosis, confirmed PTB and probable EPTB were similar (Table 3). HIV-
infected children were less likely to have been diagnosed with probable PTB (Odds Ratio 
[OR] 0.49; 95% Confidence Interval [CI], 0.31 – 0.78), P=0.001, and more likely to have 
been diagnosed with suspected tuberculosis (OR 2.00; 95% CI, 1.27 – 3.17), P=0.002, 
compared to HIV-uninfected children. When taking all episodes of tuberculosis into 
account, 141 (28.7%) of 492 episodes were bacteriologically confirmed. No significant 
difference in the yield of bacteriologically proven tuberculosis could be demonstrated 
between HIV-infected and -uninfected children when analysing for all tuberculosis 
episodes (Table 3).  
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Table 3: Proportions of tuberculosis episodes and categories according to HIV status 
 
 
 
 
 
 
Tuberculosis categories, 
n (%)* 
 
First episode of tuberculosis 
 
 
All tuberculosis episodes 
HIV-
infected 
HIV-
uninfected 
No HIV 
result 
Total P ** HIV-
infected 
HIV-
uninfected 
No HIV 
result 
Total P ** 
Definite PTB 58 (21.2) 28 (19.4)  0 (0.0) 86 (20.2) 
 
0.679 70 (21.0) 29 (19.2) 0 (0.0) 99 (20.1) 0.657 
Definite EPTB 5 (1.8) 3 (2.1) 0 (0.0) 8 (1.9) 1.000 
§
 6 (1.7) 3 (2.0) 0 (0.0) 9 (1.9) 1.000 
§
 
Confirmed PTB  15 (5.5) 8 (5.6) 1 (14.3) 24 (5.6) 
 
0.972 24 (7.2) 8 (5.3) 1 (14.3) 33 (6.7) 0.438 
Bacteriologically-
confirmed tuberculosis 
+
 
78 (28.5) 39 (27.1) 1 (14.3) 118 (27.7) 0.765 100 (29.9) 40 (26.5) 1 (14.3) 141 (28.7) 0.438 
Probable PTB  64 (23.4) 55 (38.2) 3 (42.8) 122 (28.7) 
 
0.001 75 (22.5) 58 (38.4) 3 (42.8) 136 (27.6) < 0.001 
Probable EPTB 13 (4.7) 10 (6.9) 2 (28.6) 25 (5.9) 
 
0.349 21 (6.3) 10 (6.6) 2 (28.6) 33 (6.7) 0.889 
Probable tuberculosis 
++
 77 (28.1) 65 (45.1) 5 (71.4) 147 (34.6) < 0.001 96 (28.8) 68 (45.0) 5 (71.4) 169 (34.3) < 0.001 
Suspected tuberculosis 119 (43.4) 40 (27.8) 1 (14.3) 160 (37.7) 0.002 138 (41.3) 43 (28.5) 1 (14.3) 182 (37.0) 0.007 
All tuberculosis 274 
§§
 
(100.0)  
144 
(100.0) 
7  
(100.0) 
425 
(100.0) 
 
- 334 
(100.0) 
151 
(100.0) 
7  
(100.0) 
492 
(100.0) 
- 
* Percentage (%) of cases in each category of tuberculosis, according to HIV status. 
  
** P-value derived by comparison of proportions of different tuberculosis categories in groups with known HIV status. 
+
 Bacteriologically-confirmed tuberculosis comprises „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases. 
++ Probable tuberculosis comprises „Probable PTB‟ and „Probable EPTB‟ cases.  § Fisher‟s exact test.  
§§ 
HIV-infected children contributed to 65.6% of all tuberculosis cases where a definitive HIV result was available in the analysis of „first-episode‟ tuberculosis. 
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Analysis of all tuberculosis episodes in the cohort by HIV status (Table 3) reiterates the 
findings that HIV-infected children were more likely to be diagnosed with suspected PTB 
than were HIV-uninfected children (OR 1.77; 95% CI, 1.15 – 2.75), P=0.007, and that 
HIV-uninfected children more frequently had a tuberculosis diagnosis which fulfilled 
criteria for classification as probable PTB (OR 2.15; 95% CI, 1.39 – 3.33), P<0.001.  
 
Figure 1: Classification of tuberculosis in children with defined HIV status: all tuberculosis episodes 
 
 
The proportions of children classified according to each tuberculosis diagnosis category are 
illustrated in Figure 1, above (7 tuberculosis episodes in children with undefined HIV 
status are not represented). In children with defined HIV status, PTB accounted for 427 
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(88.0%) of all cases (n=485), PTB with concomitant EPTB was encountered in 18 (3.8%) 
and EPTB occurred in 40 (8.2%) of all cases, with no significant difference in proportions 
of each type of disease when considering HIV status. Of these 485 episodes, 140 (28.9%) 
were bacteriologically confirmed (highlighted in yellow in Table 3). Of the confirmed 
cases 32 (22.9%) were smear positive alone and 108 (77.1%) were culture-confirmed. 
Culture-confirmation of tuberculosis was achieved in 108 (22.3%) of all tuberculosis cases 
identified (n=485) in the cohort of hospitalised children with known HIV status (Table 3). 
 
3.1.3 Categorisation of tuberculosis cases by PCV vaccination status 
Table 4 illustrates the proportions of tuberculosis encountered in children according to 
vaccination status (PCV versus placebo), and reveals that the PCV-vaccinated children had 
a significantly lower burden of culture-confirmed PTB than did the placebo recipients for 
first-episode tuberculosis episodes (OR 0.53; 95% CI 0.32 – 0.89), P=0.011.  
 
This analysis was not extended to include all tuberculosis episodes by vaccination status, as 
it would be expected that the vaccinated children would have had a lasting vaccination 
effect which would lead to a systematic bias in favour of PCV when conducting this 
comparison.  
 
This finding was not due to over-investigation of the placebo group or inability to retrieve 
laboratory results for PCV-vaccinated children, both of which sampling errors would lead 
to relatively poor detection rates of culture-confirmed tuberculosis in the PCV group 
compared to placebo recipients: median number of specimens sent for tuberculosis 
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microscopy and culture in the PCV recipients was 2 (IQR 0 – 3) versus 2 specimens     
(IQR 0 – 3) in the placebo group, P=0.388. Similarly, laboratory results were retrievable for 
171 (73.4%) of all 233 tuberculosis episodes identified in PCV recipients and 193 (74.5%) 
of all 259 tuberculosis episodes identified in placebo recipients with tuberculosis, P=0.776. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Proportions of tuberculosis episodes and categories according to PCV vaccination status: 
incident tuberculosis 
 
 
 
 
 
 
 
 
 
Tuberculosis categories, 
n (%)* 
 
First episode of tuberculosis 
 
PCV Placebo Total P ** 
Definite PTB 31 (15.1) 55 (25.0) 86 (20.2) 0.011 
Definite EPTB 2 (1.0) 6 (2.7) 8 (1.9) 0.287 
§
 
Confirmed PTB  14 (6.8) 10 (4.5) 24 (5.6) 0.308 
Bacteriologically-
confirmed tuberculosis 
+
 
47 (22.9) 71 (32.2) 118 (27.7) 0.032 
Probable PTB  60 (29.3) 62 (28.2) 122 (28.7) 0.805 
Probable EPTB 17 (8.3) 8 (3.7) 25 (5.9) 0.042 
Probable tuberculosis 
++
 77 (37.6) 70 (31.9) 147 (34.6) 0.214 
Suspected tuberculosis 81 (39.5) 79 (35.9) 160 (37.7) 0.444 
All tuberculosis 205 (100.0) 220 (100.0) 425 (100.0) - 
* Percentage (%) of cases in each category of tuberculosis, according to PCV vaccination status. 
** P-value derived by comparison of proportions of different tuberculosis categories in groups  
according to vaccination status. 
+
 Bacteriologically-confirmed tuberculosis comprises „Definite PTB‟, „Definite EPTB‟ and  
„Confirmed PTB‟ cases. 
++ Probable tuberculosis comprises „Probable PTB‟ and „Probable EPTB‟ cases. 
            
§
Fisher‟s exact test. 
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3.1.4 Recurrent tuberculosis episodes  
Seventy recurrent tuberculosis episodes
*
 occurred in 58 children: these occurred in 50 
(18.2%) of the 274 HIV-infected children who ever had tuberculosis compared to 8 (5.6%) 
of 144 HIV-uninfected children who ever had tuberculosis, (Risk Ratio [RR] 3.3; 95% CI, 
1.6 – 6.7), P<0.001.Whereas all of the HIV-uninfected children with tuberculosis 
recurrences had only one recurrent episode, 11 (22.0%) of the 50 HIV-infected children 
with recurrences had at least 2 recurrent episodes of tuberculosis (Table 5). Twenty-two 
(35.5%) of the 62 recurrent episodes amongst HIV-infected children were confirmed 
bacteriologically compared to 1 (12.5%) of 8 episodes in HIV-uninfected children (OR 3.9; 
95% CI, 0.4 – 181.2), P=0.257 (Fisher‟s exact test).  
 
Comparing between children according to HIV status, those who were HIV-infected more 
frequently developed recurrent tuberculosis after a previous episode of culture-confirmed 
tuberculosis (P=0.016, Fisher‟s exact test), whilst HIV-uninfected children developed a 
recurrent episode after a previous episode of probable PTB (P=0.030, Fisher‟s exact test) 
(Table 6). Thirteen (41.9%) of the 31 recurrent episodes which occurred subsequent to a 
previous bacteriologically-confirmed disease episode (in the initial tuberculosis episode or 
the recurrences) amongst HIV-infected children, were themselves bacteriologically-
confirmed. Extending this analysis to highlight culture-confirmed recurrences in cases with 
previous culture-confirmed tuberculosis, 5 (23.8%) culture-confirmed episodes arose 
subsequent to 21 episodes of culture-confirmed disease in the HIV-infected children. 
                                               
* Sixty-seven children had first and recurrent tuberculosis episodes diagnosed at CHBH; 3 (all HIV-infected) 
had the first episode of tuberculosis diagnosed in Soweto Clinics, and recurrences diagnosed at CHBH. 
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Table 5: Recurrent tuberculosis episodes according to HIV status 
 
 HIV-infected * HIV-uninfected * 
Tuberculosis 
episodes 
Initial episode 
of tuberculosis 
in children who 
had recurrent 
tuberculosis 
[n=50] 
1
st
 recurrent 
episode 
[n=50] 
2
nd
 recurrent 
episode 
[n=11] 
3
rd
 recurrent 
episode 
[n=1] 
Initial episode 
of tuberculosis 
in children who 
had recurrent 
tuberculosis 
[n=8] 
1
st
 recurrent 
episode 
[n=8] 
Definite 
tuberculosis, n (%) 
20 (39.0) 10 (20.0) 2 (18.2) 1 (100.0) 0 (0.0) 1 (12.5) 
Confirmed PTB,  
n (%) 
4 (8.0) 8 (18.0) 1 (9.1) 0 (0.0) 0 (0.0) 0 (0.0) 
Probable PTB,  
n (%) 
11 (22.0) 10 (20.0) 1 (9.1) 0 (0.0) 4 (50.0) 3 (37.5) 
Probable EPTB,  
n (%) 
0 (0.0) 6 (12.0) 2 (18.2) 0 (0.0) 1 (12.5) 0 (0.0) 
Suspected 
tuberculosis, n (%) 
15 (29.0)  16 (30.0) 5 (45.4) 0 (0.0) 3 (37.5) 4 (50.0) 
Total, n (%) 50 (100.0) 50 (100.0) 11 (100.0) 1 (100.0) 8 (100.0) 8 (100.0) 
* Columns represent the proportions of tuberculosis disease encountered at initial episode and each recurrence by category of tuberculosis. 
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Table 6: Categorisation of initial and recurrent tuberculosis episodes in children who were diagnosed with recurrent disease 
 
  
 
Initial tuberculosis episode in children 
who had recurrent tuberculosis 
Recurrent tuberculosis episodes 
1
st
  2
nd
  3
rd
  
n  
Confirmed 
n (%)  
Probable 
n (%) 
Suspected 
n (%) 
n  
Confirmed 
n (%) 
Probable 
n (%) 
Suspected 
n (%) 
n  
Confirmed 
n (%) 
Probable 
n (%) 
Suspected 
n (%) 
n  
Confirmed 
n (%) 
H
IV
-u
n
in
fe
ct
ed
 
Confirmed * 
n (%) 
8 
0 
(0.0) 
- - 
0 
- - - 
 
0 
 
- - - 
 
0 
 
- 
Probable 
n (%) 
- 5  
(62.5) 
- 
5 
1  
(12.5) 
3  
(37.5) 
1  
(12.5) 
- - - - 
Suspected 
n (%) 
- - 3  
(37.5) 
3 
- - 3  
(37.5) 
- - - - 
H
IV
-i
n
fe
ct
ed
 
Confirmed * 
n (%) 
50 
24  
(48.0) 
- - 
24 
11 
(22.0) 
8 
(16.0) 
5 
(10.0) 
5 
1 
(9.1) 
1 
(9.1) 
3 
(27.2) 
1 
1 
(100.0) 
Probable 
n (%) 
- 11 
(22.0) 
- 
11 
4 
(8.0) 
4 
(8.0) 
3 
(6.0) 
3 
1 
(9.1) 
1 
(9.1) 
1 
(9.1) 
0 
- 
Suspected 
n (%) 
- - 15 
(30.0) 
15 
3 
(6.0) 
4 
(8.0) 
8 
(16.0) 
3 
1 
(9.1) 
1 
(9.1) 
1 
(9.1) 
- 
P <0.001 
+
 0.016 
§
 0.030 
§
 0.694 
§
  
* „Confirmed‟ represents tuberculosis cases with bacteriologically-confirmed (culture- and/or smear-positive) disease. 
+
 P-value derived from proportions of children ever identified with tuberculosis: HIV-infected (n=274) and HIV-uninfected (n=144). 
§ 
Fisher‟s exact test: P-value is derived by comparison of proportions of recurrent tuberculosis according to HIV status. 
Numbers highlighted in RED represent recurrent tuberculosis episodes which arose subsequent to a previous bacteriologically-confirmed tuberculosis episode.   
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Median time between initial tuberculosis episode and first recurrence was 14.7 months          
(IQR 9.4 – 24.3) in HIV-infected children and 15.9 months (IQR 6.7 – 48.3) in HIV-uninfected 
children, P=0.793.  
 
Median time between first and second tuberculosis recurrence episodes in the HIV-infected 
children was 18.9 months (IQR 8.0 – 25.0). The time interval between the second and third 
tuberculosis recurrence episodes in the only child (HIV-infected) in the cohort that had 3 
tuberculosis recurrences after an initial episode of tuberculosis was 7.3 months. 
 
Time to tuberculosis recurrence in the HIV-infected children with previous bacteriologically-
confirmed tuberculosis was 16.1 months (IQR 8.4 – 23.4). Amongst HIV-infected children, 
median time to recurrence was significantly shorter in children who had a previous episode of 
smear-positive PTB (10.0 months; IQR 7.3 – 11.4) compared to those who had previous culture-
confirmed tuberculosis (19.0 months; IQR 8.5 – 26.8), P=0.039. 
 
3.1.5 Evaluation of the tuberculosis diagnostic algorithm 
Assessment of the tuberculosis score chart advocated for use by the 2004 SANTP Guidelines
19
       
(Appendix 1, page 127) was useful in gaining insight into the clinical characteristics of the 
children who had been identified as having active tuberculosis. 
 
Four hundred and fifty-four (93.6%) of the 485 identified tuberculosis episodes in children with 
known HIV status were scored using the diagnostic algorithm (Table 7): 401 (95.9%) of the 418 
first-episode cases and 53 (75.7%) of the 70 recurrent cases. Four hundred and forty-five 
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(98.0%) of the 454 scored episodes were evaluated by assessment of at least 9 of the 12 
parameters used by the scoring system: 165 (36.3%) of these were scored with the TST result as 
part of the assessment, and were therefore suitable for use in order to evaluate the sensitivity of 
the scoring system as per study criteria. 
 
Table 7: Proportions of children who were evaluated using the tuberculosis score chart according to HIV 
status: General Features 
 
* Expressed as a percentage of the number of admission episodes as tabulated in row 1. 
 
+ 
Expressed as a percentage of row 2. 
++ 
Expressed as a percentage of row 3. 
§ 
Fisher‟s exact test. 
 
A smaller proportion of HIV-infected children (304 [91.0%] of those who were diagnosed with 
tuberculosis) could be scored using the diagnostic algorithm compared to HIV-uninfected 
children (150 [99.3%] of those with tuberculosis), P<0.001, because clinical information 
regarding the tuberculosis diagnosis was not always available from the data sources used: this 
reflects the fact that HIV-infected children were either investigated for tuberculosis or had 
tuberculosis diagnoses made in outpatient settings e.g. paediatric HIV clinics at the hospital.  
 
 HIV-
infected 
HIV-
uninfected 
Odds Ratio  
(95% CI) 
P 
1. Tuberculosis episodes 334 151 - - 
2. Score assessed, n (%) * 304  
(91.0) 
150  
(99.3) 
0.07 
(0.001 – 0.42) 
< 0.001  
3. Score with ≥ 9 parameters, 
n (%) 
+
 
296  
(97.4) 
149  
(99.3) 
0.25 
(0.01 – 1.89) 
0.283 
§
 
4. Score with ≥ 9 parameters 
(including TST), n (%) 
++
 
85  
(28.7) 
80  
(53.7) 
0.35 
(0.23 – 0.53) 
< 0.001 
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3.1.5.1     Scoring „General Features‟ – all tuberculosis episodes 
Three hundred and eighty-five (85.9%) of 448 children with defined HIV status who were 
diagnosed with tuberculosis and had been scored presented with an acute duration (< 2 weeks) of 
cough: median cough duration was 4 days (IQR 2 – 7) in HIV-infected and -uninfected children, 
P=0.725. In children with PTB, 199 (80.6%) of 247 cases in the HIV-infected and 98 (88.3%) of 
111 cases in the HIV-uninfected presented with a cough duration of less than 14 days‟ duration 
(P=0.072). 
 
 HIV-infected children with tuberculosis were 2.40 times more likely to be underweight       
(95% CI, 1.56 – 3.71), P<0.001 and 9.84 times more frequently assessed as being marasmic 
(95% CI, 3.88 – 31.80), P<0.001 than were HIV-uninfected children (Table 8).  
 
There was no significant difference in the proportions of tuberculosis cases with a family history 
of tuberculosis according to HIV status: absence of a positive family history of tuberculosis was 
noted in 221 (72.9%) of 303 HIV-infected children diagnosed with tuberculosis in whom a 
history of family contact was enquired about, compared to 105 (70.5%) of 149 HIV-uninfected 
children, P=0.582. 
 
 HIV-infected children diagnosed with tuberculosis were more likely to exhibit TST anergy 
compared to HIV-uninfected children (OR 8.56; 95% CI, 3.83 – 19.44), P<0.001. TST responses 
in all children diagnosed with tuberculosis that were tested using the Mantoux method are 
reflected in Figures 2 and 3. Median TST induration was 0 mm (Range 0 – 25) in HIV-infected 
and 15 mm (Range 0 – 25) in HIV-uninfected children, P<0.001.  
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Parameter Score HIV-infected HIV-uninfected Odds Ratio (95% CI) P 
Weeks of illness score, 
n (%) 
0 251 (84.0)  
n=299 
134 (89.9)  
n=149 
0.59 (0.29 – 1.11) 0.086 
1 27 (9.0) 11 (7.4) 1.25 (0.58 – 2.87) 0.555 
3 21 (7.0) 4 (2.7) 2.74 (0.90 – 11.16) 0.059  
Nutrition score, n (%) 0 62 (20.9)  
n=297 
95 (64.2)   
n=148 
0.15 (0.09 – 0.23) < 0.001 
1 159 (53.5) 48 (32.4) 2.40 (1.56 – 3.71) < 0.001 
3 76 (25.6) 5 (3.4) 9.84 (3.88 – 31.80) < 0.001  
Family history of 
tuberculosis score,  
n (%) 
0 221 (72.9)  
n=303 
105 (70.5)  
n=149 
1.13 (0.71 – 1.78) 0.582 
1 81 (26.8) 43 (28.9) 0.90 (0.57 – 1.43) 0.634 
3 1 (0.3) 1 (0.6) 0.49 (0.01 – 38.72) 0.551 §  
TST Score, n (%) 0  69  (81.2) 
n=85 
25 (31.2) 
n=80 
9.49 (4.37 – 20.90) < 0.001 
3  16 (18.8) 55 (68.8) 0.11 (0.05 – 0.23) < 0.001 
Malnutrition (weight) 
not improving score,  
n (%) 
 
3 
 
55 (39.9) 
 
n=138 
 
4 (11.8) 
 
n=34 
 
4.97 (1.61  – 20.34) 
 
0.002   
Malnutrition (centile) 
not improving score,  
n (%) 
3 
 
89 (65.4) 
 
n=136 
 
16 (47.1) 
 
n=34 
 
2.13 (0.93 – 4.90) 
 
0.049 
Fever Score, n (%) 2 10 (71.4) n=14 3 (50.0) n=6 2.5 (0.22 – 27.07) 0.613 § 
Table 8: General Features as scored in PCV Study participants with tuberculosis 
§
 Fisher‟s exact test.
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Figure 2: TST responses in children with defined HIV status who were diagnosed with 
tuberculosis, inclusive of anergic TST responses 
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Figure 3: TST responses in children with defined HIV status who were diagnosed with 
tuberculosis, omitting anergic TST responses 
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Analysis of TST induration with exclusion of all negative responses was performed in order 
to determine the degree of „reactivity‟ of the TST in the two groups, according to HIV 
status (Figure 3). Although the HIV-infected children had less TST-induced induration 
compared to HIV-uninfected children, with a mean positive induration diameter of         
11.1 mm (Standard Deviation [SD] 6.3; Range 7.6 – 14.6) compared to 16.5 mm (SD 3.6; 
Range 15.4 – 17.6) in the HIV-uninfected children, P<0.001, it is important to emphasise 
that the mean induration size in HIV-infected children was nevertheless ≥ 10 mm. 
 
When analysing for „weight not improving‟, HIV-infected children were 5 times (95% CI, 
1.61 – 20.34) more likely not to have exhibited weight gain compared to HIV-uninfected 
children, P=0.002. When analysing for „centile not improving‟ HIV-infected children were 
twice (95% CI, 0.93 – 4.90) as likely not to have exhibited an improvement in their weight-
for-age centiles compared to HIV-uninfected children, P=0.049. Mean weight-for-age       
z-scores were significantly reduced in HIV-infected children diagnosed with tuberculosis     
(-2.80, SD 1.36) compared to HIV-uninfected children (-1.23, SD 1.39), P<0.001. 
 
There was no significant difference in fever duration between HIV-infected and -uninfected 
children diagnosed with tuberculosis, P=0.613 (Fisher‟s exact test). 
 
3.1.5.2     Scoring „Local Features‟ – all tuberculosis episodes 
The only local feature which exhibited a significant difference between HIV-infected and   
-uninfected children diagnosed with tuberculosis was that of lymphadenopathy: this feature 
was encountered 5-fold more frequently (95% CI, 3.34 – 8.84) in the HIV-infected children 
compared to HIV-uninfected children, P<0.001 (Table 9). 
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 Table 9: Local Features as scored in PCV Study participants with tuberculosis 
 
* Expressed as a percentage of Row 1.  + Expressed as a percentage of Row 2.  
§
 Fisher‟s exact test.
Parameter Score HIV-infected 
 
HIV-uninfected 
 
Odds Ratio  
(95% CI) 
P 
1. Tuberculosis episodes - 334 151 - - 
2. Local features assessed,  
n (%) * 
- 
299 (89.5) 149 (98.7) 0.11 (0.01 – 0.46) < 0.001 
Lymphadenopathy,  
n (%) 
+ 
 
3 258 (86.3) 80 (53.7) 5.43 (3.34 – 8.84) < 0.001 
Joint or bone swelling,  
n (%) 
+
 
3 
 
1 (0.3) 1 (0.7) 0.50 (0.01 – 39.24) 1.000 § 
Abdominal mass or ascites, 
n (%) 
+
 
3 3 (1.0) 5 (3.4) 0.29 (0.04 – 1.53) 0.123 § 
CNS signs or abnormal 
CSF, n (%) 
+
 
3 
 
33 (11.0) 13 (8.7) 1.30 (0.64 – 2.78) 0.448 
Hilar adenopathy on chest 
radiograph, n (%) 
+
 
3 
 
44 (14.7) 17 (11.4) 1.34 (0.72 – 2.60) 0.336 
Angle deformity of spine,  
n (%) 
+
 
4 1 (0.3) 0 (0.0) - 1.000 
§
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3.1.5.3     Scoring „General‟ and „Local‟ Features in cases with culture-confirmed      
tuberculosis 
When assessing the clinical parameters of children who had definite tuberculosis       
(Table 10), 56 (77.8%) of 72 children with culture-confirmed PTB presented with an acute 
duration of cough.  
 
Family history of tuberculosis was equally encountered in children with culture-confirmed 
disease, regardless of HIV status (P=0.987). 
 
Median TST induration was 0 mm in children with culture-confirmed tuberculosis, 
regardless of HIV status (P=0.792). Seven (17.5%) of 40 children with definite tuberculosis 
who had a TST (five of them HIV-uninfected) had reactive TST responses.  
 
HIV-infected children were 2.8 times (95% CI, 1.1 – 7.5), more likely to be underweight 
than were HIV-uninfected children, P=0.021, although there was no significant difference 
in proportions of marasmic children with culture-confirmed disease by HIV status          
(OR 2.5; 95% CI, 0.6 – 14.5), P=0.248 (Fisher‟s exact test). Poor weight gain (P=0.212, 
Fisher‟s exact test) and failure to thrive (P=1.000, Fisher‟s exact test) were observed with 
equal frequency in HIV-infected and -uninfected children with definite tuberculosis. 
 
As was demonstrated in the scoring of „Local Features‟ in all tuberculosis cases, the only 
finding on clinical examination of HIV-infected children which was consistently 
encountered over HIV-uninfected children, was that of lymphadenopathy (OR 15.8; 95% 
CI, 4.7 – 57.1), P<0.001. 
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Parameter HIV-infected 
n (%) 
HIV-uninfected 
n (%) 
OR 
(95% CI) 
P 
PTB cough duration 
less than 14 days 
41 (78.8) n=52 15 (75.0) n=20 1.2 (0.3 – 4.7) 0.757 § 
Median duration of 
cough (IQR) 
4 days 
(2 – 7) 
4 days 
(3 – 7) 
- 0.652 
Underweight 38 (59.4) 
n=64 
11 (34.4) 
n=32 
2.8 (1.1 – 7.5) 0.021 
Marasmic 13 (20.3) 3 (9.4) 2.5 (0.6 – 14.5) 0.248 § 
Mean  
weight-for-age  
z-score (SD)  
- 2.62 ± 1.23 - 1.37 ± 1.57 - <0.001 
Family history of 
tuberculosis 
15 (22.7) n=66 7 (22.6) n=31 1.0 (0.3 – 3.3) 0.987 
Median TST 
response (Range) 
0  
(0 – 15) 
0  
(0 – 22) 
- 0.792 
No improvement in 
nutritional status  
Weight * 
11 (44.0) 
n=25 
Weight * 
1 (14.3) 
n=7 
4.7 (0.4 – 236.2) 0.212 § 
Centile ** 
16 (64.0) 
Centile ** 
5 (71.4) 
0.7 (0.1 – 5.6) 1.000 § 
Fever - n=0 - n=0 - - 
Lymphadenopathy 60 (90.9) 
n=66 
12 (38.7) 
n=31 
15.8 (4.7 – 57.1) <0.001 
Bone involvement 0 (0.0) 0 (0.0) - - 
Abdominal signs 2 (3.0) 3 (9.7) 0.3 (0.0 – 2.7) 0.323 §  
CNS signs 11 (16.7) 3 (9.7) 1.9 (0.4 – 11.2) 0.538 § 
X-ray changes 9 (13.6) 3 (9.7) 1.5 (0.3 – 9.1) 0.747 § 
Spine changes 0 (0.0) 0 (0.0) - - 
Table 10: Scoring clinical parameters for children with culture-confirmed tuberculosis 
 
  
 
 
 
* „Weight‟ reflects no improvement or a decline in weight (in kilograms) between a  
previous admission episode and the admission episode in which tuberculosis was diagnosed.  
** „Centile‟ reflects a downward trend on weight-for-age growth reference curves between a previous admission 
episode and the admission episode in which tuberculosis was diagnosed.  
§
 Fisher‟s exact test. 
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3.1.5.4     Sensitivity of the diagnostic algorithm 
Sensitivity of the algorithm in terms of substantiating a diagnosis of tuberculosis in the 
cohort is explored in Table 11. The sensitivity analyses were conducted by identifying 
those tuberculosis episodes which were scored and attained a score of at least 7 (the cut-off 
for positivity according to the algorithm) and calculating what proportion those cases 
contributed to the total number of tuberculosis episodes which were scored in each disease 
category. This analysis was conducted using only those patients who had been scored using 
at least 9 of the 12 parameters stipulated in the algorithm and in whom the TST was 
included as part of the tuberculosis diagnostic work-up. From Table 7, 85 HIV-infected 
and 80 HIV-uninfected children fulfilled the criteria for this analysis. 
 
Forty instances of definite tuberculosis (culture-proven cases) were scored using at least 9 
parameters, including the TST. The score equalled or exceeded the cut-off value of 7 in 15 
(37.5%; 95% CI, 22.7 – 54.2) of the 40 culture-positive tuberculosis episodes, i.e. 
sensitivity of the score was 37.5 percent for culture-confirmed tuberculosis in this cohort     
(Table 11). 
 
The scoring system was not superior in sensitivity in HIV-infected children compared to 
HIV-uninfected children when analysing for all forms of tuberculosis: overall, a score 
compatible with a clinical diagnosis of tuberculosis (according to the score chart criteria) 
was achieved in HIV-infected children as frequently as in HIV-uninfected children        
(OR 1.05; 95% CI, 0.54 – 2.05), P=0.878.
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Table 11: Sensitivity of the diagnostic score chart in instances where a diagnosis of tuberculosis was achieved 
 All children with  
defined HIV status 
HIV-infected HIV-uninfected Odds Ratio 
(95% CI) 
P 
Score  
≥ 7 
All 
cases
*
 
Sensitivity (%) 
(95% CI) 
Score  
≥ 7 
All 
cases
*
 
Sensitivity (%) 
(95% CI) 
Score  
≥ 7 
All 
cases
*
 
Sensitivity (%) 
(95% CI) 
Definite 
tuberculosis 
15 40 37.5 
(22.7 – 54.2) 
8 23 34.8 
(16.4 – 57.3) 
7 17 41.2 
(18.4 – 67.1) 
0.76 
(0.17 – 3.38) 
0.680 
Confirmed PTB 2 8 25.0 
(3.2 – 65.1) 
1 4 25.0 
(0.6 – 80.6) 
1 4 25.0 
(6.3 – 80.6) 
1.00 
(0.01 – 104.37) 
1.000 
§ 
 
Bacteriologically
-confirmed 
tuberculosis 
17 48 35.4 
(22.2 – 50.5) 
9 27 33.3 
(16.5 – 54.0) 
8 21 38.1 
(18.1 – 61.6) 
0.81 
(0.21 – 3.17) 
0.732 
Probable 
PTB 
38 76 50.0 
(38.3 – 61.7) 
17 26 65.4 
(44.3 – 82.8) 
21 50 42.0 
(28.2 – 56.8) 
2.61 
(0.88 – 7.95) 
0.053 
Probable EPTB 6 8 75.0 
(34.9 – 96.8) 
3 5 60.0 
(14.7 – 94.7) 
3 3 100.0 
(29.2 – 100.0) 
- 0.464 
§
 
Suspected 
tuberculosis 
6 33 18.2 
(7.0 – 35.5) 
6 27 22.2 
(8.6 – 42.3) 
0 6 0.0 
(0.0 – 45.9) 
- 0.563 
§
  
All tuberculosis 67 165 40.6 
(33.0 – 48.5) 
35 85 41.2 
(30.6 – 52.4) 
32 80 40.0 
(29.2 – 51.6) 
1.05 
(0.54 – 2.05) 
0.878 
*
 Denominators are tuberculosis cases which were scored according to the diagnostic algorithm in children with defined HIV status,  
where at least 9 of the parameters (including the TST) were scored. 
§
 Fisher‟s exact test. 
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3.1.5.5     Comparison of the sensitivities of the algorithm and the Mantoux test 
It is interesting to compare the sensitivity of the diagnostic algorithm with the sensitivity of 
the TST response in the children who were subjected to tuberculin skin testing: 71 positive 
TST responses occurred in 165 children with defined HIV status who were diagnosed with 
tuberculosis and were tested using the Mantoux method (Table 12). The sensitivity of the 
TST in HIV-infected children (2 positive TSTs out of 27 bacteriologically-confirmed 
tuberculosis episodes that were screened with TST) was 7.4 percent (95% CI, 0.9 – 24.3) 
compared to 38.1 percent (8 positive TSTs out of 21 bacteriologically-confirmed 
tuberculosis episodes where TST results were available: 95% CI, 18.1 – 61.6) in HIV-
uninfected children.  
 
TST anergy in children with bacteriologically-confirmed tuberculosis was 3-fold (95% CI, 
0.49 – 22.46) more frequent in HIV-infected children, P=0.235 (Fisher‟s exact test), 
although small sample size failed to secure statistical significance in this analysis. 
 
Overall, sensitivity of the TST was significantly greater in HIV-uninfected compared to 
HIV-infected children (68.8 versus 18.8 percent: OR 9.49; 95% CI 4.37 – 20.90), P<0.001.  
 
A comparison of the sensitivities of the tuberculosis score chart and the TST in children 
according to tuberculosis disease category and HIV status is tabulated below (Table 13): 
this indicates that the tuberculosis score chart sensitivity was significantly better than the 
TST sensitivity in HIV-infected children with bacteriologically-confirmed tuberculosis 
(P=0.039, Fisher‟s exact test) and suggests that the score chart may be of use in augmenting 
the sensitivity of TST in providing evidence for tuberculosis in HIV-infected children.
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Table 12: TST responses in HIV-infected and HIV-uninfected children by tuberculosis category in those who were scored using at least nine parameters 
 
§ 
Fisher‟s exact test.
 All children HIV-infected HIV-uninfected Odds Ratio 
(95% CI) 
P 
TST 
Pos 
All 
cases 
Sensitivity (%) 
(95% CI) 
TST 
Pos 
All 
cases 
Sensitivity (%) 
(95% CI) 
TST  
Pos 
All 
cases 
Sensitivity 
(%) 
(95% CI) 
Definite 
tuberculosis 
7 40 17.5 
(7.3 – 32.8) 
2 23 8.7 
(1.1 – 28.0) 
5 17 29.4 
(10.3 – 56.0) 
0.23 
(0.02 – 1.73) 
0.113 
§
 
Confirmed PTB 3 8 37.5 
(8.5 – 75.5) 
0 4 0.0 
(0.0 – 60.2) 
3 4 75.0 
(19.4 – 99.4) 
- 0.143 
§
 
Bacteriologically
-confirmed 
tuberculosis 
10 48 20.8 
(10.5 – 35.0) 
2 27 7.4 
(0.9 – 24.3) 
8 21 38.1 
(18.1 – 61.6) 
0.13 
(0.01 – 0.82) 
0.014 
§
 
Probable PTB 57 76 75.0 
(63.7 – 84.2) 
13 26 50.0 
(29.9 – 70.1) 
44 50 88.0 
(75.7 – 95.5) 
0.14 
(0.04 – 0.49) 
<0.001 
§
 
Probable EPTB 4 8 50.0 
(15.7 – 84.3) 
1 5 20.0 
(0.5 – 71.6) 
3 3 100.0 
(29.2 – 100.0) 
- 0.143 
§
 
Suspected 
tuberculosis 
0 33 0.0 
(0.0 – 10.6) 
0 27 0.0 
(0.0 – 12.8) 
0 6 0.0 
(0.0 – 45.9) 
- - 
All tuberculosis 71 165 43.0 
(35.4 – 51.0) 
16 85 18.8 
(11.2 – 28.8) 
55 80 68.8 
(57.4 – 78.7) 
0.11 
(0.05 – 0.23) 
<0.001 
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Table 13: Comparison between sensitivities of the tuberculosis score chart and TST by HIV status 
 
§
 Fisher‟s exact test. 
 HIV-infected HIV-uninfected 
Tuberculosis Score 
Chart 
TST P Tuberculosis Score 
Chart 
TST P 
Score ≥ 7 Sensitivity 
(%) 
TST Pos Sensitivity 
(%) 
Score ≥ 7 Sensitivity 
(%) 
TST Pos Sensitivity 
(%) 
Definite 
tuberculosis 
8 / 23 34.8 2 / 23 8.7 0.071 
§
 7 / 17 41.2 5 / 17 29.4 0.473  
Confirmed PTB 1 / 4 25.0 0 / 4 0.0 1.000 
§
 1 / 4 25.0 3 / 4 75.0 0.486 
§
 
Bacteriologically
-confirmed 
tuberculosis 
9 / 27 33.3 2 / 27 7.4 0.039 
§
 8 / 21 38.1 8 / 21 38.1 1.000 
Probable PTB 17 / 26 65.4 13 / 26 50.0 0.262 21 / 50 42.0 44 / 50 88.0 < 0.001  
Probable EPTB 3 / 5 60.0 1 / 5 20.0 0.524 
§
 3 / 3 100.0 3 / 3 100.0 - 
Suspected 
tuberculosis 
6 / 27 22.2 0 / 27 0.0 0.023 
§
 0 / 6 0.0 0 / 6 0.0 - 
All tuberculosis 35 / 85 41.2 16 / 85 18.8 0.002 32 / 80 40.0 55 / 80 68.8 < 0.001  
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3.1.6  Cases with an untreated episode of bacteriologically-confirmed tuberculosis 
Anti-tuberculous therapy was not started in 62 (44.0%) of all bacteriologically-confirmed 
(n=141) episodes of tuberculosis, as evidenced by the finding of culture- or smear-positive 
disease in instances where children had been discharged from CHBH without a diagnosis of 
tuberculosis and ancillary data sources failed to confirm that the child had been started on 
appropriate therapy. These episodes occurred in 61 children, one of whom (an HIV-infected 
male) had a second episode of culture-confirmed tuberculosis in which treatment was 
delayed, 13 months after the initial untreated episode; he appears not to have been treated 
for tuberculosis in the period intervening between these tuberculosis episodes. 
 
Fifty-four (87.1%) of the 62 episodes with untreated bacteriologically-proven tuberculosis 
had culture-proven disease and 8 (12.9%) had smear-positive disease without culture-
confirmation.  
 
Instances where cases with bacteriologically-confirmed disease were not started on anti-
tuberculous therapy occurred with equal frequency in the HIV-infected and -uninfected 
children: 44 (16.1%) of the 274 HIV-infected children ever diagnosed with tuberculosis and 
17 (11.8%) of the 144 HIV-uninfected children with tuberculosis had an untreated episode 
of bacteriologically-confirmed disease (OR 1.43; 95% CI, 0.76 – 2.78), P=0.242. The 
results of this analysis held firm when defining the relative proportions of untreated 
bacteriologically-confirmed tuberculosis by HIV status, where 45 (45.0%) of the 100 HIV-
infected children with bacteriologically-confirmed episodes of tuberculosis and 17 (42.5%) 
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of the 40 HIV-uninfected children with bacteriologically-confirmed episodes remained 
untreated for their condition (OR 1.11; 95% CI, 0.50 – 2.50), P=0.788. 
 
Vaccination status also did not differ significantly amongst children who had untreated 
bacteriologically-confirmed disease, with 25 (44.6%) of the 56 PCV recipients with 
bacteriologically-confirmed disease and 37 (43.5%) of the 85 placebo recipients who were 
diagnosed with bacteriologically-confirmed tuberculosis remaining untreated for their 
condition (OR 1.05; 95% CI, 0.50 – 2.18), P=0.896. When limiting the analysis by 
vaccination and HIV status to untreated children who had bacteriologically-confirmed PTB 
(n=56), 14 (28.6%) of the 49 bacteriologically-confirmed PTB episodes in HIV-infected 
children who had received PCV and 27 (54.0%) of the 50 such PTB episodes in HIV-
infected children who had received placebo had untreated bacteriologically-confirmed PTB 
(OR 0.34; 95% CI, 0.14 – 0.85), P=0.010, indicating that HIV-infected PCV recipients 
were significantly less likely than placebo recipients to remain untreated for 
bacteriologically-confirmed PTB. Contrary to this finding, HIV-uninfected PCV recipients 
had significantly more episodes of untreated bacteriologically-confirmed PTB than did the 
HIV-uninfected placebo recipients, with 10 (62.5%) of 16 bacteriologically-confirmed PTB 
episodes remaining untreated compared to 5 (23.8%) of 21 such PTB episodes amongst 
placebo recipients (OR 5.33; 95% CI, 1.06 – 28.35), P=0.018.  
 
Seven (11.5%) of the 61 children who had bacteriologically-proven tuberculosis but who 
were not started on anti-tuberculous therapy died during the admission episode (Table 14): 
5 were HIV-infected (4 had CDC Category C disease and the remaining child was 
classified as having CDC Category B disease) and 2 were HIV-uninfected. Median age at 
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admission in the children who died was 10.0 months (IQR 2.5 – 20.7) with no significant 
difference in age at admission between HIV-infected (5.7 months, IQR 2.5 – 15.4) and        
-uninfected children (15.3 months, IQR 10.0 – 20.7), P=0.439. These children presented 
with mean cough duration of 3.9 days (SD 1.8). HIV-infected children who died with 
untreated bacteriologically-confirmed tuberculosis had significantly shorter duration of 
cough (3.0 days, SD 1.0) compared to the HIV-uninfected children (6.0 days, SD 1.4), 
P=0.022. Median duration of admission to time of death was 4.0 days (IQR 1.0 – 13.0). 
Diagnosis at death in 5 of the children was pneumonia (4 of these children were HIV-
infected with suspected P. jiroveci pneumonia: none of these had microbiological evidence 
to support that diagnosis). Diagnoses at death in the two remaining children were 
meningitis (in the HIV-infected child) and lymphoma with tumour lysis syndrome (in the 
HIV-uninfected child). 
 
Twenty-one (34.4%) of the 61 children with untreated bacteriologically-confirmed 
tuberculosis were never readmitted to CHBH, and have unknown outcomes. Eleven 
(52.4%) of these children were HIV-infected (14.5 months, IQR 3.4 – 29.4) and 10 (47.6%) 
were HIV-uninfected (5.1 months, IQR 3.1 – 12.3), P=0.073. Ten (90.9%) of the HIV-
infected children had been assessed by CDC categorisation of their HIV disease: 7 were 
CDC Category C patients, and 1 each was classified as having CDC Category N, A and B 
HIV disease. Median duration of cough in these patients was 3.0 days (IQR 2.0 – 6.0): 
shorter in the HIV-uninfected children (2.0 days, IQR 1.0 – 3.5) than in the HIV-infected 
children (3.0 days, IQR 3.0 – 7.0), P=0.045. 
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 All untreated episodes 
 
[n=62] 
Untreated  episodes that 
died  
[n=7] 
Untreated  episodes that 
were lost to follow-up 
[n=21] 
Untreated  episodes that 
were followed up 
[n=34] 
HIV status,  
n (%) 
HIV-infected 45 / 100 (45.0) * 5 / 45 (11.1) 
+
 11 / 45 (24.4) 
+
 29 / 45 (64.4) 
+
 
HIV-uninfected 17 / 40 (42.5) * 2 / 17 (11.8) 
+
 10 / 17 (58.8) 
+
 5 / 17 (29.4) 
+
 
OR (95% CI) 1.11 (0.50 – 2.50) 0.94 (0.13 – 10.86) 0.23 (0.06 – 0.86) 4.35 (1.14 – 18.30) 
P 0.788 1.000 
§
 0.011 0.013  
Age at 
admission 
(months) 
All 14.1 (IQR 5.4 – 39.1) 10.0 (IQR 2.5 – 20.7) 8.1 (IQR 3.4 – 14.5) 24.7 (IQR 7.6 – 52.2) 
HIV-infected 22.6 (IQR 5.6 – 45.1) 5.7 (IQR 2.5 – 15.4) 14.5 (IQR 3.4 – 29.4) 31.3 (IQR 6.3 – 52.7) 
HIV-uninfected 10.0 (IQR 3.5 – 14.0) 15.3 (IQR 10.0 – 20.7) 5.1 (IQR 3.1 – 12.3) 14.2 (IQR 10.2 – 18.8) 
P 0.028 0.439 0.073 0.395 
Cough 
duration  
(days) 
All  3.5 (IQR 2.0 – 7.0) 3.9 (SD ± 1.8) 3.0 (IQR 2.0 – 6.0) 4.0 (IQR 2.0 – 7.0) 
HIV-infected 4.0 (IQR 2.0 – 7.0) 3.0 (SD ± 1.0) 3.0 (IQR 3.0 – 7.0) 4.0 (IQR 2.0 – 7.0) 
HIV-uninfected 3.0 (IQR 1.0 – 5.0) 6.0 (SD ± 1.4)  2.0 (IQR 1.0 – 3.5) 4.0 (IQR 1.0 – 7.0) 
P 0.174 0.022 0.045 0.691 
Table 14: Analysis of episodes with untreated bacteriologically-confirmed tuberculosis 
 
 
 
 
* Expressed as percentage of all bacteriologically-confirmed tuberculosis in each HIV category.  
+ 
Expressed as a percentage of episodes with missed microbiologically-confirmed tuberculosis in each HIV category.  
§
 Fisher‟s exact test. 
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Table 14, continued: Analysis of episodes with untreated bacteriologically-confirmed tuberculosis 
 
§
 Fisher‟s exact test.
 
All  untreated  episodes 
[n=62] 
Untreated  episodes that 
died  
[n=7] 
Untreated  episodes that 
were lost to follow-up 
[n=21] 
Untreated  episodes that 
were followed up 
[n=34] 
Algorithm 
score  
≥ 7, n (%) 
 
HIV-infected 16 / 39 (41.0) 2 / 5 (40.0) 3 / 10 (30.0) 11 / 24 (45.8) 
HIV-uninfected 1 / 17 (5.9) 0 / 2 (0.0) 0 / 10 (0.0) 1 / 5 (20.0) 
OR (95% CI) 11.13 (1.39 – 495.29) - - 3.38 (0.27 – 181.55) 
P 0.009  0.222 
§
 0.211 
§
 0.370 
§
 
Length of 
admission 
(days) 
All 6.0 (IQR 4.0 – 11.0) 4.0 (IQR 1.0 – 13.0) 7.0 (IQR 4.5 – 9.5) 6.0 (IQR 5.0 – 12.0) 
HIV-infected 7.0 (IQR 5.0 – 13.0) 4.0 (IQR 3.0 – 5.0) 7.0 (IQR 6.0 – 14.0) 7.5 (IQR 5.0 – 13.0) 
HIV-uninfected 5.0 (IQR 4.0 – 8.0) 7.0 (IQR 1.0 –13.0) 7.0 (IQR 4.0 –  9.0) 5.0 (IQR 3.0 – 5.0) 
P 0.074 0.845 0.381 0.025 
Discharge 
diagnoses 
with 
respiratory 
illness, n (%)  
HIV-infected 30 / 45 (66.7)  4 / 5 (80.0)  7 / 11 (63.6)  19 / 29 (65.5)  
HIV-uninfected 11 / 17 (64.7)  1 / 2 (50.0)  7 / 10 (70.0)  3 / 5 (60.0)  
OR (95% CI) 1.09 (0.27 – 4.01) 4.0 (0.03 – 390.99) 0.75 (0.08 – 6.54) 1.27 (0.91 – 12.99) 
P 0.884 1.000 
§
  1.000 
§
 1.000 
§
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Thirty-four (54.8%) of the 62 episodes that had unrecognised bacteriologically-confirmed 
tuberculosis were followed up at CHBH: 29 of these episodes occurred in 28 HIV-infected 
children and 5 occurred in HIV-uninfected children. Twenty-four (70.6%) of these children 
presented with cough with a median cough duration in the HIV-infected children of 4.0 
days (IQR 2.0 – 7.0), equivalent to the median duration of cough in the HIV-uninfected 
children (4.0 days; IQR 1.0 – 7.0), P=0.691. Information regarding whether anti-
tuberculous therapy was started in this sub-group of patients once the positive test was 
recognised, is scanty: only 16 (48.5%) of these 33 children (all of them HIV-infected) 
appear from the available data to have been started on anti-tuberculous treatment on 
admission episodes subsequent to the one in which the positive mycobacterial result 
occurred. Mean elapsed time between the admission episode when a diagnosis of 
bacteriologically confirmed tuberculosis went unrecognised, and subsequent admission 
when the tuberculosis diagnosis was identified and the child was started on anti-tuberculous 
therapy, was 44.2 days (SD 25.3). 
3.1.7 Co-infections in the context of tuberculosis 
3.1.7.1 Co-infections regardless of tuberculosis categorisation 
Four hundred and thirty (88.7%) of the 485 episodes where tuberculosis was diagnosed or 
identified in children with defined HIV status were investigated for multiple pathogens 
during the diagnostic work-up for tuberculosis. One hundred and twelve (26.0%) of these 
430 tuberculosis episodes were confirmed to have viral or P. jiroveci co-infections, or 
infection with significant bacterial isolates on blood culture. These investigations were 
conducted in 390 children. 
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Figure 4: Microbiological investigations and yield for co-infections in tuberculosis episodes (n=430)    
amongst children with defined HIV status 
 
Note: The total number of positive specimens (n=210) differs from the number of tuberculosis episodes with 
co-infection (n=112) as some of the tuberculosis episodes had co-infection with more than one pathogen. 
 
 
Blood cultures were performed in 426, nasopharyngeal aspirates for respiratory viruses in 
304 and P. jiroveci immunofluorescence in 41 episodes in which tuberculosis was 
diagnosed or identified. Results of 27 positive sputum bacterial cultures were also recorded 
in the RMPRU database (Figure 4). Hence, a total of 798 microbiological investigations 
were sent in 430 episodes of tuberculosis from 390 children that were screened for co-
infection at the tuberculosis index episode. 
 
One-hundred and twenty-nine (30.3%) of the 426 blood cultures were positive for bacterial 
organisms, however only 57 (13.4%) of all blood cultures isolated pathogenic bacteria 
(other positive cultures yielded likely contaminating organisms such as Corynebacterium 
spp, Micrococcus spp and Coagulase negative Staphylococcus spp). Three of the episodes 
with significant organisms on blood culture isolated two bacterial species during the 
hospitalisation: an HIV-infected child cultured methicillin-resistant Staphylococcus aureus 
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(MRSA) on an admission blood culture and Enterococcus sp on a subsequent blood culture 
during the same admission episode; 2 HIV-uninfected children isolated co-pathogens in 
their blood cultures – the first isolated MRSA and Streptococcus pyogenes and the second 
isolated S. pneumoniae and non-typable H. influenzae.  
 
Information regarding sputum bacterial isolates in the cohort is incomplete: all of the 27 
children with tuberculosis who had sputum screened for bacterial co-infections had 
evidence of bacterial infection on sputum culture. Eight (29.6%) of these children had dual 
bacterial isolates on sputum culture; 7 (87.5 percent of the children with sputum isolation of 
more than one bacterial species) were HIV-infected. Combinations of dual bacterial 
infection as isolated on sputum culture in these children were: non-typable H. influenzae 
and S. aureus (3 patients, one of whom was the only HIV-uninfected child with dual 
bacterial pathogens in sputum); pneumococcus and non-typable H. influenzae (3 children); 
pneumococcus and MRSA (1 child); and E. coli and Klebsiella sp (1 child). 
 
Thirty-nine (12.8%) of 304 nasopharyngeal aspirates performed in the children with 
tuberculosis revealed evidence of concomitant respiratory virus infection, and two HIV-
uninfected children isolated dual influenza A and respiratory syncytial virus (RSV) in 
nasopharyngeal aspirates taken during the admission episode in which tuberculosis was 
diagnosed.  
 
Fifteen children (3.8 percent of the 390 children who had been screened for dual infection 
in the context of their tuberculosis index admission episode) had confirmed P. jiroveci 
pneumonia: 12 (80.0%) of these arose in HIV-infected children. 
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From Table 15, it can be appreciated that proportions of co-infections identified in 
individuals with confirmed, probable and suspected tuberculosis were 26.5, 19.6 and 31.9 
percent, respectively. Whereas significantly fewer co-infections were identified in children 
with probable tuberculosis compared to those with suspected tuberculosis (OR 0.52; 95% 
CI, 0.30 – 0.90), P=0.013, there was no significant difference in the proportions of children 
with confirmed co-infection comparing those who had definite tuberculosis and those with 
suspected disease (OR 0.77; 95% CI, 0.44 – 1.35), P=0.333. 
 
 Bacteriologically-
confirmed 
tuberculosis [n=117] 
Probable 
tuberculosis 
[n=153] 
Suspected 
tuberculosis 
[n=160] 
Individuals with polymicrobial 
infection (%) 
31 / 117 (26.5) 30 / 153 (19.6) 51 / 160 (31.9) 
Comparison of proportions OR (95% CI) P 
Probable versus Bacteriologically- 
confirmed tuberculosis 
0.68  (0.37 – 1.25) 0.180 
Probable versus Suspected 
tuberculosis 
0.52  (0.30 – 0.90) 0.013 
Bacteriologically-confirmed versus 
Suspected tuberculosis 
0.77  (0.44 – 1.35) 0.333 
Table 15: Comparison of co-infection rates according to tuberculosis disease category, irrespective of 
HIV status 
 
Table 16 explores the co-infections according to the children‟s HIV status and the strength 
of evidence of the tuberculosis diagnosis. HIV-infected children with tuberculosis were not 
significantly more likely to have dual infection than were -uninfected children: this was 
true even in HIV-infected children with a diagnosis of suspected tuberculosis                 
(OR 1.39; 95% CI, 0.56 – 3.69), P=0.446. 
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Table 16: Co-infections in children diagnosed with tuberculosis, by HIV status 
 
 
HIV-infected HIV-uninfected 
Confirmed 
TB * 
[n=80] 
Probable 
TB 
[n=92] 
Suspected 
TB 
[n=126] 
Confirmed 
 TB 
[n=37] 
Probable 
TB 
[n=61] 
Suspected 
TB 
[n=34] 
Blood cultures  
S. pneumoniae 3 5 14 1 0 2 
Strep spp 1 0 1 1 0 0 
H. influenzae 0 0 5 1 0 0 
S. aureus 1 2 1 1 0 2 
Gram Negatives 2 2 11 1 0 0 
Bacterial sputum cultures  
S. pneumoniae 0 1 3 0 0 0 
H. influenzae 3 1 3 1 2 0 
S. aureus 4 0 2 1 0 0 
Gram Negatives 1 0 2 0 1 0 
Respiratory virus isolated  
Influenza A 3 4 3 3 4 4 
RSV 0 2 2 2 1 0 
Adenovirus 1 1 3 0 1 0 
Parainfluenza 0 1 1 0 0 1 
Influenza + RSV 0 0 0 1 1 0 
Other  
P. jiroveci 6 3 3 1 1 1 
Total isolates  25  22  54  14  11  10  
Individuals with 
polymicrobial 
infection, n (%)   
21 
(26.3) 
19 
(20.7) 
42 
(33.3) 
10 
(27.0) 
11 
(18.0) 
9 
(26.5) 
Comparison of proportions with  
co-infection in each TB Category 
by HIV status: OR (95% CI), P 
Confirmed TB 0.96 (0.37 – 2.61) 0.929 
Probable TB 1.18 (0.48 – 3.00) 0.690 
Suspected TB 1.39 (0.56 – 3.69) 0.446 
* „TB‟ represents „tuberculosis‟: „Confirmed TB‟ represents cases with smear- and/or culture-positive disease. 
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HIV-infected children with tuberculosis had an overall increased burden of co-infection in 
terms of blood culture positivity for significant pathogens compared to HIV-uninfected 
children (Table 17). Forty-seven (18.8%) significant bacterial blood culture isolates were 
identified in 250 tuberculosis episodes amongst the HIV-infected children, compared to 7 
(6.0%) significant blood culture isolates amongst 116 tuberculosis episodes in HIV-
uninfected children (OR 3.61; 95% CI, 1.55 – 9.75), P=0.001. In contrast to this finding, 
HIV-uninfected children had a significantly greater burden of confirmed respiratory viral 
co-infection than did HIV-infected children (OR 2.57; 95% CI, 1.20 – 5.43), P=0.006. The 
overall burden of co-infection between HIV-infected and -uninfected children with 
bacteriologically-confirmed tuberculosis were equivalent (Table 17).  
 
Table 18 reveals equivalent rates of co-infection across tuberculosis disease categories 
according to vaccination status of the children.  
 
Table 19 explores the tuberculosis co-infection rates in the HIV-infected children 
according to PCV vaccination status and reveals no difference in co-infection amongst the 
children with bacteriologically-confirmed and probable tuberculosis; however, children 
who received PCV showed a trend towards fewer co-infection episodes in the context of 
suspected tuberculosis compared to those who received placebo (OR 0.51; 95% CI, 0.22 – 
1.15), P=0.078.  
 
There was no significant difference in co-infection rates amongst the HIV-uninfected 
children with tuberculosis according to vaccination status (Table 20).   
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Table 17: Co-infection categories in children with tuberculosis, according to HIV status 
 
* Numerators in each category represent numbers of individual children with positive results; denominators 
reflect the sum of the specimens with significant isolates and those that were negative. 
**
 
Blood cultures positive for significant pathogens – likely contaminating organisms excluded.
 
+
 Bacteriologically-confirmed tuberculosis includes „Definite TB‟ and „Confirmed PTB‟ cases. 
 
Tuberculosis episodes screened  
for co-infections * 
Odds Ratio 
(95% CI) 
P 
HIV-infected  HIV-uninfected 
A
ll
 t
u
b
er
cu
lo
si
s 
Blood culture 
positive**, n (%) 
47 / 250 
(18.8) 
7 / 116 
(6.0) 
3.61 
(1.55 – 9.75) 
0.001 
Sputum culture 
positive, n (%) 
13 / 30 
(43.3) 
4 / 6 
(66.7) 
0.38 
(0.03 – 3.24) 
0.391 
§
 
Respiratory virus 
positive, n (%) 
20 / 217 
(9.2) 
18 / 87 
(20.7) 
0.39 
(0.18 – 0.83) 
0.006 
P. jiroveci positive, 
n (%) 
12 / 35 
(34.3) 
3 / 6  
(50.0) 
0.52 
(0.06 – 4.58) 
0.651 
§
  
All co-pathogens,  
n (%) 
 
82 / 298 
(27.5) 
30 / 132 
(22.7) 
1.29 
(0.78 – 2.17) 
0. 297 
B
ac
te
ri
o
lo
g
ic
al
ly
-c
o
n
fi
rm
ed
 t
u
b
er
cu
lo
si
s 
+
 Blood culture 
positive**, n (%) 
7 / 72 
(9.7) 
3 / 34 
(8.8) 
1.11 
(0.23 – 7.11) 
1.000 
§
 
Sputum culture 
positive, n (%) 
7 / 7 
(100.0) 
1 / 1 
(100.0) 
- -  
Respiratory virus 
positive, n (%) 
4 / 58 
(6.9) 
6 / 27 
(22.2) 
0.26 
(0.05 – 1.24) 
0.067 
§
 
P. jiroveci positive, 
n (%) 
6 / 9  
(66.7) 
1 / 3 
(33.3) 
4.00 
(0.13 – 274.49) 
0.523 
§
 
All co-pathogens,  
n (%) 
21 / 80 
(26.3) 
10 / 37 
(27.0) 
0.96 
(0.37 – 2.61) 
0.929 
§
 Fisher‟s exact test. 
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Table 18: Co-infections in children diagnosed with tuberculosis, by vaccination status 
 PCV Placebo  
Confirmed 
 TB * 
[n=46] 
Probable 
TB 
[n=77] 
Suspected 
TB 
[n=81] 
Confirmed 
 TB 
[n=71] 
Probable 
TB 
[n=76] 
Suspected 
TB 
[n=79] 
Blood cultures  
S. pneumoniae 1 3 8 3 2 8 
Strep spp 1 0 1 1 0 0 
H. influenzae 1 0 0 0 0 5 
S. aureus 1 1 2 1 1 1 
Gram Negatives 1 0 5 2 2 6 
Bacterial sputum cultures  
S. pneumoniae 0 1 0 0 0 3 
H. influenzae 1 2 1 3 1 2 
S. aureus 3 0 1 2 0 1 
Gram Negatives 0 0 2 1 1 0 
Respiratory virus isolated  
Influenza A 3 4 4 3 4 3 
RSV 1 0 1 1 3 1 
Adenovirus 0 1 1 1 1 2 
Parainfluenza 0 0 2 0 1 0 
Influenza + RSV 1 1 0 0 0 0 
Other  
P. jiroveci 1 2 0 6 2 4 
Total isolates  15  15  28  24  18  36  
Individuals with 
polymicrobial 
infection, n (%) 
11 
(23.9) 
13 
(16.9) 
22 
(27.2) 
20 
(28.2) 
17 
(22.4) 
29 
(36.7) 
Comparison of proportions with  
co-infection in each TB Category by 
vaccination status: OR (95% CI), P 
Confirmed TB 0.80 (0.31 – 2.02) 0.610 
Probable TB 0.70 (0.29 – 1.69) 0.393 
Suspected TB 0.64 (0.31 – 1.32) 0.195 
* „TB‟ represents „tuberculosis‟: „Confirmed TB‟ represents cases with smear- and/or culture-positive disease. 
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Table 19: Co-infections in HIV-infected children, according to PCV vaccination status 
HIV-infected 
PCV Placebo  
Confirmed 
 TB * 
[n=32] 
Probable 
TB 
[n=45] 
Suspected 
TB 
[n=62] 
Confirmed 
 TB 
[n=48] 
Probable 
TB 
[n=47] 
Suspected 
TB 
[n=64] 
Blood cultures  
S. pneumoniae 0 3 6 3 2 8 
Strep spp 0 0 1 1 0 0 
H. influenzae 0 0 0 0 0 5 
S. aureus 0 1 1 1 1 0 
Gram Negatives 1 0 5 1 2 6 
Bacterial sputum cultures  
S. pneumoniae 0 1 0 0 0 3 
H. influenzae 1 1 1 2 0 2 
S. aureus 3 0 1 1 0 1 
Gram Negatives 0 0 2 1 0 0 
Respiratory virus isolated  
Influenza A 1 2 1 2 2 2 
RSV 0 0 1 0 2 1 
Adenovirus 0 1 1 1 0 2 
Parainfluenza 0 0 1 0 1 0 
Influenza + RSV 0 0 0 0 0 0 
Other  
P. jiroveci 1 2 0 5 1 3 
Total isolates  7  11  21  18  11  33  
Individuals with 
polymicrobial 
infection, n (%) 
6  
(18.8) 
9 
(20.0) 
16 
(25.8) 
15 
(31.3) 
10 
(21.3) 
26 
(40.6) 
Comparison of proportions with  
co-infection in each TB Category by 
vaccination status in HIV-infected 
children: OR (95% CI), P 
Confirmed TB 0.51 (0.14 – 1.64) 0.213 
Probable TB 0.93 (0.29 – 2.87) 0.880 
Suspected TB 0.51 (0.22 – 1.15) 0.078 
* „TB‟ represents „tuberculosis‟: „Confirmed TB‟ represents cases with smear- and/or culture-positive disease. 
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Table 20: Co-infections in HIV-uninfected children, according to PCV vaccination status 
 
HIV-uninfected 
PCV Placebo  
Confirmed 
 TB 
[n=14] 
Probable 
TB 
[n=32] 
Suspected 
TB 
[n=19] 
Confirmed 
 TB 
[n=23] 
Probable 
TB 
[n=29] 
Suspected 
TB 
[n=15] 
Blood cultures  
S. pneumoniae 1 0 2 0 0 0 
Strep spp 1 0 0 0 0 0 
H. influenzae 1 0 0 0 0 0 
S. aureus 1 0 1 0 0 1 
Gram Negatives 0 0 0 1 0 0 
Bacterial sputum cultures  
S. pneumoniae 0 0 0 0 0 0 
H. influenzae 0 1 0 1 1 0 
S. aureus 0 0 0 1 0 0 
Gram Negatives 0 0 0 0 1 0 
Respiratory virus isolated  
Influenza A 2 2 3 1 2 1 
RSV 1 0 0 1 1 0 
Adenovirus 0 0 0 0 1 0 
Parainfluenza 0 0 1 0 0 0 
Influenza + RSV 1 1 0 0 0 0 
Other  
P. jiroveci 0 0 0 1 1 1 
Total isolates 8  4  7  6  7  3  
Individuals with 
polymicrobial 
infection, n (%) 
5 
(35.7) 
4 
(12.5) 
6 
(31.6) 
5 
(21.7) 
7 
(24.1) 
3 
(20.0) 
Comparison of proportions with  
co-infection in each TB Category by 
vaccination status in HIV-
uninfected children: OR(95% CI), P 
Confirmed TB 2.00 (0.35 – 11.19) 0.454 § 
Probable TB 0.45 (0.09 – 2.06) 0.323 § 
Suspected TB 1.85 (0.30 – 13.77) 0.697 § 
* „TB‟ represents „tuberculosis‟: „Confirmed TB‟ represents cases with smear- and/or culture-positive disease. 
§
 Fisher‟s exact test. 
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3.1.7.2 Co-infections in children with culture-confirmed tuberculosis 
Analysis of co-infections encountered in children with culture-confirmed tuberculosis was 
conducted in order to achieve an appreciation as to which co-pathogens were encountered 
in this group of children (Table 21). Twenty-two (23.4%) of the 94 culture-positive 
tuberculosis episodes that were investigated for co-infections, had documented 
polymicrobial infections. 
 
A wide variety of micro-organisms were identified in co-infection with culture-confirmed 
tuberculosis (Table 21): Pneumocystis jiroveci was encountered in 4 (50.0%) of 8 placebo-
related culture-confirmed tuberculosis episodes and 1 (50.0%) of the 2 PCV-related 
episodes that were investigated for pneumocystis pneumonia, P=1.000 (Fisher‟s exact test). 
Viral pathogens were isolated in 4 (17.4%) of 23 PCV-vaccinated patients and 4 (8.0%) of 
50 placebo patients investigated for viral co-infection in the context of their culture-
confirmed tuberculosis, P=0.251 (Fisher‟s exact test).  
 
Clinically significant bacterial sputum isolates were encountered in one (2.9%) of 34 PCV 
recipients and 5 (8.3%) of 60 placebo recipients with culture-confirmed tuberculosis who 
were investigated for co-infections (OR 0.33; 95% CI, 0.01 – 3.19), P=0.413 (Fisher‟s 
exact test), Table 21.  
 
Similarly, clinically significant bacterial blood culture isolates were identified in 4 (11.8%) 
of 34 culture-confirmed tuberculosis episodes in which bacterial blood culture results were 
obtainable amongst PCV recipients, compared to 5 (9.6%) of 52 cultures amongst the 
placebo group, P=0.735 (Fisher‟s exact test).  
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Whilst Table 21 illustrates co-infection events amongst episodes of culture-confirmed 
tuberculosis in the PCV study cohort according to vaccination and HIV status, it does not 
detail the types of co-infections encountered in individual trial participants. A detailed 
account of the co-infections encountered in children with bacteriologically-confirmed 
tuberculosis is presented in Table 22. 
 
Three (12.5%) of 24 episodes of culture-proven tuberculosis in HIV-infected children who 
received PCV and were investigated for co-infections, had confirmed co-infections at the 
tuberculosis index admission, compared to 10 (25.0%) of 40 similarly-investigated 
episodes in HIV-infected placebo recipients, P=0.339 (Fisher‟s exact test). Amongst HIV-
uninfected children, 4 (40.0%) of 10 culture-confirmed tuberculosis episodes in PCV 
recipients were associated with co-infections, compared to 5 (25.0%) of 20 culture-
confirmed tuberculosis episodes amongst placebo recipients, P=0.431 (Fisher‟s exact test), 
Table 22. 
 
As mentioned above, 22 children with culture-confirmed tuberculosis were identified as 
having co-infections with significant bacterial or viral pathogens, or P. jiroveci in the 
context of their tuberculosis. Thirteen (59.1%) of these children were HIV-infected, and 15 
(68.2%) were placebo recipients. Neither HIV-infected children who received PCV, nor 
those who were HIV-uninfected, were more likely than placebo recipients to develop co-
infections in the context of culture-confirmed tuberculosis (Table 22). 
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Table 21: Microbiological investigations sent on children with culture-proven tuberculosis: all episodes  
 
 
 PCV Placebo  
HIV-infected 
[n=24] 
HIV-uninfected 
[n=10] 
HIV-infected 
[n=40] 
HIV-uninfected 
[n=20] 
B
lo
o
d
 C
u
lt
u
re
s 
Negative 22 8 31 16 
S. pneumoniae 0 1 3 0 
Streptococcus spp 0 1 0 0 
H. influenzae 0 1 0 0 
S. aureus 0 1 1 0 
Gram Negatives 0 0 0 1 
OR (95% CI), P * 1.25 (0.23 – 6.33) 0.735 § 
S
p
u
tu
m
 c
u
lt
u
re
s 
S. pneumoniae 0 0 0 0 
H. influenzae 0 0 1 1 
S. aureus 1 0 0 1 
Gram Negatives 0 0 1 0 
C. albicans 0 0 1 0 
OR (95% CI), P * 0.33 (0.01 – 3.19) 0.413 § 
R
es
p
ir
at
o
ry
 v
ir
u
se
s 
Negative 16 3 31 15 
Influenza A 1 2 1 1 
RSV 0 0 0 1 
Adenovirus 0 0 1 0 
Influenza + RSV 0 1 0 0 
OR (95% CI), P * 2.42 (0.40 – 14.27) 0.251 § 
P
. 
ji
ro
ve
ci
 Negative  1 0 2 2 
Positive 1 0 3 1 
OR (95% CI), P * 1.00 (0.10 – 98.00) 1.000 § 
Individuals with  
polymicrobial infection,  
n (%) 
3 (12.5) 4 (40.0) 10 (25.0) 5 (25.0) 
7 (20.6) 15 (25.0) 
OR (95% CI), P * 0.78 (0.24 – 2.35) 0.627 
* P- value compares co-infections in children according to vaccination status.    
§
 Fisher‟s exact test. 
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 HIV-infected HIV-uninfected  
PCV 
[n=24] 
Placebo 
[n=40] 
PCV 
[n=10] 
Placebo 
[n=20] 
One significant organism on blood culture - 4 - 1 
Two significant organisms on blood culture - - 1 - 
Two significant organisms on blood culture 
and two significant respiratory viruses 
- - 1 - 
One significant organism on sputum culture 1 2 - - 
Two significant organisms on sputum culture - - - 1 
One significant respiratory virus 1 1 2 2 
P. jiroveci and one significant respiratory virus - 1 - - 
P. jiroveci 1 2 - 1 
Total, n (%) 3  
(12.5) 
10 
(25.0) 
4 
(40.0) 
5 
(25.0) 
P * 0.339 
§
 0.431 
§
 
Table 22: Profile of significant co-pathogens identified in the context of culture-confirmed tuberculosis, 
according to HIV and vaccination status 
 
 
 
3.1.8 Adverse events to anti-tuberculous therapy 
Three children (all of them HIV-infected) were noted to have drug reactions that were 
attributable to anti-tuberculous therapy, and required hospitalisation to manage these 
adverse events: 2 had hepatitis and 1 had a skin reaction. As 446 tuberculosis episodes (305 
HIV-infected, 134 HIV-uninfected and 7 with unknown HIV status) were known to have 
been initiated on anti-tuberculous therapy in this cohort, this represents an adverse event 
rate of 0.7 percent (95% CI, 0.1 – 2.0) for the cohort, or a rate of 1.0 percent (95% CI, 0.2 – 
3.0) for HIV-infected children, P=0.555 (Fisher‟s exact test). 
* P-value compares proportions of children with co-infections by vaccination status, within  
HIV infection status categories. 
§
 Fisher‟s exact test. 
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3.1.9 Tuberculosis-related deaths 
Fifty-one (12.0%) of the 425 children ever identified with tuberculosis died at CHBH:      
40 (78.4%) of these deaths occurred in the HIV-infected children, 10 (19.6%) in HIV-
uninfected children, and 1 (2.0%) in a child who had no definitive HIV result: 48 (94.1%) 
of the deaths occurred during the tuberculosis index admission episode. Fifteen (29.4%) of 
the children who died with tuberculosis at the hospital had bacteriologically-confirmed 
disease. As has been discussed in Section 3.1.6, seven of these cases had not been started 
on anti-tuberculous therapy.  
 
Eight children (6 HIV-infected and 2 HIV-uninfected) died in the context of 
bacteriologically-confirmed tuberculosis and had been started on anti-tuberculous therapy 
prior to their demise. Mean cough duration in these children was 4.7 days (SD 2.3), this 
cough duration being similar to that in the group of children with untreated tuberculosis 
(see Table 14) who died with bacteriologically-confirmed disease (3.9 days, SD 1.8), 
P=0.483.  
 
Median length of hospitalisation in the children who died on anti-tuberculous therapy was 
12.0 days (IQR 4.5 – 40.0), not significantly longer than that encountered in the children 
with untreated bacteriologically-confirmed disease who died (4.0 days, IQR 1.0 – 13.0), 
P=0.201.  
 
Seven of these children were scored using the diagnostic algorithm (all of the scores 
utilised at least 9 of the 12 parameters enumerated in the scoring system), and only one of 
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these seven (an HIV-infected child) had a total score which was compatible with a 
diagnosis of tuberculosis according to the algorithm. The yield of score positivity in this 
group of children compared to those who died with undiagnosed bacteriologically-
confirmed tuberculosis (where 2 out of 7 children had a total score compatible with the 
algorithm diagnosis of tuberculosis) was equivalent, P=1.000 (Fisher‟s exact test). 
 
 HIV-infected 
[n=274]  
HIV-uninfected 
[n=144] 
Odds Ratio 
 (95% CI) 
P 
Bacteriologically-
confirmed 
tuberculosis, n (%) 
11 (4.0) 4 (2.8) 1.46 
(0.42 – 6.41) 
0.593 
§
 
Probable 
tuberculosis, n (%) 
4 (1.5) 2 (1.4) 1.04 
(0.15 – 11.67) 
1.000 
§
 
Suspected 
tuberculosis, n (%) 
23 (8.4) 3 (2.1) 4.31 
(1.26 – 22.74) 
0.011 
Same episode 
tuberculosis, n (%) 
2 (0.7) 1 (0.7) 1.05 
(0.05 – 62.2) 
1.000 
§
  
All tuberculosis, 
n (%) 
40 (14.6) 10 (6.9) 2.29 
(1.08  – 5.30) 
0.022 
Tuberculosis with 
confirmed co-
infection, n (%) * 
9 / 38 
(23.7) 
2 / 9 
(22.2) 
1.09 
(0.16 – 12.52) 
1.000 
§
 
Table 23: Deaths in study participants, according to HIV status and category of tuberculosis 
* Expressed as a percentage of those children who died who were investigated for co-infections.
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Case fatality rates amongst children who died during an admission in which tuberculosis 
was diagnosed (see Table 23) were similar in HIV-infected and -uninfected children for all 
categories of tuberculosis besides that of „suspected tuberculosis‟ (OR 4.31; 95% CI, 1.26 – 
22.74), P=0.011. Overall, HIV-infected children had a greater tuberculosis-related case 
fatality rate (OR 2.29; 95% CI, 1.08 – 5.30), P=0.022. 
 
HIV-infected children
9 3 18
1
2 1 5
1
0%
50%
100%
Bacteriologically-
confirmed TB*
Probable TB Suspected TB Same episode TB
Confirmed co-infection No confirmed co-infection
HIV-uninfected children
3
1
3 1
1
1
0%
50%
100%
Bacteriologically-
confirmed TB
Probable TB Suspected TB Same episode TB
Confirmed co-infection No confirmed co-infection
 Figure 5: Proportions of children dying with confirmed co-infection in the context of their 
tuberculosis, by HIV status 
 
Forty-seven (92.2%) of the tuberculosis episodes in which children died were investigated 
for bacterial, viral or P. jiroveci co-infections and 11 (23.4%) of these revealed evidence of 
polymicrobial infection. From Figure 5, it can be appreciated that 9 HIV-infected children 
died with confirmed co-infections compared to 2 HIV-uninfected children (OR 1.09; 95% 
CI, 0.16 – 12.52), P=1.000 (Fisher‟s exact test).  
* „TB‟ represents „tuberculosis‟. 
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A diverse spectrum of co-pathogens was identified in children dying with a diagnosis of 
tuberculosis: these are tabulated in Table 24 (below). 
 
 
Specimen type Organisms HIV-
infected  
 
HIV-
uninfected 
Category of Tuberculosis 
Confirmed * Probable Suspected 
Blood culture 
isolates 
S. pneumoniae 3 - 1 1 1 
Pseudomonas spp - 1 1 - - 
Sputum isolates Enterobacter spp - 1 - 1 - 
Blood culture and 
sputum isolates 
Klebsiella spp 
and E. coli 
1 - - - 1 
Nasopharyngeal 
aspirates  
Adenovirus 1 - - - 1 
RSV 1  - - 1 
Other isolates P. jiroveci 1 - 1 - - 
Mixed isolates H. influenzae  
and P. jiroveci 
1 - - - 1 
Neisseria spp  
and RSV 
1 - - - 1 
Table 24: Organisms identified in children dying with tuberculosis, according to HIV status and 
category of tuberculosis disease 
 
* „Confirmed‟ represents tuberculosis cases with smear- and/or culture-positive disease. 
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3.2 The Role of Pneumococcal Co-infection as a Cause for Hospitalisation in Children 
with Pulmonary Tuberculosis 
By using the 9-valent PCV as a probe, it was possible to estimate the proportion of 
hospitalised tuberculosis cases which ordinarily arise in the context of an intercurrent 
pneumococcal co-infection. We postulated that, if pneumococcal co-infections do play a 
significant role in co-infection amongst children who require hospitalisation for PTB, then 
children who had received the vaccine would have a lower burden of tuberculosis 
compared to those who had received placebo. 
 
Tables 25 and 26, which illustrate the initial analysis comparing all forms (definite, 
probable and suspected) of PTB as diagnosed in the cohort, and stratified according to age 
at which the tuberculous episode was diagnosed and vaccination status, showed no 
difference in the overall incidence of tuberculosis between PCV and placebo groups 
(Incidence Rate Ratio [IRR] 0.90; 95% CI, 0.73 – 1.10), P=0.292 for first episode 
tuberculosis (Table 25 and Figure 6) and IRR 0.87 (95% CI, 0.72 – 1.05), P=0.146, for all 
PTB episodes (Table 26). 
 
When using the more specific diagnosis of culture-confirmed PTB (excluding recurrent 
episodes of culture-confirmed disease), 31 cases of all culture-confirmed PTB occurred in 
the vaccinated group compared to 55 cases amongst the placebo recipients                     
(IRR 0.56; 95% CI, 0.35 – 0.89), P=0.010, representing a 44 percent (95% CI, 11 – 65) risk 
reduction in culture-confirmed PTB amongst PCV recipients (Table 27 and Figure 7).  
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 Table 25: Incidence of PTB as diagnosed at CHBH, according to vaccination status: incident tuberculosis 
 
* All PTB cases excluding cases with recurrent tuberculosis episodes. 
 
 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of PTB  
cases diagnosed * 
 
Tuberculosis incidence  
(cases per 100 000 hospital  
child-years of follow-up, 95% CI) 
 
 
Incidence 
Rate Ratio 
(95% CI) 
 
P 
 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0  7365 7356 38 43 516 
(365 – 708) 
585 
(423 – 787) 
0.88 
(0.56 – 1.40) 
0.577 
6.1 – 12.0 9841 9827 33 46 325 
(222 – 459) 
468 
(343 – 624) 
0.72 
(0.44 – 1.14) 
0.144 
1.5 – 12.0  17 206 17 183 71 89 413 
(322 – 521) 
518 
(416 – 637) 
0.80 
(0.74 – 1.10) 
0.153 
12.1 – 24.0 19 675 19 647 43 43 219 
(158 – 294) 
219 
(158 – 295) 
1.00 
(0.64 – 1.56) 
0.995 
24.1 – 36.0 19 666 19 639 20 26 101 
(62 – 157) 
132 
(86 – 194) 
0.77 
(0.41 – 1.43) 
0.379 
36.1 – 48.0 19 664 19 637 18 17 92 
(54 – 145) 
87 
(50 – 139) 
1.06 
(0.51 – 2.18) 
0.871 
48.1 – 60.0  21 596 21 685 17 13 79 
(46 – 126) 
60 
(32 – 103) 
1.31 
(0.60 – 2.94) 
0.466 
>60.0  52 478 52 595 16 18 30 
(17 – 50) 
34 
(20 – 54) 
0.89 
(0.43 – 1.85) 
0.741 
All ages 150 285 150 386 185 206 123 
(106 – 142) 
137 
(119 – 157) 
0.90 
(0.73 – 1.10) 
0.292 
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Table 26: Incidence of PTB as diagnosed at CHBH, according to vaccination status: all tuberculosis episodes  
 
+
 All PTB cases (including recurrent episodes). 
 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of PTB 
cases diagnosed 
+
 
 
Tuberculosis incidence  
(cases per 100 000 hospital 
child-years of follow-up, 95% CI) 
 
 
Incidence 
Rate Ratio 
(95% CI) 
 
P 
 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0  7365 7356 38 43 516 
(365 – 708) 
585 
(423 – 787) 
0.88 
(0.56 – 1.40) 
0.577 
6.1 – 12.0 9841 9827 35 47 356 
(248 – 495) 
478 
(351 – 636) 
0.74 
(0.47 – 1.18) 
0.185 
1.5 – 12.0  17 206 17 183 72 90 418 
(327 – 527) 
524 
(421 – 644) 
0.80 
(0.58 – 1.10) 
0.156 
12.1 – 24.0 19 675 19 647 48 46 244 
(180 – 323) 
234 
(171 – 312) 
1.04 
(0.68 – 1.60) 
0.843 
24.1 – 36.0 19 666 19 639 24 29 122 
(78 – 182) 
148 
(99 – 212) 
0.83 
(0.46 – 1.47) 
0.494 
36.1 – 48.0 19 664 19 637 18 27 92 
(54 – 145) 
138 
(91 – 200) 
0.67 
(0.35 – 1.25) 
0.182 
48.1 – 60.0  21 596 21 685 22 20 102 
(64 – 154) 
92 
(56 – 142) 
1.10 
(0.58 – 2.13) 
0.751 
>60.0  52 478 52 595 24 28 46 
(29 – 68) 
53 
(35 – 77) 
0.86 
(0.48 – 1.54) 
0.589 
All ages 150 285 150 386 209 240 139 
(121 – 159) 
160 
(140 – 181) 
0.87 
(0.72 – 1.05) 
0.146 
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 Table 27: Incidence of definite PTB, according to vaccination status: incident tuberculosis 
 
* Culture-confirmed PTB cases excluding cases with recurrent tuberculosis episodes. 
 
 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of culture-positive 
PTB cases diagnosed 
*
 
 
Definite tuberculosis incidence  
(cases per 100 000 hospital  
child-years of  
follow-up, 95% CI) 
 
 
Incidence  
Rate Ratio 
(95% CI) 
 
P 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0 7365 7356 6 12 81 
(30 – 177) 
163 
(84 – 285) 
0.50 
(0.15 – 1.44) 
0.166 
6.1 – 12.0 9841 9827 4 9 41 
(11 – 104) 
92 
(42 – 174) 
0.44 
(0.10 – 1.59) 
0.179 
1.5 – 12.0 17 206 17 183 10 21 58 
(28 – 107) 
122 
(76 – 187) 
0.48 
(0.20 – 1.06) 
0.050 
12.1 – 24.0 19 675 19 647 9 12 46 
(21 – 87) 
61 
(32 – 107) 
0.75 
(0.28 – 1.94) 
0.521 
24.1 – 36.0 19 666 19 639 0 7 0 
(0 – 19) 
36 
(14 – 73) 
0.0 
(0.0 – 0.69) 
0.008 
36.1 – 48.0 19 664 19 637 7 6 36 
(14 – 73) 
31 
(11 – 67) 
1.17 
(0.34 – 4.20) 
0.792 
48.1 – 60.0 21 596 21 685 2 4 9 
(1 – 33) 
18 
(5 – 47) 
0.50 
(0.05 – 3.50) 
0.456 
>60.0 52 478 52 595 3 5 6 
(1 – 17) 
10 
(3 – 22) 
0.60 
(0.09 – 3.09) 
0.510 
All ages 150 285 150 386 31 55 21 
(14 – 29) 
37 
(28 – 48) 
0.56 
(0.35 – 0.89) 
0.010 
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Figure 6: Incidence of PTB according to PCV vaccination status 
 
 
* P=0.292 
* This Figure is derived from Table 25: P-value describes the difference in incidence of PTB between PCV 
and placebo recipients in the „All ages‟ category. 
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Figure 7: Incidence of culture-confirmed PTB according to PCV vaccination status  
 
* This Figure is derived from Table 27: P-value describes the difference in rates of culture-confirmed PTB 
between PCV and placebo recipients in the „All ages‟ category. 
 
Although significant reductions in culture-confirmed tuberculosis could not be 
demonstrated in the PCV recipients by age group (on the basis of small numbers of 
tuberculosis cases and relatively short cumulative follow-up periods), the overall effect of 
the PCV was to appreciably reduce the burden of culture-positive disease in vaccinated 
over placebo recipients until 3 years of age (Table 25 and Figure 7). This indicates that a 
substantial proportion of children below five years of age hospitalised for culture-
confirmed PTB in Soweto may have concomitant pneumococcal co-infection precipitating 
the acute illness. 
* P=0.010 
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A similar reduction in culture-confirmed PTB amongst PCV recipients was demonstrated 
when analysing for all definite PTB episodes (Table 28), with an overall PCV effect giving 
rise to an apparent reduction in culture-confirmed PTB of 43 percent (95% CI, 13 – 63), 
P=0.007, compared to placebo recipients. 
 
The cumulative PCV effect of revealing likely pneumococcal co-infection in children 
hospitalised with PTB could also be demonstrated for children in the vaccinated cohort 
when the analysis was extended to include all cases with bacteriologically-confirmed 
(culture- and microscopy-positive PTB), as in Table 29, which illustrates that 45 cases of 
bacteriologically-confirmed tuberculosis occurred in the vaccinated group compared to 65 
in the placebo group (IRR 0.69; 95% CI, 0.46 – 1.03), P=0.058. Extending the analysis to 
include all episodes of bacteriologically-confirmed PTB (Table 30) enhanced the statistical 
significance of the findings in Table 29, and revealed significant reductions of up to 31 
percent (95% CI, 1 – 52) amongst PCV recipients, P=0.037. 
 
The apparent PCV-induced reductions in the case load of bacteriologically-confirmed PTB 
in the cohort was due to effects on culture-proven disease only, as can be appreciated from 
Table 31 which indicates that there was a tendency for PCV recipients to have more 
episodes of smear-positive PTB without culture confirmation than did the placebo 
recipients (OR 1.20; 95% CI, 0.57 – 2.56), P=0.606. That this tendency failed to erode the 
statistical significance of the analysis of the combined bacteriologically-confirmed cases 
(Table 30) highlights the significance of the analysis as conducted for culture-confirmed 
disease.
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Table 28: Incidence of definite PTB, according to vaccination status: all tuberculosis episodes 
 
+
All culture-confirmed PTB cases (including recurrent episodes). 
 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of culture-positive 
PTB cases diagnosed 
+
 
 
Definite tuberculosis incidence  
(cases per 100 000 hospital  
child-years of  
follow-up, 95% CI) 
 
 
Incidence 
Rate Ratio 
(95% CI) 
 
P 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0 7365 7356 6 12 81 
(30 – 177) 
163 
(84 – 285) 
0.50 
(0.15 – 1.44) 
0.166 
6.1 – 12.0 9841 9827 4 9 41 
(11 – 104) 
92 
(42 – 174) 
0.44 
(0.10 – 1.59) 
0.179 
1.5 – 12.0 17 206 17 183 10 21 58 
(28 – 107) 
122 
(76 – 187) 
0.48 
(0.20 – 1.06) 
0.050 
12.1 – 24.0 19 675 19 647 10 12 51 
(24 – 93) 
61 
(32 – 107) 
0.83 
(0.32 – 2.10) 
0.675 
24.1 – 36.0 19 666 19 639 1 8 5 
(0.1 – 28) 
41 
(18 – 80) 
0.12 
(0.00 – 0.93) 
0.021 
36.1 – 48.0 19 664 19 637 7 7 36 
(14 – 73) 
36 
(14 – 73) 
1.00 
(0.30 – 3.34) 
0.998 
48.1 – 60.0 21 596 21 685 4 7 19 
(5 – 47) 
32 
(13 – 67) 
0.57 
(0.12 – 2.26) 
0.391 
>60.0 52 478 52 595 4 8 8 
(2 – 20) 
15 
(7 – 30) 
0.50 
(0.11 – 1.87) 
0.269 
All ages 150 285 150 386 36 63 24 
(17 – 33) 
42 
(32 – 54) 
0.57 
(0.37 – 0.87) 
0.007 
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Table 29: Incidence of bacteriologically-confirmed PTB, according to vaccination status: incident tuberculosis 
 
* Bacteriologically-confirmed PTB (smear and culture-positive), excluding recurrent cases. 
 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of culture- and 
smear-positive PTB  
cases diagnosed * 
 
Confirmed tuberculosis 
incidence  
(cases per 100 000 hospital  
child-years of 
follow-up, 95% CI) 
 
 
Incidence  
Rate Ratio 
(95% CI) 
 
P 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0 7365 7356 9 16 122 
(56 – 232) 
218 
(124 – 353) 
0.56 
(0.22 – 1.35) 
0.168 
6.1 – 12.0 9841 9827 6 11 61 
(22 – 133) 
112 
(56 – 200) 
0.54 
(0.17 – 1.61) 
0.237 
1.5 – 12.0 17 206 17 183 15 27 87 
(49 – 144) 
157 
(104 – 229) 
0.55 
(0.27 – 1.08) 
0.065 
12.1 – 24.0 19 675 19 647 11 14 56 
(28 – 100) 
71 
(39 – 120) 
0.78 
(0.32 – 1.86) 
0.555 
24.1 – 36.0 19 666 19 639 2 8 10 
(1 – 37) 
41 
(18 – 80) 
0.25 
(0.03 – 1.25) 
0.065 
36.1 – 48.0 19 664 19 637 7 6 36 
(14 – 73) 
31 
(11 – 67) 
1.17 
(0.34 – 4.20) 
0.792 
48.1 – 60.0 21 596 21 685 4 5 19 
(5 – 47) 
23 
(7 – 54) 
0.80 
(0.16 – 3.73) 
0.759 
>60.0 52 478 52 595 6 5 11 
(4– 25) 
10 
(3 – 22) 
1.20 
(0.31 – 4.98) 
0.772 
All ages 150 285 150 386 45 65 30 
(22 – 40) 
43 
(33 – 55) 
0.69 
(0.46 – 1.03) 
0.058 
  83 
Table 30: Incidence of bacteriologically-confirmed PTB, according to vaccination status: all tuberculosis episodes 
 
+
 All bacteriologically-confirmed PTB (smear and culture-positive cases), including recurrences.
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of culture- and 
smear-positive PTB 
 cases diagnosed 
+
 
 
Confirmed tuberculosis 
incidence  
(cases per 100 000 hospital 
child-years of 
follow-up, 95% CI) 
 
 
Incidence 
Rate Ratio 
(95% CI) 
 
P 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0 7365 7356 9 16 122 
(56 – 232) 
218 
(124 – 353) 
0.56 
(0.22 – 1.35) 
0.168 
6.1 – 12.0 9841 9827 6 11 61 
(22 – 133) 
112 
(56 – 200) 
0.54 
(0.17 – 1.61) 
0.237 
1.5 – 12.0 17 206 17 183 15 27 87 
(49 – 144) 
157 
(104 – 229) 
0.55 
(0.27 – 1.08) 
0.065 
12.1 – 24.0 19 675 19 647 12 14 61 
(32 – 107) 
71 
(39 – 120) 
0.86 
(0.36 – 1.99) 
0.698 
24.1 – 36.0 19 666 19 639 3 9 15 
(3 – 45) 
46 
(21 – 87) 
0.33 
(0.06 – 1.33) 
0.092 
36.1 – 48.0 19 664 19 637 7 9 36 
(14 – 73) 
46 
(21 – 87) 
0.78 
(0.25 – 2.34) 
0.627 
48.1 – 60.0 21 596 21 685 6 8 28 
(10 – 60) 
37 
(16 – 73) 
0.75 
(0.22 – 2.48) 
0.613 
>60.0 52 478 52 595 11 11 21 
(10 – 38) 
21 
(10 – 37) 
1.00 
(0.39 – 2.55) 
0.996 
All ages 150 285 150 386 54 78 36 
(27 – 47) 
52 
(41 – 65) 
0.69 
(0.48 – 0.99) 
0.037 
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Table 31: Incidence of confirmed PTB, according to vaccination status: all tuberculosis episodes 
 
+ All smear-positive PTB cases, including recurrences. 
 
Age group 
(months) 
 
Hospital child-years of  
follow-up 
 
 
Number of smear-positive 
PTB cases diagnosed * 
 
Confirmed PTB incidence  
(cases per 100 000 hospital  
child-years of 
follow-up, 95% CI) 
 
 
Incidence  
Rate Ratio 
(95% CI) 
 
P 
PCV  Placebo PCV Placebo PCV Placebo 
1.5 – 6.0 7365 7356 3 4 41 
(8 – 119) 
54 
(15 – 139) 
0.75 
(0.11 – 4.43) 
0.725 
6.1 – 12.0 9841 9827 2 2 20 
(2 – 73) 
20 
(2 – 74) 
1.00 
(0.07 – 13.78) 
0.999 
1.5 – 12.0 17 206 17 183 5 6 29 
(9 – 68) 
35 
(13 – 76) 
0.83 
(0.20 – 3.27) 
0.773 
12.1 – 24.0 19 675 19 647 2 2 10 
(1 – 37) 
10 
(1 – 37) 
1.00 
(0.07 – 13.78) 
0.999 
24.1 – 36.0 19 666 19 639 2 1 10 
(1 – 37) 
5 
(0.1 – 28) 
2.00 
(0.10 – 117.83) 
0.626 
36.1 – 48.0 19 664 19 637 0 2 0 
(0 – 19) 
10 
(1 – 37) 
0 
(0 – 5.32) 
0.250 
48.1 – 60.0 21 596 21 685 2 1 9 
(1 – 33) 
5 
(0.1 – 26) 
2.01 
(0.10 – 118.48) 
0.623 
>60.0 52 478 52 595 7 3 13 
(5 – 27) 
6 
(1 – 17) 
2.33 
(0.53 – 14.01) 
0.225 
All ages 150 285 150 386 18 15 12 
(7 – 19) 
10 
(6 – 16) 
1.20 
(0.57 – 2.56) 
0.606 
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When exploring the relationship between vaccine and culture-proven tuberculosis by HIV 
status, significant differences in the incidences of culture-confirmed PTB could be 
demonstrated in the HIV-infected children, and a similar (although non-significant) trend 
was observed in the HIV-uninfected children. HIV-infected children who received PCV 
exhibited a 47 percent (95% CI, 10 – 69) reduction in hospitalisation with culture positive 
PTB compared to those who received placebo, P=0.017 (Table 32).  
 
When children who were diagnosed with recurrent tuberculosis episodes were included in 
the analysis (Table 33), this effect was again demonstrated amongst the culture-confirmed 
cases that were HIV-infected, with a calculated 44 percent decrease in culture-confirmed 
tuberculosis cases (95% CI, 10 – 66), P=0.015, amongst PCV recipients compared to 
placebo recipients. 
 
These data suggest that up to 47 percent of culture-confirmed PTB in HIV-infected children 
occurs in the context of concurrent S. pneumoniae infection. As proportions of HIV-
infected children in the definite PTB group according to vaccine status (20 [64.5%] of 31 
cases in PCV recipients versus 38 [69.1%] of 55 cases in placebo recipients, Table 32) did 
not differ significantly, P=0.664, these findings are likely to represent a true PCV effect, 
and not merely a chance finding following selection bias between the vaccination groups. 
  
The intention-to-treat analysis (as conducted in Table 34) failed to erode the statistical 
significance of the reduction in culture-confirmed tuberculosis amongst PCV-vaccinated 
HIV-infected children compared to those who received placebo (RR 0.53; 95% CI, 0.31 – 
0.90), P=0.017.
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Table 32: PTB cases according to HIV and vaccination status: incident tuberculosis 
 
* Excluding recurrent PTB episodes. Denominators for each group by HIV and vaccination status are derived from Table 1. 
 
§
 Fisher‟s exact test.
  
All PTB * 
 
Confirmed PTB * 
 
 
Culture-confirmed PTB *  
 
All cases 
 
HIV-
infected 
HIV-
uninfected 
All cases HIV-
infected 
HIV-
uninfected 
All cases HIV-
infected 
HIV-
uninfected 
Vaccinated 
group  
(%) 
 
185 / 19 922 
(0.93) 
119 / 1289 
(9.23) 
66 / 18 633 
(0.35) 
14 / 19 922 
(0.07) 
9 / 1289 
(0.70) 
5 / 18 633 
(0.03) 
31 / 19 922 
(0.16) 
20 / 1289 
(1.55) 
11 / 18 633 
(0.06) 
Placebo group 
(%) 
 
204 / 19 914 
(1.02) 
138 / 1288 
(10.71) 
66 / 18 626 
(0.35) 
9 / 19 914 
(0.05) 
6 / 1288 
(0.47) 
3 / 18 626 
(0.02) 
55 / 19 914 
(0.28) 
38 / 1288 
(2.95) 
17 / 18 626 
(0.09) 
Risk Ratio 
 
 
0.91 
 
0.86 1.00 1.55 1.50 1.67 0.56 0.53 0.65 
95% 
Confidence 
Interval 
0.74 – 1.11 0.68 – 1.09 0.71 – 1.41 0.67 – 3.59 0.54 – 4.20 0.40 – 6.97 0.36 – 0.87 0.31 – 0.90 0.30 – 1.38 
P 0.331 0.209 0.998 0.298 0.438 0.727 
§
 0.010 0.017 0.256 
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Table 33: PTB cases according to HIV and vaccination status: all tuberculosis episodes 
 
+ 
Including recurrent PTB cases. Denominators for each group by HIV and vaccination status are derived from Table 1. 
 
§
 Fisher‟s exact test. 
 
  
All PTB 
+
 
 
Number Confirmed PTB  
cases diagnosed 
+
 
 
 
Culture-confirmed PTB 
+
 
 
All cases HIV-
infected 
HIV-
uninfected 
All cases HIV-
infected 
HIV-
uninfected 
All cases HIV-
infected 
HIV-
uninfected 
Vaccinated 
group 
(%) 
 
211 / 19 922 
(1.06) 
143 / 1289 
(11.09) 
68 / 18 633 
(0.36) 
18 / 19 922 
(0.09) 
13 / 1289 
(1.01) 
5 / 18 633 
(0.03) 
36 / 19 922 
(0.18) 
25 / 1289 
(1.94) 
11 / 18 633 
(0.06) 
Placebo group 
(%) 
239 / 19 914 
(1.20) 
168 / 1288 
(13.04) 
71 / 18 626 
(0.38) 
 
14 / 19 914 
(0.07) 
11 / 1288 
(0.85) 
3 / 18 626 
(0.02) 
 
63 / 19 914 
(0.32) 
45 / 1288 
(3.49) 
18 / 18 626 
(0.10) 
 
Risk Ratio 
 
 
0.88 0.85 0.96 1.81 1.18 1.67 0.57 0.56 0.61 
95% 
Confidence 
Interval 
0.73 – 1.06 0.69 – 1.05 0.69 – 1.33 0.53 – 2.63 0.53 – 2.63 0.40 – 6.97 0.38 – 0.86 0.34 – 0.90 0.29 – 1.29 
P 0.183 0.129 0.797 0.683 0.683 0.727 
§
 0.007 0.015 0.193 
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Table 34: Risk for PTB amongst children by HIV and vaccination status 
     
 
      
 All PTB* Culture-confirmed PTB* 
 
 
Intention-to-treat 
+
 
 
 
Per protocol 
++
 
 
 
Intention-to-treat
 +
 
 
 
Per protocol 
++
 
 
H
IV
-i
n
fe
ct
ed
 
Vaccinated group (%) 
 
118 / 1289 (9.2) 104 / 1201 (8.7) 20 / 1289 (1.6) 17 / 1201 (1.4) 
Placebo group (%) 
 
138 / 1288 (10.7) 132 / 1200 (11.0) 38 / 1288 (3.0) 34 / 1200 (2.8) 
Risk Ratio 
 
0.85 0.79 0.53 0.50 
95% Confidence Interval 0.68 – 1.08 0.62 – 1.00 0.31 – 0.90 0.28 – 0.89 
P 0.186 0.054 0.017 0.016 
H
IV
-u
n
in
fe
ct
ed
 
Vaccinated group (%) 
 
63 / 18633 (0.3) 55 / 17356 (0.3) 11 / 18633 (0.06) 11 / 17356 (0.06) 
Placebo group (%) 
 
66 / 18626 (0.4) 62 / 17350 (0.4) 17 / 18626 (0.09) 16 / 17350 (0.09) 
Risk Ratio 
 
0.95 0.89 0.68 0.69 
95% Confidence Interval 0.68 – 1.35 0.62 – 1.27 0.32 – 1.45 0.32 – 1.48 
P 0.790 0.516 0.319 0.335 
* Excluding recurrent PTB cases. 
+ 
Intention-to-treat analysis includes children who received fewer than 3 doses of PCV or placebo. 
++
 Per protocol analysis: children that received 3 doses of PCV or placebo as per study schedule and in whom vaccine efficacy-
related events occurred more than 14 days following the third dose of study vaccine. 
. 
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3.3 The Burden of Tuberculosis Amongst PCV Study Participants 
3.3.1 Incidence rates of tuberculosis for the cohort by HIV status 
The incidence rate for PTB, of which 391 cases were identified in the PCV Study cohort, 
was 982 per 100 000 (95% CI, 887 – 1084). Three hundred and eighty-six incident cases of 
PTB arose in children with defined HIV status: 255 (66.1%) of these arose amongst HIV-
infected children, yielding an incidence rate for PTB in these children of 9895 per 100 000        
(95% CI, 8718 – 11 187), whilst 131 (33.9%) incident PTB cases were identified in HIV-
uninfected children (352 cases per 100 000 children: 95% CI, 294 – 417). HIV-infected 
children had a 28-fold increased risk for incident PTB (95% CI, 22.9 – 34.6) compared to 
HIV-uninfected children, P<0.001 (Table 35). 
 
The tuberculosis incidence rate for all forms of the disease (425 incident cases in the study 
cohort of 39 836 children) was 1067 cases per 100 000 (95% CI, 968 – 1173): 296 per    
100 000 (95% CI, 245 – 355) for bacteriologically-confirmed tuberculosis (Table 35). 
HIV-infected children carried an incidence rate of 10 633 (95% CI, 9411 – 11 969) per   
100 000 for all forms of tuberculosis, and a rate of 3027 (95% CI, 2393 – 3778) per        
100 000 for bacteriologically-confirmed disease. HIV-uninfected children carried incidence 
rates of 386 (95% CI, 326 – 455) per 100 000, and 105 (95% CI, 74 – 143) per 100 000 for 
all forms of tuberculosis and bacteriologically-confirmed tuberculosis, respectively (Table 
35 and Figure 8). This translated into a significantly greater risk of active tuberculosis 
amongst the HIV-infected children compared to those who were HIV-uninfected (RR 27.5; 
95% CI, 22.6 – 33.5), P<0.001, for all forms of tuberculosis, as well as for 
bacteriologically-confirmed tuberculosis (RR 28.9; 95% CI, 19.7 – 42.4), P<0.001. 
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Table 35: Incidence rates for tuberculosis in the PCV Study cohort: first episode tuberculosis 
 
 
 
 
  
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(HIV-infected to  
HIV-uninfected, using 
baseline cohort size
+
) 
 
P 
 
 
All * 
 
HIV-
infected  
HIV-
uninfected 
All HIV-infected HIV-
uninfected 
Definite PTB 86 58 28 216 
(173 – 267) 
2251 
(1709 – 2910) 
75 
(50 – 109) 
29.9 (19.1 – 46.9) < 0.001 
Definite EPTB 8 5 3 20 
(9 – 40) 
194 
(63 – 453) 
8 
(2 – 24) 
24.1 (5.8 – 100.8) < 0.001 § 
Confirmed PTB 24 15 8 60 
(39 – 90) 
582 
(326 – 960) 
21 
(9 – 42) 
27.1 (11.5 – 63.9) < 0.001 § 
Bacteriologically-
confirmed 
tuberculosis** 
118 78 39 296 
(245 – 355) 
3027 
(2393 – 3778) 
105 
(74 – 143) 
28.9 (19.7 – 42.4) < 0.001 
Probable PTB 122 64 55 306 
(254 – 366) 
2484 
(1913 – 3171) 
148 
(111 – 192) 
16.8 (11.8 – 24.1) < 0.001 
Probable EPTB 25 13 10 63 
(41 – 93) 
504 
(269 – 863) 
27 
(13 – 49) 
18.7 (8.2 – 42.8) < 0.001 § 
Suspected tuberculosis 160 119 40 402 
(342 – 469) 
4618 
(3825 – 5526) 
107 
(77 – 146) 
43.0 (30.1 – 61.4) < 0.001 
All PTB 391 255 131 982 
(887 – 1084) 
9895 
(8718 – 11 187) 
352 
(294 – 417) 
28.1 (22.9 – 34.6) <0.001 
All tuberculosis  425 274 144 1067 
(968 – 1173) 
10 633 
(9411 – 11 969) 
386 
(326 – 455) 
27.5 (22.6 – 33.5) < 0.001 
* Including cases with undefined HIV status. 
 
** Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
  
+ 
Baseline cohort size: HIV-infected (n=2577), HIV-uninfected (n=37 259).  
§
 Fisher‟s exact test. 
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Figure 8: Tuberculosis disease categories for incident tuberculosis according to HIV status 
 
This Figure is derived from Table 35. 
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Table 36: Incidence rates for tuberculosis in the PCV Study cohort: all episodes 
  
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(HIV-infected to  
HIV-uninfected, using 
baseline cohort size
+
) 
 
P 
 
 
All * 
 
HIV-
infected 
HIV-
uninfected 
All HIV-infected HIV-
uninfected 
Definite PTB 99 70 29 249 
(202 – 303) 
2716 
(2118 – 3432) 
78 
(52 – 112) 
34.9 
(22.7 – 53.7) 
< 0.001 
Definite EPTB 9 6 3 23 
(10 – 43) 
233 
(85 – 507) 
8 
(2 – 24) 
28.9 
(7.2 – 115.6) 
< 0.001  
Confirmed PTB 33 24 8 83 
(57 – 116) 
931 
(597 – 1386) 
21 
(9 – 42) 
43.4 
(19.5  – 96.5) 
< 0.001 
§
 
Bacteriologically-
confirmed 
tuberculosis** 
141 100 40 354 
(298 – 417) 
3880 
(3157 – 4720) 
107 
(77 – 146) 
36.1 
(5.1 – 52.0) 
< 0.001 
Probable PTB 136 75 58 341 
(286 – 404) 
2910 
(2289 – 3648) 
156 
(118 – 201) 
18.7 
(13.3 – 26.3) 
< 0.001 
Probable EPTB 33 21 10 83 
(57 – 116) 
815 
(504 – 1246) 
27 
(13 – 49) 
30.4 
(14.3 – 64.4) 
< 0.001 
§
 
Suspected tuberculosis 182 138 43 457 
(393 – 528) 
5355 
(4499 – 6327) 
115 
(84 – 155) 
46.4 
(33.0 – 65.2) 
< 0.001 
All PTB 449 306 138 1127 
(1025 – 1236) 
11 874 
(10 581 – 13 282) 
370 
(311 - 438) 
32.1 (26.3 – 39.0) <0.001 
All tuberculosis  492 334 151 1235 
(1128 – 1349) 
12 961 
(11 608 – 14 428) 
405 
(343 – 475) 
32.0 
(26.5 – 38.6) 
< 0.001 
* Including cases with undefined HIV status. 
 
** Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: HIV-infected (n=2577), HIV-uninfected (n=37 259).  
§
 Fisher‟s exact test. 
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Table 36 explores the Public Health impact of hospital-diagnosed tuberculosis in the PCV 
study cohort according to HIV status by including all tuberculosis episodes in the analysis. 
This analysis is important, as the hospital-based diagnosis of tuberculosis in these children 
would have necessitated referral to primary health care clinics for on-going treatment of 
their disease. It is therefore useful to estimate the additional burden which recurrent 
tuberculosis episodes would have on the Primary Health Care System. 
 
3.3.2 HIV-uninfected status as a proxy for ‘tuberculosis vaccination’ 
An alternative means of confirming the calculated relative risk for active tuberculosis 
disease in HIV-infected compared to HIV-uninfected children, is to apply a „vaccine 
efficacy‟ calculation using the proportions of cases of tuberculosis arising within a cohort 
according to the HIV status of the participants
48 49
.  As all of the study participants received 
BCG at birth regardless of HIV-infection status, some degree of BCG-derived background 
immunity against tuberculosis would be anticipated in the cohort. 
 
In the context of tuberculosis, one could consider HIV infection (with its adverse impact on 
immune status) as diminishing the BCG-primed, intact immune system‟s ability to maintain 
tuberculosis infection in its latent state; consequently, HIV-infected individuals are at 
greater risk for progression to active tuberculosis disease after primary infection with MTB. 
BCG-vaccinated, HIV-uninfected children are essentially protected (or „vaccinated‟) 
against active tuberculosis compared to HIV-infected children by virtue of their intact 
immune surveillance mechanisms. The calculation is highlighted in Appendix 6, page 133. 
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When comparing the relative burden of tuberculosis in the HIV-infected children to that in 
the HIV-uninfected children, the IRR of 27.5 using the „vaccine efficacy‟ calculation was 
equivalent to the measured Risk Ratio of 27.5 which was derived from the statistical 
analysis of the cohort disease burden in Section 3.3.1. It is noteworthy that, by using this 
method, it can also be shown that HIV-infected children were 29.4 times more likely to 
develop culture-confirmed tuberculosis compared to HIV-uninfected children (see 
Appendix 6, page 133). An additional important finding of this approach is that the 
immune response to BCG in an HIV-uninfected child appears to be 96.4 percent relatively 
more effective in preventing progression to active tuberculosis compared to the immune 
system of a BCG-vaccinated HIV-infected child. 
 
3.3.3 Incidence rates of tuberculosis for the cohort by vaccination status 
As has been demonstrated in Section 3.2, PCV played a significant role in limiting the 
incidence of culture-confirmed PTB amongst HIV-infected children.  
 
When analysing the tuberculosis incidence rates for different categories of tuberculosis 
disease in the cohort according to vaccination status, children who received PCV had a 
significantly lower burden of culture-confirmed PTB episodes (RR 0.56; 95% CI, 0.36 – 
0.87), P=0.010, compared to the placebo recipients (Table 37). 
 
In the incidence rate calculation of all tuberculosis cases in children with defined HIV 
status (Table 38), PCV was associated with a significant reduction in culture-confirmed 
PTB (RR 0.57; 95% CI, 0.38 – 0.86), P=0.007.  
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Table 37: Incidence of tuberculosis according to disease category and vaccination status: first episode tuberculosis 
 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=19 922), Placebo (n=19 914).  
§
 Fisher‟s exact test.
  
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 86 31 55 216 
(173 – 267) 
156 
(106 – 221) 
276 
(208 – 360) 
0.56 
(0.36 – 0.87) 
0.010 
Definite EPTB 8 2 6 201 
(87 – 396) 
10 
(1 – 36) 
30 
(11 – 66) 
0.33 
(0.07 – 1.65) 
0.180 
§
 
Confirmed PTB 24 14 10 60 
(39 – 90) 
70 
(38 – 118) 
50 
(24 – 92) 
1.40 
(0.62 – 3.15) 
0.415 
Bacteriologically-
confirmed tuberculosis* 
118 47 71 296 
(245 – 355) 
236 
(173 – 314) 
357 
(278 – 450) 
0.66 
(0.46 – 0.96) 
0.027 
Probable PTB 122 60 62 306 
(254 – 366) 
301 
(230 – 388) 
311 
(239 – 399) 
0.97 
(0.68 – 1.38) 
0.854 
Probable EPTB 25 17 8 63 
(41 – 93) 
85 
(50 – 137) 
40 
(17 – 79) 
2.12 
(0.92 – 4.92) 
0.072 
Suspected tuberculosis 160 81 79 402 
(342 – 469) 
407 
(323 – 505) 
397 
(314 – 494) 
1.02 
(0.75 – 1.40) 
0.876 
All PTB 391 185 206 1067 
(968 – 1173) 
1029 
(893 – 1180) 
1034 
(898 – 1156) 
0.90 
(0.74 – 1.09) 
0.284 
All tuberculosis  425 205 220 1067 
(968 – 11 733) 
1029 
(893 – 1180) 
1105 
(964 – 1261) 
0.93 
(0.77 – 1.13) 
0.462 
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Table 38: Incidence of tuberculosis according to disease category and vaccination status: all episodes 
 
  
  
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 99 36 63 249 
(202 – 303) 
181 
(127 – 250) 
316 
(243 – 405) 
0.57  
(0.38 – 0.86) 
0.007 
Definite EPTB 9 2 7 23 
(10 – 43) 
10 
(1 – 36) 
35 
(14 – 72) 
0.29 
(0.06 – 1.37) 
0.109 
§
  
Confirmed PTB 33 18 15 83 
(57 – 116) 
90 
(54 – 143) 
75 
(42 – 124) 
1.20 
(0.60 – 2.38) 
0.602 
Bacteriologically-
confirmed tuberculosis* 
141 56 85 354 
(298 – 417) 
281 
(212 – 365) 
427 
(341 – 528) 
0.66 
(0.47 – 0.92) 
0.014 
Probable PTB 136 65 71 341 
(286 – 404) 
326 
(252 – 416) 
357 
(278 – 450) 
0.92 
(0.65 – 1.28) 
0.605 
Probable EPTB 33 21 12 83 
(57 – 116) 
105 
(65 – 161) 
60 
(31 – 105) 
1.75 
(0.86 – 3.55) 
0.117 
Suspected tuberculosis 182 91 91 457 
(393 – 528) 
457 
(368 – 561) 
457 
(368 – 561) 
1.00 
(0.75 – 1.34) 
1.000 
All PTB 449 209 240 1127 
(1025 – 1236) 
1049 
(912 – 1201) 
1205 
(1058 – 1368) 
0.87 
(0.72 – 1.05) 
0.140 
All tuberculosis  492 233 259 1235 
(1128 – 1349) 
1170 
(1024 – 1330) 
1301 
(1147 – 1469) 
0.90 
(0.75 – 1.07) 
0.236 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=19 922), Placebo (n=19 914).  
§
 Fisher‟s exact test. 
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3.3.4 Incidence rates of tuberculosis for the cohort by vaccination and HIV status 
Tables 39 through 42 illustrate the tuberculosis incidence rates by category of tuberculosis 
disease according to vaccination and HIV status, and highlight the fact that PCV recipients 
who were HIV-infected had a significant reduction in incident and recurrent culture-
confirmed PTB.  
 
PCV-vaccinated HIV-infected children with incident tuberculosis exhibited a 47 percent 
(95% CI, 10 – 69) reduction in culture confirmed PTB compared to the placebo recipients, 
P=0.017 (Table 39); there was a 44 percent (95% CI, 10 – 66), P=0.015, reduction in 
culture-confirmed PTB in HIV-infected PCV recipients compared to the placebo recipients 
when analysing for all tuberculosis episodes (Table 40). 
 
This effect was not readily appreciated in PCV-vaccinated HIV-uninfected children in 
whom relative risks for culture-confirmed PTB were not statistically diminished compared 
to those in the placebo group (Tables 41 and 42). The inability to demonstrate a reduction 
in culture-confirmed tuberculosis amongst HIV-uninfected PCV recipients, whereas 
significance was demonstrated in the HIV-infected children, may be because the study was 
not adequately powered to explore this effect amongst HIV-uninfected children.  
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Table 39: Incidence of tuberculosis according to vaccination status in HIV-infected children: first episode tuberculosis  
 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=1289), Placebo (n=1288).  
§ 
Fisher‟s exact test. 
 
HIV-infected 
 
Tuberculosis cases 
identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 58 20 38 2251 
(1709 – 2910) 
1552 
(948 – 2396) 
2950 
(2088 – 4050) 
0.53 
(0.31 – 0.90) 
0.017 
Definite EPTB 5 2 3 194 
(63 – 453) 
155 
(19 – 560) 
233 
(48 – 681) 
0.67 
(0.11 – 3.98) 
0.687 
§
 
Confirmed PTB 15 9 6 582 
(326 – 960) 
698 
(319 – 1325) 
466 
(171 – 1014) 
1.50 
(0.54 – 4.20) 
0.438 
Bacteriologically-
confirmed tuberculosis* 
78 31 47 3027 
(2393 – 3778) 
2405 
(1634 – 3414) 
3649 
(2681 – 4852) 
0.66  
(0.42 – 1.03) 
0.065 
Probable PTB 64 32 32 2484 
(1913 – 3171) 
2483 
(1698 – 3505) 
2484 
(1699 – 3507) 
1.00 
(0.62 – 1.62) 
1.000 
Probable EPTB 13 7 6 504 
(269 – 863) 
543 
(218 – 112) 
466 
(171 – 1014) 
1.17 
(0.39 – 3.46) 
0.782 
Suspected tuberculosis 119 58 61 4618 
(3825 – 5526) 
4500 
(3417 – 5817) 
4736 
(3623 – 6084) 
0.95 
(0.67 – 1.35) 
0.775 
All PTB 255 118 137 9895 
(872 – 11 187)) 
9154 
(7577 – 10 963) 
10 637 
(893 – 12 574) 
0.86 
(0.68 – 1.09) 
0.208 
All tuberculosis  274 128 146 10 633 
(9411 – 11 969) 
9930 
(8285 – 11 807) 
11 335 
(9571 – 13 330) 
0.88 
(0.70 – 1.10) 
0.247 
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Table 40: Incidence of tuberculosis according to vaccination status in HIV-infected children: all episodes 
 
 
HIV-infected 
 
Tuberculosis cases 
identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using 
baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 70 25 45 2716 
(2118 – 3432) 
1939 
(1255 – 2863) 
3494 
(2548 – 4675) 
0.56 
(0.34 – 0.90) 
0.015 
Definite EPTB 6 2 4 233 
(85 – 507) 
155 
(19 – 560) 
311 
(85 – 795) 
0.50 
(0.09 – 2.72) 
0.453 
§
  
Confirmed PTB 24 13 11 931 
(597 – 1386) 
1009 
(537 – 1725) 
854 
(426 – 1528) 
1.18 
(0.53 – 2.63) 
0.683 
Bacteriologically-
confirmed tuberculosis* 
100 40 60 3880 
(3157 – 4720) 
3103 
(2217 – 4226) 
4658 
(3555 – 5996) 
0.67 
(0.45 – 0.99) 
0.041 
Probable PTB 75 36 39 2910 
(2289 – 3648) 
2793 
(1956 – 3867) 
3028 
(2153 – 4139) 
0.92 
(0.59 – 1.44) 
0.723 
Probable EPTB 21 11 10 815 
(504 – 1246) 
853 
(426 – 1527) 
776 
(372 – 1428) 
1.10 
(0.47 – 2.58) 
0.828 
Suspected tuberculosis 138 67 71 5355 
(4499 – 6327) 
5198 
(4028 – 6601) 
5512 
(4305 – 6953) 
0.94 
(0.68 – 1.30) 
0.723 
All PTB 306 140 166 11 874 
(10 581 – 13 282) 
10 861 
(9137 – 12 817) 
12 888 
(11 002 – 15 005) 
0.84 
(0.68 – 1.04) 
0.112 
All tuberculosis  334 154 180 12 961 
(11 608 – 14 428) 
11 947 
(10 135 – 13 990) 
13 975 
(12 008 – 16 173) 
0.85 
(0.70 – 1.05) 
0.125 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=1289), Placebo (n=1288).  
§
 Fisher‟s exact test. 
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Table 41: Incidence of tuberculosis according to vaccination status in HIV-uninfected children: fist episode tuberculosis 
 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=18 633), Placebo (n=18 626).  
§
 Fisher‟s exact test. 
 
HIV-uninfected 
 
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 28 11 17 75 
(50 – 109) 
59  
(29 – 106) 
91 
(53 – 146) 
0.65 
(0.30 – 1.38) 
0.256 
Definite EPTB 3 0 3 8 
(2 – 24) 
0 
(0 – 20) 
16 
(3 – 47) 
- 0.125 
§
 
Confirmed PTB 8 5 3 21 
(9 – 42) 
27 
(9 – 63) 
16 
(3 – 47) 
1.67 
(0.40 – 6.97) 
0.727 
§
 
Bacteriologically-
confirmed tuberculosis* 
39 16 23 105 
(74 – 143) 
86 
(49 – 139) 
123 
(78 – 185) 
0.70 
(0.37 – 1.32) 
0.262 
Probable PTB 55 27 28 148 
(111 – 192) 
145 
(95 – 211) 
150 
(100 – 217) 
0.96 
(0.57 – 1.63) 
0.892 
Probable EPTB 10 8 2 27 
(13 – 49) 
43 
(19 – 85) 
11 
(1 – 39) 
4.00 
(0.85 – 18.83) 
0.109 
§
 
Suspected tuberculosis 40 22 18 107 
(77 – 146) 
118 
(74 – 179) 
97 
(57 – 153) 
1.22 
(0.66 – 2.28) 
0.528 
All PTB 131 65 66 352 
(294 – 417) 
349 
(269 – 445) 
354 
(274 – 251) 
0.98 
(0.70 – 1.39) 
0.929 
All tuberculosis  144 73 71 386 
(326 – 455) 
392 
(307 – 493) 
381 
(298 – 481) 
1.03 
(0.74 – 1.42) 
0.869 
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Table 42: Incidence of tuberculosis according to vaccination status in HIV-uninfected children: all episodes 
 
 
HIV-uninfected 
 
Tuberculosis cases identified 
 
Tuberculosis Incidence Rates 
(cases per 100 000 PCV participants), 95% CI 
 
 
Risk Ratio 
(PCV and Placebo 
groups, using baseline  
cohort size
+
) 
 
P 
 
 
All 
 
PCV Placebo All PCV Placebo  
Definite PTB 29 11 18 78 
(52 – 112) 
59 
(29 – 106) 
97 
(57 – 153) 
0.61 
(0.29 – 1.29) 
0.193 
Definite EPTB 3 0 3 8 
(2 – 24) 
0 
(0 – 20) 
16 
(3 – 47) 
- 0.125 
§
 
Confirmed PTB 8 5 3 21 
(9 – 42) 
27 
(9 – 63) 
16 
(3 – 47) 
1.69 
(0.40 – 6.97) 
0.727 
§
 
Bacteriologically-
confirmed tuberculosis* 
40 16 24 107 
(77 – 146) 
86 
(49 – 139) 
129 
(83 – 192) 
0.67 
(0.35 – 1.25) 
0.205 
Probable PTB 58 28 30 156 
(118 – 201) 
150 
(100 – 217) 
161 
(109 – 230) 
0.93 
(0.56 – 1.56) 
0.792 
Probable EPTB 10 8 2 27 
(13 – 49) 
43 
(19 – 85) 
11 
(1 – 39) 
4.00 
(0.85 – 18.83) 
0.109 
§
 
Suspected tuberculosis 43 23 20 115 
(84 – 155) 
123 
(78 – 185) 
107 
(66 – 166) 
1.15 
(0.63 – 2.09) 
0.648 
All PTB 138 67 71 370 
(311 – 438) 
360 
(279 – 457) 
381 
(298 – 481) 
0.94 
(0.68 – 1.32) 
0.731 
All tuberculosis  151 75 76 405 
(343 – 475) 
403 
(317 – 505) 
408 
(321 – 511) 
0.99 
(0.72 – 1.36) 
0.933 
* Bacteriologically-confirmed tuberculosis consists of „Definite PTB‟, „Definite EPTB‟ and „Confirmed PTB‟ cases.  
 
+ 
Baseline cohort size: PCV (n=18 633), Placebo (n=18 626).  
§
 Fisher‟s exact test. 
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4.0 DISCUSSION 
4.1 General Comments 
This retrospective analysis of secondary endpoints of an important PCV efficacy trial 
which was conducted in Soweto from 1998 to 2006 elucidates some intriguing information 
regarding the burden and spectrum of tuberculosis in children below the age of six years 
that were resident in the study setting. 
 
A large proportion (64.5%) of the children with tuberculosis, and 66 percent of all incident 
culture-proven disease in this cohort, had confirmed HIV infection, as has been 
demonstrated in a number of descriptive studies from Southern Africa which have revealed 
that 11 to 64 percent of childhood tuberculosis cases in the region are HIV-infected 
15
 
51
 
52
.  
 
As this study was largely conducted before April 2004, when antiretroviral therapy was 
first made widely available to patients in the public health sector of South Africa, these 
findings represent the natural history of HIV and tuberculosis (HIV-TB) co-infection in 
high HIV-TB burdened settings in the absence of antiretroviral therapy. 
 
The finding that the median age of children diagnosed with tuberculosis was significantly 
older in HIV-infected children (19.8 months; IQR 7.7 – 44.3) compared to HIV-uninfected 
children (12.3 months; IQR 6.0 – 26.3), P<0.001, indicates that these individuals remain 
persistently vulnerable to progression of LTBI to active disease. This was further illustrated 
by the finding of significantly higher tuberculosis incidence rates amongst the HIV-infected 
children in the cohort, these children having a 27.5-fold greater burden of tuberculosis 
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(95% CI, 22.6 – 33.5), P<0.001, compared to HIV-uninfected children (Table 35 and 
Figure 8). This relative risk for tuberculosis corresponds well with that which was 
estimated to have occurred in a cohort of paediatric patients with pneumonia that was 
investigated by Madhi et al. at CHBH in 1997 and 1998, where HIV-infected children were 
found to have a 22.5-fold increased risk for active tuberculosis compared to HIV-
uninfected children
23
; additionally, a recent study reporting on the incidence of culture-
confirmed tuberculosis in an infant cohort in Cape Town identified a relative risk of 
tuberculosis amongst HIV-infected compared to HIV-uninfected infants of 24.2 (95% CI, 
17 – 34)53. 
 
A novel finding in this study, through the application of the „vaccine efficacy‟ calculation 
in order to derive the degree of protection which a BCG-vaccinated, immunocompetent  
(i.e. HIV-uninfected) immune system confers in limiting progression to active tuberculosis, 
is that BCG vaccine in HIV-uninfected children is 96 percent relatively more effective in 
protecting against active disease (all forms, as well as culture-confirmed cases) compared 
to BCG-vaccinated HIV-infected children in children hospitalised with tuberculosis (see 
Section 3.3.2, page 93 and Appendix 6, page 133). This finding adds further motivation to 
strengthen prevention of mother to child transmission (PMTCT) programmes in high-
burdened settings, in an effort to prevent vertical transmission of HIV to infants
54
. 
 
Although there is evidence to support a reduction in vulnerability to tuberculosis in HIV-
infected children who have been initiated on highly active antiretroviral therapy 
(HAART)
55
, this effect could not be adequately explored in this cohort because data 
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relating to which of the children were initiated on HAART during the study period were not 
captured for analysis.  
 
Not only do the results of this study offer a window onto the natural history of HIV-TB   
co-infection in the pre-HAART era as mentioned above, but it also offers a unique 
perspective on the interplay between S. pneumoniae, the PCV and MTB, highlighting the 
fact that a substantial proportion of culture-confirmed tuberculosis in hospitalised children 
in a sub-Saharan African setting arises in the context of pneumococcal co-infection. 
Demonstration of the latter effect may be difficult to reproduce in South Africa because the 
National Department of Health has recently included the PCV in the Expanded Programme 
on Immunisation (EPI) schedule and nation-wide coverage of infants is anticipated to 
commence in April 2009
56
. 
 
4.2 Effect of the PCV on Tuberculosis Incidence in the Study Cohort 
Receipt of the 9-valent PCV was demonstrated to be associated with a significant reduction 
in culture-confirmed tuberculosis in the study cohort for incident tuberculosis episodes 
(Table 4), with an apparent 40 percent (95% CI, 10 – 59) risk reduction in incident culture-
confirmed PTB, P=0.011, in vaccine compared to placebo recipients, suggesting that 
pneumococcal co-infection frequently plays a role in co-infection in paediatric cases with 
culture-confirmed tuberculosis.     
 
The incidence of PTB was demonstrably lower in vaccine recipients compared to those 
who received placebo up to the age of 36 months in the analysis of incident cases, although 
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numbers of cases and cohort size constrained demonstration of statistical significance in 
this analysis (Table 25).  
 
Reductions in the burden of culture- and bacteriologically (i.e. microscopy and/or culture 
positive) confirmed PTB could be demonstrated in the combined analysis, where case 
numbers and the magnitude of the follow-up time over which cases were detected 
combined to secure statistical significance (Tables 27, 28 and 30): PCV recipients 
exhibited apparent reductions of incident culture-confirmed tuberculosis of up to 44 percent        
(95% CI, 11 – 65), P=0.010. PCV recipients exhibited a trend towards reduction in incident 
bacteriologically-confirmed disease (RR 0.69; 95% CI, 0.46 – 1.03), P=0.058, compared to 
placebo recipients and a more striking reduction when incident and recurrent 
bacteriologically-confirmed disease episodes were combined (RR 0.69; 95% CI, 0.48 – 
0.99), P=0.037. 
 
The apparent reduction in bacteriologically-confirmed tuberculosis, indicating that culture-
confirmed disease frequently arises in the context of pneumococcal co-infection, was 
attributable mainly to the disease burden experienced by HIV-infected children, as is 
demonstrated in Tables 32 and 33. The risk ratio for incident culture-confirmed PTB 
comparing HIV-infected children who had received the PCV and those who received 
placebo was 0.53, indicating a 47 percent risk reduction (95% CI, 10 – 69), P=0.017, in 
vaccinees; therefore, up to 47 percent of culture-confirmed tuberculosis may arise in the 
context of pneumococcal co-infection in HIV-infected children.  
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An intention-to-treat analysis as represented in Table 34 suggests that the benefit of the 
apparent PCV effect on culture-confirmed tuberculosis in HIV-infected children was 
experienced in partially-vaccinated children as well as those who had completed a full 
course (3 doses, given four weeks apart) of PCV. HIV-infected children who completed a 
full course of PCV exhibited a 50 percent (95% CI, 11 – 72) reduced burden of culture-
confirmed tuberculosis compared to placebo recipients, P=0.016; this was finding was only 
marginally eroded by the intention-to-treat analysis. 
  
Three postulated PCV-related effects may explain why the incidence of culture-confirmed 
tuberculosis was significantly lower in the vaccinated children compared to those who 
received placebo. The first, and most intuitive, effect is that in high-burdened settings the 
pneumococcus is frequently implicated as a coincidental co-infecting agent in childhood 
tuberculosis and that in settings where an effective vaccine which protects children from 
pneumococcal infection can be administered, less co-infection with tuberculosis is 
appreciated.  
 
The second postulated effect relies on the assumption that co-infection with the 
pneumococcus is a significant immune regulatory disruption event and that children who 
are infected with S. pneumoniae and have LTBI are at significant risk of acutely 
reactivating their tuberculosis, with subsequent development of active tuberculosis disease; 
hence the propensity for LTBI to reactivate in the presence of an acute pneumococcal 
infection would be diminished in PCV-vaccinated compared to -unvaccinated individuals.  
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Thirdly, the corollary to the above-mentioned postulated effect may also apply: namely, 
that infection with MTB causes immune dysregulation which increases childhood 
susceptibility to infection with S. pneumoniae; in this context, children who had received 
PCV (which is known to be highly effective in protecting against invasive disease caused 
by S. pneumoniae in both HIV-infected and -uninfected children
41
) would be relatively 
better protected against secondary infection with the pneumococcus.  
 
The fact that HIV-infected children were demonstrated to have the most significant PCV-
related reductions in pneumococcal-tuberculosis co-infections (as mentioned above) may 
support either of the last two proposed explanations, as HIV-infected children invariably 
have background immune surveillance dysregulation which would be further compromised 
with the additional „hit‟ of infection with the pneumococcus and/or MTB. 
 
It has been noted that “[a]ntecedent or current infections can alter the immunopathologic 
outcome of a subsequent unrelated infection.”57 Our current understanding as to how 
pathogens interact with the host immune system, potentially creating an immunological 
milieu which may predispose to infection with other pathogens, is constantly being 
improved. Whilst the specific interactions between MTB and S. pneumoniae have not been 
studied to date, numerous experiments conducted using the murine model
58
 
59
 
60
 
61
 
62
 
highlight potential effects on both the innate and adaptive arms of the immune response 
which may impact on infection caused by either of these organisms. These immunological 
interactions are summarised in Figure 9. 
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Figure 9: Possible immunological interactions between M. tuberculosis and S. pneumoniae as 
demonstrated in the mouse model 
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Experiments conducted by Rubins et al. demonstrate that serum concentrations of gamma 
interferon (IFN-γ) have been found to increase dramatically within 48 hours of intranasal 
infection of mice with virulent strains of S. pneumoniae, the magnitude of the rise in IFN-γ 
correlating proportionately with the organism‟s virulence58. This finding is intriguing, as it 
highlights the fact that similar cytokine responses are elicited in host defense against 
pneumococci and MTB (IFN- γ is a pivotal cytokine in the immune response against 
tuberculosis
12
). 
 
Neutrophils, traditionally thought to be involved in defense against bacterial pathogens 
rather than mycobacteria per se, have been found to be essential in containing MTB 
infection in mice through nonphagocytic mechanisms, probably by immunomodulatory 
activity through the production of interleukin-12 (IL-12) at the sites of bacillary deposition 
in infected organs
59
. IL-12, which is an important immunomodulatory cytokine in the 
immune response against tuberculosis, tips the inflammatory cytokine response in favour of 
early IFN-γ production. Additionally, it has been demonstrated that neutropaenia at the time 
of infection with MTB predisposes to wide-spread dissemination of tuberculous bacilli and 
disseminated tuberculosis in mice
59
. 
 
Intracellular components of Gram positive bacteria, such as would be encountered as a 
consequence of a successful immune response to infection caused by these organisms 
(through destruction of bacterial cells by the actions of the neutrophil oxidative burst or by 
the actions of complement, for example) down-regulate the production of IL-12
60
; hence, 
recovering Gram positive infection could potentially dampen immune responses which 
control LTBI.  
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Prior influenza infection has been found to have long-term effects on Toll-like receptor 
(TLR) function in the lung, causing their desensitisation to bacterial molecular patterns 
with consequent lack of neutrophil recruitment to sites of bacterial colonisation in the 
lungs, followed by bacterial overgrowth and secondary pneumonia
61
. There is mounting 
evidence that MTB or its antigenic components can dampen TLR signaling in the lung
63
, 
and it is feasible that chronic pulmonary infection with MTB could predispose individuals 
to secondary bacterial pneumonias by similar mechanisms seen to those observed after 
recovery from influenza. 
 
Infection caused by intracellular bacteria such as Mycobacterium bovis BCG, Listeria 
monocytogenes, and Salmonella typhimurium have been found to irreversibly deplete pre-
existing CD8 memory T-cells in mice, this effect being mediated through the production of 
IFN-γ62. The effect that tuberculosis has on immunological memory has not yet been 
studied, however it is feasible that infection caused by MTB could deplete memory CD8 T-
cell populations to previously-encountered pathogens in a similar manner to that observed 
for BCG.  
 
 
4.3 Strength of Evidence for Tuberculosis in the PCV Study Cohort 
The WHO categorisation of childhood tuberculosis was adopted for use in this study in 
order to attribute the strength of evidence for a diagnosis of tuberculosis in the PCV 
efficacy trial cohort.  
 
   111 
The gold standard for a diagnosis of active tuberculosis in childhood subjects is 
demonstration of M. tuberculosis by culture from clinical specimens; however, current 
methodologies of microbiological isolation remain insensitive despite recent advances in 
culture techniques
64
, so children in whom the organism is not isolated cannot with certainty 
be classified as being tuberculosis disease free. The frequently made statement that a 
diagnosis of tuberculosis is difficult to confirm in children, rests on the fact that the 
methodologies of suitable specimen collection are labour intensive (and so frequently not 
performed), and that the yield is generally perceived to be too low to be worth the effort of 
subjecting paediatric patients to these invasive procedures.  
 
This study revealed that 26 percent of all tuberculosis episodes (and 23.4 percent of those 
with culture-confirmed disease) that were worked up for the presence of co-pathogens, had 
co-infections with significant viral and bacterial pathogens, or P. jiroveci at the tuberculosis 
index admission. This further confounding factor to accurate diagnosis of tuberculosis in 
children raises concern that children with tuberculosis may have their illness misattributed 
to identified co-pathogens rather than to tuberculosis, should microbiological tests for MTB 
remain negative.  
 
In contrast to studies in adult tuberculosis patients, where HIV-infected status tends to 
confer consistently lower yields of microbiological testing
65
, there was no difference in 
bacteriological yield between HIV-infected and -uninfected children with bacteriologically-
confirmed tuberculosis in this cohort: 78 (28.5%) of 274 HIV-infected children with 
tuberculosis had smear- and/or culture-proven disease compared to 39 (27.1%) of 144 HIV-
uninfected children, P=0.765. This phenomenon has previously been demonstrated amongst 
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children hospitalised with tuberculosis at CHBH
52 66
, and is most likely due to the fact that 
paucibacillary forms of disease (i.e. disease manifestations where a robust CMI response 
has not been directed against the infective focus, with consequent lack of development of 
tissue-destructive lesions such as pulmonary cavitation which tends to yield higher smear- 
and culture-positive microbiological samples) predominate in both immunocompromised 
and immunocompetent children with primary tuberculosis, whilst immunocompetent adults 
with PTB frequently present with cavitary disease (frequently smear-positive) whereas 
adults with advanced HIV disease tend to present with paucibacillary forms of disease. 
Children will therefore tend to have lower microbiological yields regardless of HIV status, 
whilst HIV-uninfected adults will have higher yields compared to HIV-infected adults 
because of this phenomenon. 
 
As the WHO classification system (Appendix 5, page 132) stipulates a positive TST 
reaction as being one of the criteria by which paediatric patients can be labelled as having 
probable tuberculosis, and TST reactivity is known to be impaired in HIV-infected 
children
15
 
67
, the finding that HIV-uninfected children were more frequently classified as 
having probable tuberculosis than were HIV-infected children (OR 2.11; 95% CI, 1.35 – 
3.28), P<0.001, was expected. Conversely, in situations where the clinical picture is 
consistent with a diagnosis of tuberculosis based on history, clinical examination and 
radiological findings but without the supportive evidence of TST reactivity or 
bacteriological confirmation, HIV-infected children (8.6 times [95%CI, 3.83 – 19.44], 
P<0.001, more likely to exhibit TST anergy than HIV-uninfected children in this analysis) 
are significantly more likely to be classified as suspected tuberculosis cases (OR 2.00; 95% 
CI, 1.27 – 3.17), P=0.002. 
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TST using the Mantoux method generally performed poorly in this cohort, with negative 
responses occurring in 25 (92.6%) of 27 HIV-infected children with bacteriologically-
confirmed tuberculosis and 13 (61.9%) of 21 HIV-uninfected children with the same 
disease classification (OR 7.69; 95% CI, 1.22 – 81.00), 0=0.014 (Fisher‟s exact test), Table 
12. Although this may be an unrepresentative result, attributable to the small numbers of 
children tested, it is worth noting that the observed under-performance of the TST in 
bacteriologically-confirmed cases in this cohort is concerning as this is the most widely-
utilised screening tool for tuberculosis in low-income, high tuberculosis burdened settings. 
TST anergy in HIV-infected children with bacteriologically-confirmed disease was 3-fold 
(95% CI, 0.49 – 22.46), P=0.235 (Fisher‟s exact test) more frequent than in HIV-uninfected 
children with the same disease classification, although small sample size limited the 
demonstration of statistical significance in this analysis. 
 
It is interesting to note that, in this cohort, the score chart proposed for use by the SANTP 
Guidelines (2004)
19
 was demonstrated to have improved sensitivity (33.3 versus 7.4 
percent) in diagnosing bacteriologically-confirmed disease in HIV-infected children 
compared to the TST alone (Table 13); this would indicate that the scoring system may be 
useful when evaluating HIV-infected children presenting with a disease process suggestive 
of tuberculosis, albeit only with moderate sensitivity.  
 
 HIV-infected children with the most tenuous evidence for active tuberculosis (those with 
suspected disease) were no more likely to have polymicrobial infections than were HIV-
uninfected children with suspected tuberculosis (OR 1.39; 95% CI, 0.56 – 3.69), P=0.446 
   114 
(Table 16). This finding suggests that HIV-infected children classified as having suspected 
disease were not merely misdiagnosed with tuberculosis on the basis of an intercurrent 
infection which took some time to respond to broad-spectrum therapy.  
 
Similarly, Table 15 illustrates that although the proportion of co-infections identified in 
children with probable tuberculosis were significantly smaller than that encountered in 
children with suspected tuberculosis (OR 0.52; 95% CI, 0.30 – 0.90), P=0.013, there was 
no significant difference in the proportions of children with confirmed co-infection 
comparing those who had bacteriologically-confirmed tuberculosis and those with 
suspected disease (OR 0.77; 95% CI, 0.44 – 1.35), P=0.333. This analysis is important as it 
likewise supports the argument that disease categorisation in instances where there was less 
robust evidence of causation by MTB, was not merely attributed on the basis of 
misdiagnosis of a disease process caused by a co-pathogen as „tuberculosis‟ because of 
lengthy time to clinical resolution. 
 
It must be noted that a proportion of the children diagnosed with tuberculosis in this cohort 
may not truly have had active MTB disease, although clinical presentation was suggestive 
enough to warrant a discharge diagnosis of tuberculosis in these children. Children with 
smear-positive but culture-negative disease may have had colonisation or infection with 
non-tuberculous mycobacterial species, and those with suspected disease may not have had 
tuberculosis at all. This is a commonly-occurring paradox in clinical practice, which 
nevertheless results in the notification and referral of paediatric cases to the Primary Health 
Care system for directly observed treatment of tuberculosis.  
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The public health burden of childhood tuberculosis inevitably accommodates the 
management of misdiagnosed cases in National Tuberculosis Programmes (NTPs) globally, 
and it is therefore important to document the impact of tuberculosis diagnoses regardless of 
strength of evidence for tuberculosis because these cases add to the case load which 
primary level care needs to manage. It is striking that HIV-infected children carried an 
overall tuberculosis incidence (once recurrent tuberculosis cases were included in the 
analysis) of 12 961 per 100 000 (95% CI, 11 608 – 14 428), or 3880 per 100 000 (95% CI, 
3157 – 4720) for bacteriologically-confirmed disease (Table 36), suggesting that HIV-TB 
co-infection has a substantial impact on the Primary Health Care infrastructure in the study 
setting. 
 
In the era of HIV, and in settings with high dual burdens of HIV and tuberculosis, over-
diagnosis (e.g. in HIV-infected children with clinical signs such as chronic weight loss and 
lymphadenopathy which may be misattributed to tuberculosis) and under-diagnosis of 
tuberculosis (e.g. in those who have HIV-related lung disease such as lymphocytic 
interstitial pneumonitis who are not investigated for the presence of dual tuberculosis 
infection) in children who lack bacterial confirmation of active disease caused by MTB is a 
possibility
68
. When considering how vulnerable immunocompromised children are to the 
infection, it has been suggested that children presenting with pneumonia in developing 
countries with high tuberculosis and HIV prevalence rates, should be suspected as having 
tuberculosis and that anti-tuberculous therapy should not be withheld because of a lack of 
bacteriological evidence of infection caused by MTB
66
. 
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4.4 Recurrent Tuberculosis Episodes 
HIV-infected children had a 3-fold (95% CI, 1.6 – 6.7), P<0.001, increased risk of 
developing recurrent tuberculosis compared to HIV-uninfected children, equivalent to the 
risk of recurrence observed in HIV-infected compared to -uninfected patients with 
tuberculosis described by Driver et al. (RR 3.6; 95% CI, 1.9 – 6.7) in New York in 200169.  
 
Comparing the HIV-infected and -uninfected groups, HIV-infected children tended to 
manifest recurrent tuberculosis after a previous episode of bacteriologically-confirmed 
disease (P=0.016, Fisher‟s exact test) whereas HIV-uninfected children who developed 
recurrences, tended to do so after an episode of previous probable tuberculosis (P=0.030, 
Fisher‟s exact test), Table 6. Twenty-two percent of the HIV-infected children with 
recurrent tuberculosis had more than one recurrence of disease, whereas no HIV-uninfected 
child had more than one recurrence. Time to first recurrence was similar regardless of HIV 
status (14.7 months in HIV-infected children compared to 15.9 months in the HIV-
uninfected, P=0.793). However, bacterial burden of disease demonstrably shortened time to 
recurrence in the HIV-infected children (10.0 months in those with previous smear-positive 
disease compared to 19.0 months in those with previous smear-negative but culture-
confirmed disease, P=0.039). 
 
Clinicians caring for children have raised concern about the efficacy of short-course anti-
tuberculous chemotherapy in HIV-infected children, questioning whether a prolonged 
continuation phase of therapy should not be adopted in order to prevent recurrence of 
disease in these patients
15 70
; this concern is also becoming more widely appreciated in the 
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general medical literature
71
. Recurrent tuberculosis in high-burdened settings frequently 
arises as a result of exogenous re-infection
72
 but may also arise as a result of endogenous 
reactivation of dormant foci of bacilli which failed to respond to a previous course of anti-
tuberculous therapy; HIV-infection as a cause of severe immunosuppression may cause an 
increase in both exogenous re-infection and endogenous reactivation of disease
73
.  
 
The tuberculosis recurrence rate amongst HIV-uninfected children was 5.6 percent (8 cases 
amongst 144 HIV-uninfected children who were ever diagnosed with tuberculosis during 
the study duration), which is commensurate with the expected 2 to 7 percent recurrence rate 
of disease described in HIV-uninfected patients with active drug-susceptible tuberculosis, 
treated with six months of short-course antituberculous therapy
74
 
75
 
76
 
77
. The overall 
recurrence rate in HIV-infected children was 18.2 percent (50 cases amongst 274 HIV-
infected children ever diagnosed with tuberculosis over the study time period).  
 
Schaaf et al. calculated a relapse rate of 19.6 percent for culture-confirmed tuberculosis in 
HIV-infected children who had had previous definite tuberculosis
73
. Similarly, in the 
CHBH PCV Study cohort, amongst 21 HIV-infected children who had had previous 
definite tuberculosis, 5 (23.8%) culture-confirmed relapses were identified. It is noteworthy 
that, in the CHBH cohort, 31 recurrent tuberculosis episodes arose amongst HIV-infected 
children who had had previous bacteriologically-confirmed (smear- and/or culture-positive) 
disease, and 13 (41.9%) of these recurrent episodes were themselves bacteriologically-
confirmed. 
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The findings of enhanced recurrence of disease in HIV-infected children who had prior 
bacteriologically-confirmed disease and shorter time to recurrence in those with previous 
smear-positive disease, may suggest that an extension of the continuation phase of therapy 
would be of benefit in treating HIV-infected children with bacteriologically-confirmed 
tuberculosis. An important adjunct to monitor disease response to therapy in children with 
bacteriologically-confirmed tuberculosis would be to submit repeat samples for 
bacteriological evaluation at the end of the intensive phase of therapy in order to 
demonstrate reversion to smear- and/or culture negativity, as is the practice in adult 
patients. Radiological follow-up in order to demonstrate improvement in parenchymal lung 
disease during antituberculous therapy is another important strategy by which efficacy of 
therapy can be determined
73
. 
 
4.5 Untreated Tuberculosis Episodes 
This is the third study which has demonstrated that substantial proportions of children 
investigated for tuberculosis at CHBH do not access appropriate care for their 
bacteriologically-confirmed disease, highlighting deficiencies in the follow-up care of 
children that are investigated for active tuberculosis at the facility.  
 
The first study that highlighted deficiencies in this aspect of tuberculosis management at 
the hospital was conducted by Ntwaza by retrospective review of children admitted to the 
general paediatric wards from February 1997 to February 1999
28
. Seven hundred and forty-
five children had culture-confirmed tuberculosis during the study period, 342 (45.9%) of 
whom were included for review in that study: 173 (50.6%) of these children had not been 
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notified for tuberculosis. A firm recommendation was made in response to the study 
findings, to adopt strategies that would improve the notification and treatment of paediatric 
bacteriologically-confirmed tuberculosis at the hospital
28
. 
 
Edginton et al. describe the outcome of a prospective study conducted at CHBH which 
sought to critically analyse the practice of tuberculosis culture submission by clinicians 
caring for patients with suspected tuberculosis at the facility
78
. The study was conducted 
from January to March 2006, during which time period 5404 samples were submitted from 
3909 patients with suspected tuberculosis; 1160 (29.7%) of the patients were children under 
15 years of age. Of all children investigated for tuberculosis, 122 (10.5%) had positive 
culture results and, by review of all available data sources, 44 (36.1%) of these children 
may not have been on initiated on antituberculous therapy
78
.  
 
The analysis in the PCV Study cohort as presented in this dissertation, intermediate in time 
sequence between the previous two studies, identified that 62 (44.0%) of all 
bacteriologically-proven tuberculosis episodes had not been started on anti-tuberculous 
therapy. When assessing untreated episodes in HIV-infected and -uninfected children 
according to culture-positivity, 38 (50.0%) of the 76 culture-confirmed episodes in HIV-
infected children and 16 (50.0%) of the 32 culture-confirmed episodes in HIV-uninfected 
children were not started on appropriate treatment, P=1.000. A similar analysis, focussing 
on smear-positive episodes without culture-confirmation that were not started on 
appropriate therapy, reveals that amongst HIV-infected children 7 (29.2%) of 24 episodes 
with confirmed PTB compared to 1 (12.5%) of 8 such episodes in HIV-uninfected children 
were not started on appropriate therapy, P=0.642 (Fisher‟s exact test).  
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Neither HIV-infected children with culture-proven tuberculosis (OR 2.42; 95% CI,        
0.83 – 7.69), P=0.074, nor those with culture-confirmed disease who were HIV-uninfected       
(OR 7.0; 95% CI, 0.72 – 334.74), P=0.107 (Fisher‟s exact test) were significantly more 
likely to have remained untreated for their disease compared to those with smear-positive 
disease. 
 
Median cough duration in these children was 3.5 days (IQR 2.0 – 7.0) lending feasibility to 
the hypothesis that, as these children presented with an acute illness, the diagnosis of 
tuberculosis was not considered likely, although clinical suspicion was sufficient to submit 
tests to investigate for active disease caused by MTB.  
 
The median duration of admission in the children with bacteriologically-confirmed disease 
who remained untreated and survived was 6.0 days (IQR 4.0 – 11.0): comparing this to the 
duration of admission amongst the bacteriologically-confirmed tuberculosis cases who 
survived (9.0 days [IQR 4.0 – 21.0]), P=0.222, fails to clarify the possible reason for 
omission of antituberculous therapy as being a perceived lack of clinical severity of the 
untreated cases.  
 
It is likely that omission in commencing appropriate therapy in children with culture-
proven tuberculosis is a challenge in other centres in high tuberculosis-burdened settings, 
and that CHBH does not stand alone in this regard. A diagnosis of tuberculosis was missed 
in 25 (21.2%) of 118 children with culture-confirmed tuberculosis at a Durban hospital in 
1998 and 1999
15
. Possible reasons for omission of commencement of therapy in the Durban 
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cohort, such as overburdened hospital settings with pressure on clinicians to discharge 
patients before tuberculosis culture results become available, as well as frequent acute 
presentations (in 43 percent) of tuberculosis in this cohort which may have prompted 
clinicians not to consider the diagnosis of tuberculosis
15
, would apply to the clinical 
environment at CHBH and other large hospitals in under-resourced settings.  
 
Other factors which impair initiation of bacteriologically-confirmed tuberculosis cases on 
appropriate therapy may result from inability to trace patients once results become available 
because of inaccurate or incomplete patient records in which addresses and/or contact 
numbers have been erroneously recorded
78
, or erratic retrieval of laboratory results because 
of rapid turn-over of medical staff in busy teaching hospitals
79
. 
 
A recent critical analysis of the diagnostic value of culture-confirmation of tuberculosis in 
children, conducted in a tertiary centre whose staff complement includes experienced 
paediatric tuberculosis clinicians, highlighted that 127 (80.4%) of 158 children with 
culture-confirmed tuberculosis had been diagnosed on clinical grounds and had been started 
on antituberculous therapy prior to tuberculosis culture result retrieval. Thirty-one (19.6%) 
of the children were diagnosed subsequent to culture result availability, with 17 of these 
(9.2 percent of the cohort) not being started on appropriate therapy by hospital clinicians
79
. 
The authors commented that, although tuberculosis culture results take 2 to 8 weeks to 
achieve positivity and as such these investigations add very little to the acute management 
decisions surrounding children admitted with and investigated for tuberculosis, culture is 
important in order to obtain isolates for drug susceptibility testing
79
. Paediatric tuberculosis 
is a sentinel public health event, which often reflects recent infection acquired from adults 
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in the child‟s immediate environment, and drug susceptibility profiles of paediatric isolates 
are a useful indicator of current drug-resistant tuberculosis isolates in circulation in that 
environment
80
.   
 
4.6 The Burden of Tuberculosis in Hospitalised Children Under 5.3 Years of Age in 
Soweto 
Few studies have described the tuberculosis incidence in a cohort of children enrolled in 
early infancy over time using a longitudinal approach, because active tuberculosis is seen as 
being a „rare event‟ in many settings, and this approach would necessitate the enrolment of 
very large baseline cohorts with careful follow-up of the cohort over time in order to 
identify those who develop active tuberculosis
81
.  
 
Cross-sectional approaches to disease incidence estimation offer a reasonable compromise 
to the longitudinal approach; however the cross-sectional approach is not without its 
inherent difficulties, chiefly the fact that it relies on population estimates which are used as 
denominators in the disease incidence calculations.  
 
Using the longitudinal approach to disease incidence estimation, this study demonstrates 
that the Soweto paediatric tuberculosis incidence is 425 incident cases and 118 incident 
bacteriologically-confirmed cases in a cohort of 39 836 children that were followed up for a 
period of 5.3 years. These figures translate into a tuberculosis incidence rate of 1067 per 
100 000 children (95% CI, 968 – 1173), or 296 per 100 000 (95% CI, 245 – 355) for 
bacteriologically-confirmed disease (Table 35).  
   123 
 
It is interesting to note that, even if all incident cases of suspected tuberculosis (n=160) 
were omitted from the incidence analysis in this cohort, on the basis of insufficient grounds 
for a diagnosis of the disease because of the lack of robust clinical, radiological or 
bacteriological evidence, 265 incident cases (of bacteriologically-confirmed and probable 
disease) were identified in the hospitalised cohort: 665 cases per 100 000 (95% CI,         
588 – 750).  
 
As mentioned above, the incidence rate calculations highlighted that HIV-infected children 
bore the brunt of the tuberculosis burden: 10 633 cases per 100 000 HIV-infected children 
compared to 386 per 100 000 HIV-uninfected children (RR 27.5; 95% CI, 22.6 – 33.5). 
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5.0 STUDY LIMITATIONS 
 
Although a rigorous strategy was adopted in order to identify all cases of tuberculosis 
amongst PCV Study participants that had been admitted to CHBH, areas of uncertainty 
remain as to the true burden of tuberculosis in the study cohort. The inevitable 
disadvantages of a retrospective data collection strategy were experienced during the course 
of this study, and it is possible that children who participated in the PCV Study and had a 
hospital-based diagnosis of tuberculosis were unintentionally omitted in this analysis, 
especially when considering that many of the data sources used were incomplete. For 
example, the change-over in NHLS data-recording and retrieval systems in 2000 may have 
led to an under-appreciation of bacteriologically-confirmed cases prior to 2000, and there 
were no notification booklets retrievable for the period before 2002 coupled with the fact 
that systematic recording of tuberculosis notification data was only adopted at CHBH in 
2003. These sampling errors could have impacted on the yield of tuberculosis cases in this 
cohort quite substantially, as they would have diminished the detection of tuberculosis 
cases at a time when the study cohort would have been at its youngest, and consequently 
most vulnerable to developing active tuberculosis
7
.   
 
Mitigating against the above-mentioned tendency to under-estimate the true tuberculosis 
burden in the study cohort, numerous sources of bias arise when assessing tuberculosis 
disease burdens from hospitalised cohorts, some of which would tend to inflate the true 
tuberculosis burden in a cohort, as well as potentially exaggerating the negative effects 
which HIV-infection has on children co-infected with tuberculosis.  
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Compared to children diagnosed with tuberculosis in the community, hospitalised children 
usually have more severe or advanced disease, and as such may have more 
bacteriologically-confirmed tuberculosis; there may be higher proportions of HIV-infected 
children in hospital-derived cohorts, as these patients tend to present with more severe 
disease; mortality rates are also greater in hospitalised tuberculosis cohorts. It is also 
possible that there is a lower threshold for making a diagnosis of tuberculosis in 
hospitalised children, with a propensity to over-diagnose the condition in very ill children 
responding poorly to treatment of community-acquired pneumonia.  
 
It is anticipated that the dual effects of under-estimating tuberculosis burden through the 
retrospective approach to case-finding, as was adopted in this study, would be counter-
balanced by the potential to over-diagnose tuberculosis in ill hospitalised children where 
bacteriological confirmation of disease is not available. 
 
Whilst incidence rates derived from hospitalised cohorts may give a biased perspective of 
disease, such analyses are useful in order to gauge trends of disease burden over time, and 
baseline analyses such as this serve as reference points for comparison of incidence rates in 
future incidence analyses. 
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6.0 CONCLUSIONS 
 
 
In summary, this longitudinal study has demonstrated a high burden of tuberculosis in a 
cohort of 39 836 children that were enrolled in a PCV efficacy trial and followed up over 
5.3 years in Soweto, with the greatest disease burden occurring in HIV-infected children. 
 
By using a vaccine-probe approach in comparing the relative incidences of PTB amongst 
PCV and placebo recipients, it has been possible to demonstrate that co-infection with       
S. pneumoniae occurs in up to 44 percent (95% CI, 11 – 65) of children hospitalised with 
culture-confirmed tuberculosis, this effect being most marked in HIV-infected children in 
whom a 47 percent (95% CI, 10 – 69) apparent reduction in culture-confirmed tuberculosis 
was demonstrated in vaccinees, P=0.017. The occurrence of tuberculosis and pneumococcal 
co-infections in settings with a high prevalence of both HIV and tuberculosis may be 
explained by heterologous immune interactions, although studies designed to analyse the 
specific immunologic interactions between these two organisms have not been conducted.  
 
A substantial proportion of children with bacteriologically-confirmed disease remained 
untreated for their condition, highlighting operational barriers to translating laboratory 
results into meaningful management outcomes at CHBH. This failure of management is 
likely not unique to the study setting, and probably reflects intrinsic deficiencies which 
occur in many high HIV-TB burdened settings. Laboratory and clinical feedback 
mechanisms need to be strengthened and maintained in order to secure favourable 
outcomes in paediatric patients investigated for active tuberculosis in hospitals in high-
burdened settings. 
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APPENDICES 
 
Appendix 1: Childhood Tuberculosis Diagnostic Score Chart Recommended for Use 
by the SANTP (2004) 
 
General  
Feature 
0 1 2 3 4 Score 
Weeks of 
illness 
< 2  2 – 4  > 4   
Nutrition  
(% weight for 
age) 
> 80% 60 – 80%  < 60%   
Family history 
of tuberculosis 
None Reported 
by family 
 Proved sputum 
positive 
  
Tuberculin 
skin test 
    Positive 
 
  
Malnutrition    Not improving 
after four weeks 
  
Unexplained 
fever 
  No 
response  
to 
treatment 
   
Local  
Feature 
   3 4 Score 
Findings on 
clinical 
examination 
 
   
 
Lymph-
adenopathy 
  
   Joint or bone 
swelling 
  
   Abdominal mass 
or ascites 
  
   CNS signs, CSF 
abnormal 
  
Radiological 
findings 
   Broad 
mediastinum due 
to enlarged hilar 
glands 
Angle 
deformity 
of spine 
 
 
Total (any score  ≥7 is suggestive of tuberculosis)  
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Appendix 2: Data Collection Sheet Utilised in the PCV Study 
 
Vaccine patient data form: 
1. Admission Date:______________ 2. Unit:____  3. Ex-unit:_____ 
4. Date of birth:________________ 5. Sex: M / F  6. Hosp No:_______________ 
7. Surname:___________________ 
8. Study number:_______________ 
9. Dates of doses: 1.________________2.__________________3.__________________ 
 
History: 
10. Cough duration (days):_____ 
11. Fever: Y / N   12. Fever duration (days):______ 
13. Refusing feeds:  Y / N 
14. Vomiting:   Y / N 
15. Diarrhoea:   Y / N  16. Frequency: ____/day 17. Duration (days):____ 
18. Loss of weight: Y / N  19. Duration (days):____ 
20. Night sweats: Y / N 
21. Seizures:   Y / N 
22. Irritable / Excessive crying: Y / N   23. Duration (days):_____ 
24. Hospitalization in previous 2 weeks: Y / N  25. Diagnoses:_________ 
26. > 2 admissions for pneumonia: Y / N  27. Number of pneumonia admissions:___  
28. On oral antibiotics: Y / N  29. Name:___________30. Date started:___________ 
31. Bactrim prophylaxis: Y / N     32. Date started:___________ 
33. TB contact: Y / N   34. Who:____________35. When:________________ 
36. Predisposing medical cause for pneumonia: Y / N 
37. Diagnosis: 1=Ex-prem  2=Cardiac condition  3=RVD  4=Chronic lung  5=TB 
37a. Neonatal history: Birth weight (g) ________     Gestational age (weeks): ______        
        Ventilated: Y / N 
 
Examination details: 
38. Weight (kg):______    39. Weight centile:_______  
40. Height (cm):______    41. Height centile:_______ 
42. Head circumference (cm):_______  43. Head circumference centile:_______ 
44. Temperature (thermoscan):______  45. Temperature (axillary):_______ 
46. Respiratory rate (per min):______   
47. Room air sats (%):_______   48. Sats on O2 (%):_______  
49. Pulse rate (per min):______ 
50. Kwashiorkor: Y / N 
51. Cyanosis: Y / N    52. Clubbing: Y / N 
53. Intercostal recession: Y / N   54. Subcostal retractions: Y / N 
55. Crepitations: Y / N    56. Wheezing: Y / N 
57. Stridor: Y / N    58. Bronchial breathing: Y / N 
59. Oral candidiasis: Y / N   60. Perineal candidiasis: Y / N 
61. Chronic ear discharge: Y / N  62. Chronic sinusitis: Y / N 
63. Acute otitis media: Y / N   
64. Hepar (exclude hyperinflation): Y / N 65. Splenomegaly: Y / N 
66. LN: Y / N     67. Dermatitis: Y / N 
68. CDC HIV Class: N  A  B  C 
69. Neck stiffness: Y / N   70. Bulging fontanelle: Y / N 
71. GCS:_____{E:___M:___V:___}  72. Dehydration (%):_____        73. Other:______ 
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74. Outcome:  1=Discharged   2=Demised   3=RHT   
75. Date of discharge:_______________ 
76. ICU admission: 1=No   2=Yes   3=Not considered re: HIV   4=no bed   5=in 36 
Discharge diagnosis:  77. Primary Dx:______ 78. Secondary Dx:_______ 79. Underlying Dx:___  
 
 
Result sheet: 
FBC:  78. WCC_____  79. Hb____  80. MCV____  81. Plt_____  
82. Neut_____  83. Lymph____  84. Mono_____  85. Eosino____ 
86. CRP:__________ 
87. LDH:__________ 
 
88. HIV ELISA:  1=Pos  2=Neg  3=Not done 
89. HIV PCR:   1=Pos  2 =Neg  3=Not done 
 
90. Blood cultures:  1=Neg  2=Pneumococcus 3=Hib  4=S. aureus  
   5=Not done 6=Other  
 
CSF:   91. Neut___   92.Lymph___   93.RBC_____    
         94.Tot prot____ 95.Gluc ____     96.Cl____         97.LDH_______ 
98. Gram stain:    1=GPC 2=GNB  3=GNDC 4=Other 5=Neg 
99. Latex:       1=Pn 2=Hib  3=Nmen 4=Neg  5=Not done 
100. Culture:       1=Pn 2=Hib  3=Nmen 4=Neg  5=Not done 
 
Other fluids:  101.    1=Pleural  2=Other:_____________ 
Results:  102.Neut____  103.Lymph____ 104.RBC_____  
105.Tot prot____ 106.Gluc____ 107.Cl _____ 108. LDH_______  
109. Gram stain:  1=GPC 2=GNB  3=GNDC 4=Other 5=Neg 
110. Culture:       1=Pn       2=Hib  3=Nmen 4=Neg  5=Not done 
 
111. PPD (mm):_______   
112. Gastric washings: 1=1 done       2=2 done      3=3 done      4=>3 done      5=Not done 
113. Ao Results:            1=Neg       2=Pos           3=Not done 
114. Bactec Result:  1=Neg       2=Pos           3=Not done 
 
115. Nasopharyngeal aspirates:  1=Done 2=Not done 
116. Result: 1=Neg 2=RSV  3=Inf A 4=Inf B  5=Para I 6=Adeno 
117. PCP: Y / N 
118. PCP results:  1=Pos  2=Neg  3=Not done 
 
Chest Radiographic Changes: 
Parenchymal changes:  117._________118.__________ 
1=Patchy infiltrate 2=Interstitial infiltrate  3=Dense non-lobar 4=Lobar/multi- 
5=Poor quality  6=Normal   7=Not done 
Secondary changes:  119._________120.__________ 
1=Effusion  2=Cavitation   3=Atelectasis  4=Hilar LN 
5=Hyperinflation  
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Appendix 4: Strategy of Data Collection Utilised in this MMed Project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pneumococcal Vaccine Study Cohort 
Identify children that were admitted to CHBH by review 
of RMPRU Databases 
 
TB diagnosis unknown 
to PCV study 
 
Look for evidence of a 
TB diagnosis in the 
following databases: 
 
 CHBH paediatric 
discharge 
summaries (from 
PCV study source 
documents) 
 
 TBCC database 
 
 Paediatric HIV 
clinics at CHBH 
 
 Notification 
booklets 
 
 NHLS database 
TB results 
TB diagnosis 
made 
 
or 
 
TB specimens 
positive in 
NHLS 
database, but 
no TB 
diagnosis 
made at 
discharge 
from CHBH  
 
No TB 
Diagnosis 
Made 
 
 Algorithm score (see Appendix 1)  
 
 Classify tuberculosis (see Appendix 4)   
 
 Tuberculosis and pneumococcal co-
infections as probed for by PCV 
 
 Clinical spectrum of TB  
 
 
 PCV study database 
o Vaccine status 
o HIV status 
o Clinical 
parameters 
o Results of 
microbiological 
investigations 
 
 NHLS Database 
o Review results 
of TB specimens 
sent 
o Retrieve TB 
microscopy, 
culture and 
sensitivity results 
o Bacterial blood 
culture and CSF 
results 
 
TB diagnosis known to 
PCV study 
 
No further 
analysis 
required 
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Appendix 5: Categorisation of Childhood Tuberculosis
 
Bacteriologically-confirmed tuberculosis 
47
 
 
Probable tuberculosis 
47
 
 
Suspected tuberculosis 
47 
 
Same-episode 
tuberculosis 
 
MTB detected on smear or culture from secretions or 
tissues 
 
A suspected case (see alongside) with 
any of the following: 
 
 
1. Positive TST 
2. Suggestive chest radiograph 
3. Suggestive histology 
4. Favourable response to anti-
tuberculous therapy 
 
 
Ill child with a history of 
contact with a confirmed 
case of PTB 
 
or 
 
Any child: 
 
1. Not regaining 
normal health after 
measles or 
whooping cough 
 
2. With weight loss, 
cough or wheeze 
not responding to 
antibiotic therapy 
for respiratory 
disease 
 
3. With painless 
swelling in a group 
of superficial nodes 
 
For the  
purposes of  
this study 
 
 
Cases diagnosed with 
tuberculosis who 
required subsequent 
hospitalisation within the 
six months of anti-
tuberculous treatment 
(these cases were often 
listed in the PCV 
databases as having a 
discharge diagnosis of 
tuberculosis)  
Definite 
tuberculosis 
Confirmed PTB Untreated 
tuberculosis 
 
For the 
purposes of  
this study * 
 
Disease with 
cultures positive 
for MTB: 
 
1. PTB if 
culture-positive 
on respiratory 
specimens 
 
2. EPTB if 
culture-positive 
on samples from 
extrapulmonary 
sites 
 
 
For the 
purposes of  
this study 
 
Respiratory 
illness with 
specimens 
positive on 
microscopy for 
AFB, without 
culture-
confirmation 
 
For the 
purposes of  
this study 
 
Instances of 
bacteriologically-
confirmed 
disease where a 
discharge 
diagnosis of 
tuberculosis was 
not made 
according to 
PCV source 
documents 
Probable  
PTB 
Probable EPTB 
 
For the  
purposes of  
this study 
 
Compatible 
history, clinical 
features and chest 
radiograph; no 
bacteriological 
confirmation 
 
For the  
purposes of  
this study 
 
Compatible 
history, clinical 
features and 
radiological 
investigations ± 
histology; no 
bacteriological 
confirmation 
* Shaded columns, labelled “For the purposes of this study” reflect definitions devised for analysis in this dissertation; 
other definitions are derived from Reference 47. 
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Appendix 6: Vaccine Efficacy Calculation to Determine the Incidence Rate Ratio 
(IRR) for Tuberculosis Between HIV-infected and -uninfected Children 
 
 
The following calculation, which adopts a „vaccine efficacy‟ approach48 49 to determine the 
degree of intrinsic protectivity which a BCG-vaccinated, intact immune system confers in 
protecting against active tuberculosis, is described below. 
 
1. If: 
Proportion of HIV-uninfected children with tuberculosis (pcv) =  
1 – (Proportion of HIV-infected children with tuberculosis) 
 
2. And: 
Proportion of cohort which is HIV-uninfected (ppv) =  
1 – (Proportion of cohort which is HIV-infected)  
 
3. And: 
Vaccine Efficacy (VE) = 1 – (pcv(1 – ppv)) / (ppv(1 – pcv)) 49 
VE = 1 – (tuberculosis incidence in HIV-uninfected / tuberculosis incidence in  
HIV-infected) 
49
 
 
4. From Table 3, 65.6 percent of first-episode tuberculosis cases where a definitive HIV 
result was available were identified in HIV-infected children: 
pcv = 1 – 0.656 = 0.344 
   134 
5. From population estimates 43 44, the estimated proportion of the PCV study cohort 
which is HIV-infected is 6.5 percent: 
ppv = 1 – 0.065 = 0.935 
 
6. Then, 
VE = 1 – (0.344 (1 – 0.935)) / (0.935 (1 – 0.344))  
VE = 1 – (0.344 × 0.065) / (0.935 × 0.656) 
VE = 1 – (0.022 / 0.613) 
VE = 1 – 0.036 = 0.964 
 
7. BCG vaccination is therefore 96.4 percent relatively more effective in protecting 
against progression to active tuberculosis in HIV-uninfected compared to HIV-infected 
children. The Incidence Rate Ratio (IRR) of tuberculosis between HIV-infected and      
-uninfected children in this cohort (from the alternative form of the Vaccine Efficacy 
formula in point 3, above) is: 
Incidence Rate Ratio (IRR) = incidence in HIV-infected / incidence in HIV-uninfected 
where 
VE = 1 – 1 / (IRR) 
hence 
IRR = 1 / (1 – VE) 
and  
IRR = 1 / (1 – 0.964) 
IRR = 1 / 0.036 = 27.5 
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The calculation (for all forms of incident tuberculosis as well as incident culture-confirmed  
disease) is tabulated below: 
 
 
 
‘Vaccine efficacy’ calculations for Section 3.3.2 
 
* The term „vaccinated‟ here refers to the „immunological advantage‟ conferred to individuals in the analysis: 
„vaccinated‟ individuals are those who are HIV-uninfected. 
** “Definite tuberculosis” refers to incident cases with culture-confirmed PTB and EPTB (63 cases in HIV-
infected children and 31 cases in HIV-uninfected children, Table 3).  
+ Vaccine Efficacy (VE) = 1 – (pcv(1 – ppv)) / (ppv(1 – pcv)). 
++ 
Incidence Rate Ratio (IRR) = 1 / (1 – VE). 
 
  
Section 3.3.2 
 
Efficacy of HIV-uninfected status in 
„protecting‟ against incident tuberculosis 
All forms of 
tuberculosis 
Definite 
tuberculosis ** 
pcv 
(proportion of tuberculosis cases which were 
„vaccinated‟*) 
 
0.344 
 
0.330 
1 - pcv 
(proportion of tuberculosis cases which were 
„unvaccinated‟) 
0.655 0.670 
ppv 
(proportion of the population which was 
„vaccinated‟*) 
0.935 0.935 
VE 
+ 
(„vaccine efficacy‟) 
0.964 0.966 
Efficacy of „vaccine‟ in preventing 
tuberculosis in the cohort (%) 
96.4 96.6 
IRR 
++ 
(incidence rate ratio) 
 27.5 29.4 
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